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ABSTRACT 
Coronary heart disease (CHD) is one of the most common causes of death in Western 
Countries. Genetic factors playa major role in the aetiology of CHD, however, the primary 
defects responsible for the disease have not been identified in most cases. With the 
application of recombinant DNA technology, it is possible to analyse the putative 
aetiological role of candidate genes. 
The role of the Lipoprotein Lipase (LPL) gene and the Apolipoprotein AI-CIII-AIV gene 
cluster were examined in German and Chinese controls, dyslipidaemics and arteriopaths 
(coronary artery disease and/or peripheral artery disease). Analyses of four allelic 
distributions (HindIlI-RFLP, Ser447_Ter, Asp9-Asn and Asn291 _Ser mutations) of the LPL 
gene in German and Chinese populations with or without arterial disease did not show 
any significant frequency differences. In the German group, plasma triglycerides and 
VLDL-triglycerides were lower in subjects possessing the Ser447_Ter mutation (p=0.06 and 
< 0.05 respectively), this mutation was also significantly less frequent in the highest tertiles 
for triglycerides (p<0.02) and VLDL(P<0.04). The Ser447_Ter variant was found at lower 
frequencies in the Chinese lipaemic subjects. In addition, two disease related genetic 
variants (Asp9-Asn and Asn291 _Ser) in Europeans were not found in the Chinese group 
(P<0.03). 
Analyses of four genotypic distributions (the ApoAI PstI, MspI, XmnI RFLPs and the 
ApoCIII G3175_C variant) of the ApoAI-CIII-AIV gene cluster in German and Chinese 
populations with or without arterial disease did not show any significant differences. 
However, significant associations between high triglyceride, VLDL, TGIHDL ratio and 
the PstI RFLP at the ApoAI gene were shown in the German group (p=O.OOl, p<0.02 and 
p<0.04). In the Chinese group, the rare alleles of the Apo CIII G3175 -C variant and the Apo 
AI MspI polymorphic variant were both found more frequently in the upper tertile 
distributions for apo CIII levels and plasma triglyceride/HDL ratios (p<0.05 and p<0.04 
respectively). The frequencies of two disease related RFLPs of the ApoAI gene (detected 
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with Mspl and Xmnl) and the ApoC1I1 G3175 -C variant were significantly different 
(p<0.0006, p<0.004 and p<0.003 respectively) between Chinese and German control 
groups. 
Out of eighteen French patients with diabetes m., obesity and severe hypertriglyceridaemia, 
eight subjects were found to possess mutations at the LPL gene locus by direct DNA 
sequencing. Three of these: Arg l92_Ter (C829_ T); Phe351 _Leu (C1308_ G) and Thr361 -Thr 
(C1338 _ A) had not previously been described. Thr361 _ Thr appears to be a common 
population polymorphism whose allele frequency in normolipidaemic diabetics was found 
to be 0.120 (162 chromosomes studied). The others are all rare at frequencies of <0.01 and 
may contribute to the phenotype by impairi~g clearance of plasma triglycerides. In eleven 
of the most lipaemic Chinese subjects, Thr361 _Thr (C1338_A) was observed, additionally, the 
previously published mutations, Ala261 _ Thr and Ser447 -Ter, were also noticed. 
Finally, a Finnish kindred, with premature coronary heart disease and decreased HDL 
cholesterol levels, was identified having an ApoAI variant (Lys 107 ~~) by Single-Strand 
Conformation Polymorphisms (SSCP) and direct DNA sequencing. This variant was 
caused by a 3 bp deletion of nucleotides 1396 through 1398 in exon 4 of the ApoAI gene. 
Ten family members were heterozygous for this mutation. Mean serum apoAI and apoAII 
levels in heterozygotes were reduced by 18% and 220/0, and cholesteryl ester transfer 
protein activity (CETP) was reduced by 25% compared with unaffected family members 
(both p<0.05) respectively, while the plasma lecithin:cholesterol acyltransferase (LCAT) 
activity did not show any difference between heterozygotes and unaffected family 
members. The ability of the isolated apoAI variant to serve as a co-factor for LCAT in 
vitro did not differ from that of normal apoAI. 
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Chapter 1 
1.1 CORONARY HEART DISEASE 
1.1.1 Description of coronary heart disease 
Coronary heart disease (CHD) is usually a consequence of atherosclerosis of the coronary 
vessels. Premature coronary artery disease (CAD) can be defmed as atherosclerosis arising 
in the coronary vessels and giving rise to ischaemic symptoms before the age of 55 years. 
The underlying lesion is atheroma, which can lead to angina and myocardial infarction 
when coronary arteries are involved. Various biochemical and epidemiological studies have 
given a considerable insight into the mechanism of atherosclerosis. However, factors that 
affect an individual's susceptibility to atheroma formation are poorly understood. The 
progression of atherosclerosis and the consequent risk of developing CHD are determined 
by the interaction of several genetic and environmental factors known as "risk factors'. The 
major established risk factors for CHD are hypercholesterolaemia, hypertension, 
hypertriglyceridaemia, cigarette smoking and diabetes mellitus. Studies of concordance 
rates in monozygotic twins with premature coronary artery disease have emphasised the 
importance of family history and demonstrate that genetic risk factors contribute to the 
susceptibility of individuals to the disease (Berg, 1984). There are also some common 
familial lipid disorders that are associated with premature heart disease, which include 
Familial Hypercholesterolemia (elevated low density lipoprotein (LDL) cholesterol levels), 
Familial Combined Dyslipidemia (elevated triglycerides and decreased high density 
lipoprotein (HDL) cholesterol), Familial Combined Hyperlipidemia (elevations of LDL 
cholesterol and triglycerides, and often decreased HDL cholesterol), Familial 
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Hypoapobetalipoproteinemia (elevated apolipoprotein B levels), and Familial 
Hypoalphalipoproteinemia (low HDL cholesterol levels) (Schaefer et al., 1994). 
Nevertheless, the nature of the genetic factors predisposing to the disease are not fully 
understood. Only a small proportion of CHD cases (5%) result from a single gene defect, 
e.g. Familial Hypercholesterolaemia, which has a population incidence of 1: 500. The 
majority of the cases are polygenic, i.e. several different genes interact cumulatively with 
multiple environmental factors to produce the disease, thus giving a multifactorial 
inheritance. For any individual, the expression of the disease may be dependent on the 
levels of expression of one or more genes and the presence of certain environmental factors. 
Thus, the multifactorial aetiology of the disorder makes it difficult to identify the genetic 
factors involved in the process. The candidate gene approach may help to disect some of the 
genetic components involved in the disease, by determining whether associations exist with 
alleles of candidate loci and the presence of the disease and/or its risk factors. 
1.1.2 Epidemiology of coronary heart disease 
CHD is one of the most common causes of death in the developed countries, accounting 
for almost 300/0-400/0 of mortality (Stamler et al., 1993). In the United Kingdom, 
approximately 160,000 deaths occur per annum as a result of CAD (Shaper et al., 1991). 
The disease manifests as angina pectoris, myocardial infarction (MI), sudden death or 
heart failure. The incidence of MI in the United Kingdom is 11200, affecting 
approximately 200,000 people per annum. A third of the UK men suffer premature death 
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from CHD before the age of 65 years. The frequency of the disease is lower in pre-
menopausal women, although it increases with age in both sexes (Dodu, 1984). 
There is considerable variation in the incidence of mortality from CHD between 
countries: Finland, United Kingdom, Ireland, West Germany are high. whilst France, 
Japan and China are in the lowest mortality group. Some of the differences may be 
accounted for by social and dietary habits. The prevalence and mortality of CHD are 
higher in lower socio-economic classes than in non-manual workers (Galton & Krone. 
1991 ). 
A decline in mortality of CHD during the past three decades has been achieved in certain 
industrialised countries by national campaigning to increase public awareness to alter 
certain lifestyle factors, such as reducing dietary fat intake and cigarette smoking and 
increasing the intake of polyunsaturated fats and physical exercise (McGovern et al., 
1996; Stephen & Sieber, 1994). 
1.1.3 Pathology of coronary heart disease 
CHD is a consequence of the formation of atherosclerosis in the coronary arteries. 
Atherosclerosis involves the deposition of lipid and other materials in the subini~l space. 
Although the process begins in childhood, clinical symptoms are usually not observed 
until middle age (Navab et al., 1995). The events leading to atherosclerosis have been 
studied in both animal models and cell culture (endotheliaL smooth muscle and platelets) 
(Faggiotto, 1988). 
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The earliest lesion is a fatty streak, composed of lipid-laden smooth muscle cells and 
macrophages, then it progresses to a fibro-fatty plaque, composed of smooth muscle cells 
and macrophages plus collagen, elastic fibres, proteoglycans and lipids. The final 
'complicated lesion' is the formation of a fibrous cap by the process of calcification, cell 
necrosis and thrombosis, centred on the fibrous plaque (Navab et at.. 1995). This results 
in narrowing of the lumen, consequently reducing the blood flow, and leading to 
ischaemia, which manifests as angina, or to myocardial infarction when there is total 
occlusion due to thrombosis or haemorrhage. 
1.1.4 Risk factors of coronary heart disease 
Various epidemiological studies have shown the association of 'risk factors' with 
incidence of CHD (Genest & Cohn, 1995; Gotto, 1986; Kannel & Higgins, 1990; Kannel 
& Sytkowski, 1987). The major risk factors associated with CHD include elevated 
plasma cholesterol concentrations, low HDL cholesterol, hypertension, diabetes mellitus 
and cigarette smoking (Goldbourt et ai., 1975; Miller, 1979). There is a continuous risk 
gradient with changing values of these risk factors. Other risk factors are raised levels of 
plasma triglycerides, obesity, male gender, family history of CHD, physical activity and 
personality type (Beaglehole et ai., 1975; Godsland et ai., 1987; Grundy et ai., 1987; 
Segers & Mertens, 1977). 
Risk factors can be divided into those which are environmental or those which are 
genetically determined. Most risk factors fall into both categories. Blood cholesterol 
concentrations, for example, can be modified by altering the intake of fats, but in some 
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individuals, in spite of a reduction in saturated fat intake, cholesterol concentrations 
remain elevated, suggesting a strong genetic contribution in regulation of lipid levels. 
Studies of migrants have shown that the risk changes in accordance with the new 
environment and lifestyle. Japanese, living in Japan have lower serum cholesterol 
concentrations paralleled with a low incidence of CHD; but Japanese emigrants to 
Hawaii, have much higher concentrations of cholesterol, due to increased intake of 
saturated fats and an increased incidence of CHD (Marmot et ai., 1975~ Syme et ai., 
1975). 
1.1.4.1 Hypertriglyceridaemia 
Hypertriglyceridaemia is a common metabolic disorder usually defined by serum 
triglyceride levels above 2.3 mM in 12-hour fasting serum samples (Study Group, 1987; 
International Committee, 1991). It is a prevalent dyslipoproteinaemia in the population: 
10% of men 35-39 years old have triglyceride levels above 2.7mM. Concentrations above 
11 mM and especially above 20 mM are associated with a high risk of Pancreatitis. 
Hepatosplenomegaly, Eruptive Xanthomata and Lipaemia Retinalis may also occur in 
association with severe hypertriglyceridaemia. 
The underlying pathophysiological mechanisms that result in elevations of plasma 
triglycerides are heterogeneous and, in most cases, incompletely understood. However, in 
a subset of patients presenting with this lipid disorder (e.g. Familial Chylomicronemia). 
the biochemical and genetic defects that lead to hypertriglyceridaemia have been well 
characterized. Abnormalities of lipoprotein metabolism may be inherited (monogenic or 
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polygenic), acquired, or of mixed aetiology. Most hypertriglyceridaemic subjects have 
substantial dietary, lifestyle, or disease-related contributions added to a polygenic 
predisposition. Secondary causes of hypertriglyceridaemia include alcohol excess 
, 
Diabetes Mellitus or glucose intolerance, Obesity, Hypothyroidism, Renal disease, a high 
fat diet and certain drugs ( e.g., oestrogens or beta-blockers). Bile-acid-binding resins 
such as cholestyramine can also aggravate hypertriglyceridaemia (Reckless, 1996). 
1.2. THE OVERVIEW OF LIPOPROTEIN METABOLISM 
1.2.1 Lipoproteins 
Lipoproteins are complexes of lipids and proteins that circulate in the blood stream. They 
are spherical particles with a coat consisting principally of amphiphilic phospholipids and 
apolipoproteins and a core of varying proportions of cholesteryl esters and triglycerides. 
The plasma lipoproteins have traditionally been grouped in five major lipoprotein classes: 
Chylomicrons, Very Low Density Lipoprotein (VLDL), Intermediate Density 
Lipoproteins (IDL), Low Density Lipoprotein (LDL) and High Density Lipoprotein 
(HDL), and several subpopulations of VLDL, LDL and HDL have been described. An 
unusual lipoprotein, Lipoprotein(a), a complex of LDL and apolipoprotein(a), has also 
been recognised. A number of studies have defined a group of proteins that directly 
control lipoprotein transport. These include: 
(a) the apoliproteins: AI. AIL AIV, B, CL CIL CIlI, D, E, and apo(a), 
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(b) the lipoprotein-processing proteins: lipoprotein lipase (LPL), hepatic lipase (HL). 
lecithin cholesteryl acyltransferase (LCAT), and cholesteryl ester transfer protein 
(CETP), 
(c) the lipoprotein receptors: LDL receptor, chylomicron remnant receptor. and scavenger 
receptors. 
Since 1982, the genes for most of these lipoprotein transport proteins have been isolated, 
for the most part, sequenced and mapped in the human genome (Breslow. 1991). 
1.2.2 Outline of lipoprotein metabolism 
The two principal triglyceride-rich lipoproteins, chylomicrons and VLDL, are synthesised 
and secreted from the small intestine and liver. After circulation to peripheral tissues 
(muscle, adipose tissue and heart), they are delipidated by the action of lipolytic enzymes 
(such as LPL and HL) to smaller particles (IDL), which are removed by the liver or are 
converted to the main cholesterol-carrying LDL and chylomicron remnants. HDL is 
mainly synthesised in the intestine and liver and it has been postulated that it is involved 
in the reverse transport pathway, returning cholesterol from cholesterol-replete tissues to 
the liver (Fig 1.2-1), (Breslow, 1992). 
At least two mechanisms link the triglyceride (VLDL) metabolism to HDL. In the 
hydrolysis of VLDL triglycerides by LPL. excess surface components are transferred to 
HDL. This can result in an increase in HDL particle size. In addition. VLDL triglycerides 
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can exchange cholesteryl esters with HDL in the presence of CETP, and the hydrolysis of 
the resulting HDL triglycerides by HL can cause a decrease in HDL particle size. In 
normal human plasma, the major species are HDL3 and HDL2, accounting for two-thirds 
and one-third of the HDL-cholesterol content (Breslow, 1992). 
Figure 1.2-1 
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Legend to figure 1.2-1: Lipoprotein transport pathways. 
Details are presented in section 1.2.2. C represents cholesterol; nHDL, nascent HDL; 
LCAT, lecithin cholesteryl acyltransferase; CETP, cholesteryl ester transfer protein; 
LDLR, LDL receptor; Remnant R, remnant receptor; B.A., bile acid: B48, apolipoprotein 
B48; B 1 00, apolipoprotein B 1 00; E, apolipoprotein E. Adapted and modified from 
(Breslow, 1991). 
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1.3 MOLECULAR GENETICS OF CHD 
1.3.1. Genetic susceptibility to coronary heart disease 
The aetiology of CHD has a substantial genetic component (Berg, 1983), as evidenced by 
family history (Friedlander et al., 1985; Rissanen, 1979; Rissanen & Nikkila, 1977) and 
monozygotic twin studies. Analysis of first degree relatives of 121 men and 96 women 
with CAD (Slack & Evans, 1966) showed that the increased risk of death from CAD was 
five and seven fold greater than in matched controls for males and females respectively. 
Many studies have confirmed this trend (Nora et al., 1980; Rissanen & Nikkila, 1979). 
The aggregation of premature coronary artery disease within families is well established. 
A positive family history of premature CHD (before the age of onset of 55 years for men 
and before 65 years for women) increases the chance of developing CHD two to five fold 
compared to those with a negative history (Yater et al., 1948). This effect may be 
independent of age, plasma total cholesterol and hypertension (Friedlander et al., 1985), 
although not all studies have supported this possibility (Conroy et al., 1985). Further 
evidence for the implication of a genetic predisposition to atherosclerosis comes from 
twin studies showing the concordance rates for angina pectoris or myocardial infarction 
in monozygotic twins to be 0.65 as compared with 0.25 for dizygotic twins (Berg, 1984). 
If the monozygotic and dizygotic twins with premature CAD were alone considered, 
these figures for males were then 0.83 and 0.22 respectively, for females, concordance in 
monozygotic twins is 0.44 and only 0.14 in dizygotic twins (Berg, 1983). Familial 
clustering of risk factors such as hyperlipidaemia and hypertension usually accompanies 
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familial aggregation of CHD in first degree relatl·ves (R· lssanen & Nikkila. 1979~ 
Rissanen & Nikkila, 1977 ~ Slack & Evans, 1966). 
1.3.2 Multifactorial inheritance 
The genetic contribution to coronary heart disease is not well defined. Hence, the mode of 
inheritance remains uncertain. First-degree relatives of affected patients have a two to 
seven -fold increased risk of developing the disease, compared to relatives of unaffected 
patients (Rissanen & Nikkila, 1979). Despite a greater frequency of affected relatives in 
the families of pro bands than in the general population, the frequency is less «5%) than 
that would be expected with Mendelian segregation (Emery, 1986), where at least 25% 
(autosomal recessive inheritance) or 50% (autosomal dominant inheritance) of relatives 
would be affected (e.g. familial hypercholesterolaemics) (Motulsky, 1976; Motulsky, 
1989). The lower frequency of expected affected individuals may be explained by another 
mode of inheritance, namely multifactorial inheritance. Where the aetiology is partly 
environmental and partly genetic; the genetic contribution probably consist of several 
different genes, i.e. polygenic. In polygenic inheritance, several genes, each having a 
small effect, at different loci interact additively, and the superimposition of the 
environment results in a multifactorial inheritance. The genes involved probably occur 
with variable frequencies in the popUlation and still remain to be identified. 
Realizing multifactorial inheritance can help explain some of the more enigmatic features 
of the genetics of polygenic diseases. The relatively high incidence of these diseases can 
be related to the fact that genes conferring susceptibility are often under no seiecti\'e 
Page 29 
Chapter 1 
disadvantage during favourable environmental conditions and thus may be widespread in 
healthy sub-groups, indeed under certain environmental conditions these genes might 
confer a selective advantage on the organism. In the face of such complexity, the failure 
of classical genetics to elucidate recognisable patterns of disease inheritance is easily 
explained. 
1.3.3 Approaches to studying molecular genetics of human disease 
1.3.3.1 Monogenic disease 
Over 6000 single gene traits and disorders have been discovered. The majority of these 
are individually extremely rare, however, some are relatively common, notably the 
Haemoglobinopathies, Cystic Fibrosis and Duchenne Muscular Dystrophy (Mueller & 
Young, 1995). 
Disease causing gene defects could be due to . f jfat genes or portIOns 0 genes "may be 
deleted or fused with other genes; regions of DNA can become inverted; additional DNA 
can become inserted into coding regions or point mutations. These types of mutation may 
be associated with a failure of transcription or lead to defective protein products. More 
unusual mutations may involve the promoter site; recognition sites for splicing, or the 
initiation or termination codons of the gene. e.g. Duchenne Muscular Dystrophy. 
Point mutations within the coding regIOn of a gene can lead to defective protein 
formation. The best known example of this is haemoglobin S. Several point mutations 
associated with defective receptor function have been described. Some cases of familial 
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hypercholesterolaemia are consistent with a single gene being a major factor determining 
genetic susceptibility within some families and has been shown to be due to either 
deletions or duplications of parts or all of the LDL receptor gene (Lehrman et al .. 1987a~ 
Lehrman et al., 1987b~ Lehrman et al., 1987c). In these cases, mutations can lead to: 
reduced transport from the endoplasmic reticulium to the Golgi apparatus~ reduced LDL 
binding; and a failure of the receptor-LDL ligand complex to cluster in coated pits. In 
other hyperlipidaemias, such as type III hyperlipidQl.t11ia, certain polymorphic variants of 
the apolipoprotein, apoE, appear to be important determinants of predisposition to early 
coronary artery disease. 
1.3.3.2 PolygeniC disease 
Most common genetic diseases, those which have the greatest impact on morbidity and 
mortality in the population, are not the result of single-gene defects. Nevertheless, 
Diseases which account for serious public health problems, such as Ischaemic 
Cardiovascular Disease, Hypertension, Diabetes Mellitus and Cancer, do run in families. 
Environmental factors undoubtedly exert an important effect in the development of these 
diseases (e.g. the relationship between smoking and cancer, diet and cardiovascular 
disease), but at the same time, inherited factors clearly contribute. 
Polygenic disease can be defined as those disorders in which more than one gene plays a 
major aetiological role. The genetic study of disorders where multiple-gene inheritance 
contributes is complex. One of the problems in understanding this important category of 
disease (which includes atherosclerosis and hyperlipideamia) is to distinguish the 
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inherited components of the disorders from their environmental components. One 
approach is to make a calculated guess that particular genes, so called '"candidate genes". 
might influence susceptibility to a disease. Candidate genes are selected from the 
physiological and pathological data available on the disease. The demonstration that 
susceptibility to a disease is associated with alleles at a specific polymorphic locus 
provides evidence for a major role of that locus in the etiology of the disease. The major 
gene could be the polymorphic locus itself or a closely linked marker in linkage 
disequlibrium with the gene locus. Linkage disequlibrium is said to be present when 
certain alleles at one locus occur with certain alleles at another locus at frequencies 
greater than that can be expected by chance alone. 
It would seem that atherosclerosis is primarily a multifactorial disease with a strong 
genetic component. Many genes must be involved in the development of atherosclerosis, 
with different defects or combinations of defects occurring in different patients. All genes 
coding for proteins that are involved in lipid metabolism are possible "candidate genes" 
for the study of atherosclerosis. For example, in the study of cardiovascular disease due to 
atheroma, where epidemiological studies indicate a clear association between plasma 
cholesterol and ischaemic heart disease, and where cholesterol is known to be a major 
component of the atheromatous plaque, a study of polymorphism among the 
apolipoproteins would be a rational approach. In remnant hyperlipoproteinaemia, an 
association is seen between an apolipoprotein polymorphism (i.e. apoE) with 
environmental factors (e.g. obesity) in the genesis of atheroma. These studies may also 
reveal monogenetic contributions to the susceptibility to atheroma, as familial defective 
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apo B, in which an abnormal apo BIOO is produced that reduces the binding of LDL to its 
receptor, leading to elevated plasma LDL-cholesterol (Gaffney et al., 1995). 
Of most molecular genetic work undertaken to date on multifactorial disease, the majority 
has been of the candidate gene approach, this is especially true of the work relating to 
hyperlipidaemia and atherosclerosis. 
1.3.3.3 Methodology 
1.3.3.3i Markers 
A genetic marker is any inherited character which is studied to track the inheritance of a 
particular segment of a chromosome in a family or a population. 
DNA Polymorphism 
A polymorphic locus is one at which there are at least two alleles each with frequencies 
greater than 10/0. Alleles with frequencies of less than 1 % are referred to as rare variants 
(Vogel & Motulsky, 1986). Two main classes of DNA polymorphisms have been 
recognised: restriction fragment length polymorphisms (RFLPs) and hypervariable DNA 
length polymorphisms. 
1. Restriction Fragment Length Polymorphisms (RFLPs) 
RFLPs are recognised as differences in the length of DNA fragments after digestion of 
specific restriction enzymes (Botstein et al., 1980) and are usually the result of single 
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base-pair changes that create or destroy a cleavage site for specific restriction 
endonucleases, although other mechanisms for DNA mutation such as deletions 
, 
insertions, or other rearrangements can be involved. RFLPs are extremely frequent in the 
genome and have been estimated to occur every 200-500bp of DNA (White & LaloueL 
1988). 
2. Hypervariable DNA length polymorphisms 
Hypervariable DNA length polymorphisms include Minisatellites or Variable Number of 
Tandem Repeats(VNTRs), Microsatellites or Simple Tandem Repeats (STRs). 
Minisatellites or VNTRs (Jeffreys et ai., 1985; Nakamura et ai., 1987) are highly 
polymorphic sequences consisting of tandem repeats of a short (11-60) oligonucleotide 
sequence. The length of the VNTR is a function of the number of copies of the tandem 
repeat. VNTRs are scattered throughout the genome, and can be very useful markers for 
genetic analysis. However, they are less frequent than micro satellites and have very large 
sequence motifs extending over more than 1 kb, this could present practical difficulties in 
their use (Horn et ai., 1989). 
Microsatellites or STRs consist of around 10-30 copies of a 1-6bp motif, are highly 
polymorphic and are extremely frequent within the genome. By using the Polymerase 
Chain Reaction (PCR), these microsatellites can be amplified and used as genetic markers 
(Hearne et ai., 1992; Sutherland & Richards, 1995). 
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Polymorphism information content (PIe) 
The essence of a useful genetic marker is that it should show differences between people, 
so that the differences can be tracked through a pedigree. e.g. linkage between 
Huntington's disease and a marker, a DNA polymorphism revealed by the randomly 
generated DNA probe, 08 (Ousella et al., 1983). A marker is informative when it is 
possible to tell which of two alleles of a person has passed on to a child. The 
polymorphism information content (PIC) of a marker can measure the probability that this 
will occur. PIC is a number between 0 and 1 and can be calculated by a simple formula 
based on the heterozygosity of the marker (Mueller & Young, 1995); the nearer it is to 1, 
the more likely it is that a polymorphic marker will be of value in linkage analysis and 
gene tracking. 
The application of DNA polymorphism 
All the above described polymorphisms (RFLPs, VNTRs, STRs) can be used as markers 
for candidate gene studies in populations and for linkage analysis in families. The use of 
DNA polymorphisms for candidate gene studies is based on a simple assumption: since 
these polymorphisms are so frequent within the human genome, some of them are bound 
to lie within or near a candidate gene for a disease. If a mutation is present in the 
candidate gene, one of the marker alleles should be transmitted together with the 
mutation, that is the marker allele and the mutation are in linkage disequlibrium. 
Therefore, a marker allele with a higher frequency in a disease population compared to 
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normal subjects indicates that candidate gene may be involved in the etiology of the 
disease. 
We would like to determine, at the DNA level, the "mutations" that are contributing to 
the increased risk of coronary atherosclerosis. However, the initial problems are to 
determine which of the candidate genes to study first, and how to tell whether genetic 
variation in any particular gene does indeed contribute to the development of 
hyperlipidaemia and CHD. The genetic markers allow the study of genetic variation in 
the population; in large pedigrees; to compare affected with unaffected sibs, any 
associations between the disease and genetic markers studied would indicate a potentially 
important gene, or gene-cluster, that influences the development of the disease under 
investigation. 
There are two different ways to approach this which will be examined in turn: family 
studies and population association studies comparing groups of patients and normal 
controls. 
1. Family studies (Pedigree linkage studies) 
A genetic susceptibility to a disease can be suggested by finding a higher frequency of a 
disease in relatives than in the general population. Linkage analysis in pedigrees is one of 
the most powerful methods for genetic analysis, in particular for single gene disorders, 
such as Cystic Fibrosis (Tsui et al., 1985). The basic methodology involves the study of 
the segregation of the disease in large families with polymorphic markers from each 
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chromosome. Eventually a marker will be identified which cosegregates with the disease 
more often than would be expected by chance, i.e. the loci are linked. The mathematical 
analysis involves the use of likelihood ratios, the logarithms of which are Lod Scores 
(logarithms of the odds). When studying the segregation of alleles at two loci which 
could be linked, a series of likelihood ratios are calculated for different values of the 
recombination fraction (8), ranging from 0.0 for loci so closely linked that recombination 
is never observed, to 0.5 for loci very widely separated. A lod of zero means the 
assumptions of linkage or no linkage are equally likely. A positive lod score favours 
linkage and a negative lod is evidence against linkage at the given recombination fraction 
(Morton, 1955). 
The demonstration that a disease co segregates in families with alleles at a marker locus 
provides some of the most convincing evidence for the contribution of a major locus to 
the disease susceptibility. However, it is likely that hypertriglyceridaemia and CHD in 
different families may be caused by variation in several different genes, as well as by 
interaction between different genes or genetic factors and environment, this causes some 
difficulities in identifing loci or alleles contributing to the common multifactorial 
disorders. To overcome this problem of heterogeneity, large sibships and multigeneration 
families will need to be analysed, alternatively, if affected siblings inherit a particular 
allele more often than would be expected by chance, pedigree studies could be replaced 
by sib pair analysis, which is a simplifed form of linkage analysis used for mapping 
recessive characteristics, and as a quick test of whether a candidate cloned sequence 
might be the gene for a disease. 
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2. PopUlation association studies 
The second example of the use of RFLPs in the study of genetic hyperlipidaemia and 
CHD is the search for population associations between the neutral genetic variation 
detected by the RFLP, and functionally significant genetic variation in a nearby gene. The 
approach is to determine the frequency of a particular RFLP in a sample of individuals 
from the normal population and in a group of patients with a particular form of 
hyperlipidaemia or CHD. A difference in frequency gives a clue that variation at or near 
this locus is involved in the development of the phenotype studied. 
It is not surprising that the allele frequency of many of the RFLPs so far examined has 
been shown to vary in different populations. There are several possible reasons for the 
discrepancies between the observations made in different laboratories and in different 
countries (Humphries et al., 1993). It is possible that the differences in the allele 
frequency between patients and controls are chance observation due to: 
a), the small sample sizes involved, and in several instances larger studies have failed to 
confirm them, 
b), the different criteria used by different workers to define patients, 
c), the disease heterogeneity in different populations, e.g. disease predisposing mutations 
in a candidate gene are each in linkage disequilibrium with a different marker allele. or 
sites of high frequency recombination occur between the marker and the mutation, or the 
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mutation is linked to the most common allele of the marker, which would certainly 
influence and confound comparison. 
d), the most likely reason for the differences observed between different laboratories is 
the different ethnic origin of cases vesus controls (Humphries et al., 1993). One of the 
consequences of evolutionary history is that the allele frequency of protein and DNA 
polymorphisms may differ between populations with different ethnic backgrounds. This 
may be the result of chance differences in the frequency of the polymorphism in the 
group of individuals who originally founded the population. Alternatively, it could be due 
to the fact that the DNA changes causing the variation may have arisen independently in 
the different populations. Finally, these frequency differences may be the result of 
selection pressure; e. g. nutritional factors; after parasitic or bacterial infection; are strong 
selective forces. 
One of the important topics of research is therefore to analyse the genetic component of 
the determination of lipid levels within the normolipidaemic population. This approach 
will clearly require analysis of genetic variation in a number of different genes, since in 
the general population, elevated lipid levels are not determined by variation at a single 
gene locus, but are the result of polygenic interaction between variation at many 
contributing gene loci and environmental factors. 
1.3.3.3ii Genetic resources 
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Base changes which create or abolish restriction sites can be detected easily by PCR-
restriction enzyme digestion or Southern blotting methods. However, not every base change 
does fall within a palindromic sequence of the type that can be recognized by restriction 
enzymes. Direct DNA sequencing can be used to identify mutations within a gene, but 
many genes in humans are several hundred thousand or even million base pairs in length 
making this an enormous task, especially if a single gene disorder is mutationally 
heterogeneous, or when the precise site of a point mutation is not known, it is necessary to 
first determine the region harboring the defect. A number of techniques can be used to 
screen for those mutations. The following are major methods of seeking unknown changes 
which might occur anywhere within a gene. 
Single-strand conformation polymorphisms (SSCPs) and Heteroduplex DNA 
Single-stranded DNA tends to fold up, just like a polypeptide, into complex structures 
stabilised by intramolecular weak bonds. Mostly these will be base-paring hydrogen bonds, 
and so the precise structure formed will depend on the nucleotide sequence. If such 
structures are electrophoresed through a non-denaturing gel, their mobility will depend on 
not just the chain length, as in normal DNA electrophoresis, but also the shape of the 
molecule which is dependent on the DNA sequence. This forms the basis of SSCPs for 
picking out abnormal sequences (ref. Chapter 3) (Orita et al., 1989). It was concluded that 
PCR-SSCPs could detect >900/0 of all single-base substitutions in 200 nucleotide fragments 
and >800/0 in 400 nucleotides fragment (Hayashi, 1992). 
Paoe 40 := 
Chapter 1 
A variation of this method is to look for abnormal mobility of heteroduplex DNA. 
Heterozygotes for the common cystic fibrosis mutation, a three-base deletion (~F508), can 
easily be detected by this way (Davies & Read, 1992). A region containing the mutation is 
amplified, and the product is denatured and allowed to renature. Th~Sallows heteroduplexes 
to form which have a noticeably lower mobility in agarose gels than either the normal or the 
mutant homoduplex. This method may be applicable to screening heterozygotes for 
unknown mutations (Keen et al., 1991). 
Ribonuclease A cleavage of mismatched heteroduplexs 
Ribonuclease A will cleave RNA in a DNA-RNA duplex at a point of mispairing. A single-
stranded RNA probe is synthesized by in vitro run-off transcription of a cloned DNA 
fragment (with the normal sequence) in an appropriate vector. The probe is hybridized to 
the test DNA. If the test DNA contains a single base change, there will be a mismatch, 
which will be cleaved by ribonuclease A. The products are run on a denaturing geL where 
the mutation will be revealed because the RNA runs as two bands instead of one. Their 
sizes pinpoint the position of the mutations (Kaufman et al., 1990). 
Chemical cleavage of mismatched heteroduplexs 
Mispaired bases in a double helix are more reactive than correctly paired bases. A reaction 
is used which leads to cleavage of the sugar-phosphate backbone. Hydroxylamine reacts 
specifically with mismatched cytosine in the DNA double helix, and osmium tetroxide 
reacts with mismatched thymine (and more slowly with mismatched cytosine). In either 
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case, treatment of the reaction product with piperidine breaks the DNA at the position of the 
mismatch (Cotton et al., 1988). The method is capable of locating precisely the position of 
mutation. 
Denaturing gradient gel electrophoresis 
Homoduplexes or heteroduplexes of DNA can be detected by altered melting profiles, and 
the denaturant can be chemical (usually formamide) or high temperature (Cariello & 
Skopek, 1993; Cariello et al., 1991). The point mutation of the Factor IX gene in families 
segregating haemophilia B (Attree et al., 1989) has been detected by using thermal gradient 
gels (containing a 20-80% gradient of formamide at a constant 60°C). Alternatively, using a 
temperature gradient, this can run either in the direction of electrophoresis (cold or hot) or 
perpendicular to this. Attachment of a GC-rich sequence of up to 40 nucleotides (a GC-
clamp) enables minor sequence differences in the higher temperature domains to be 
detected (Costes et al., 1993; Sheffield et al., 1989). This method can reveal the presence of 
sequence variants in large fragment sizes (>500bp) and resolve close to 1000/0 of single base 
pair differences, however, as it can only identify a region containing one or more mutations 
just like SSCPs, DNA sequencing is then necessary to locate and identify the exact site. 
1.3.3.3iii Animal models 
Studies of human genetic disease are difficult because of the small numbers of large 
informative families available for linkage studies and the small quantities of tissue that 
can be extracted for the analysis of candidate gene sequences. Studies of homologous 
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genes in the mouse overcome these problems. The mouse genome is now extensively 
mapped with highly infomative microsatellite markers. The map is powerful enough such 
that genes involved in polygenic traits can be located. The studies of the mdx mouse have 
been very informative in the study of Duchenne Muscular Dystrophy (Cavanna et aL 
1988) and the role of dystrophin. Human lipoprotein transport genes have also either been 
added to the germ line of mice by transgenic techniques or knocked out by homologous 
recombination in embryonic stem cells, e.g. the human Apolipoprotein elII gene was 
introduced into transgenic mice, and this resulted in hypertriglyceridemia (Ito et ai., 
1990). Therefore, these transgenic mouse models of lipoprotein metabolism and 
atherosclerosis provide a valuable system for understanding disease pathology and great 
assistance in studies of diets, genes and drugs influencing atherosclerosis (Breslow, 
1993). 
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1.4 CANDIDATE GENES 
Lipoprotein disorders result from abnormal synthesis, processIng, or catabolism of 
plasma lipoprotein particles. Four types of abnormalities are found frequently in the 
population: increased LDL-cholesterollevels; decreased HDL-cholesterol levels, usually 
accompanied by increased triglyceride or VLDL levels~ increased concentrations of 
chylomicron remnants and IDL; and finally the presence in plasma of increased 
concentrations of an abnormal lipoprotein called Lipoprotein(a). One or more of these 
abnormalities is present in 50%-80% of myocardial infarction survivors (Breslow, 1993). 
In order to elucidate the genetic abnormalities underlying lipoprotein disorders associated 
with CHD susceptibility, candidate genes implicated in each of these abnormal 
lipoprotein phenotypes have been studied. Possible candidates include the genes encoding 
proteins involved in lipoprotein catabolism and transport, such as the apolipoprotein E 
variants (Utermann, 1987); variants at the apolipoprotein AIICIII! AIV gene cluster 
(Chamberlain et al., 1991) and Lipoprotein (a) (Armstrong et al., 1986). Other candidates 
are genes coding for lipoprotein receptors, and the lipolytic enzymes such as Lipoprotein 
Lipase and Hepatic Triglyceride Lipase (Galton & Ferns, 1989) (Table 1.4-1). However, 
there remain many more worthy of study as the search for the major aetiological genes for 
atherogenesis continues. Any new information about these genes might be applied to 
understand the genetic abnormalities underlying lipoprotein disorders. 
Page -t-t 
Chapter 1 
Table lA-I. Genetic factors in lipoprotein abnormalities 
Lipoprotein Profile 
t LDL cholesterol 
~ HDL cholesterol 
t Triglyceride (VLDL) 
t Remnants and IDL 
t Lipoprotein (a) 
Gene( s) implicated 
Apolipoprotein B 
Apolipoprotein E 
LD L receptor 
Lysosomal acid lipase 
Apolipoprotein AI 
Apolipoprotein CII 
Apolipoprotein CIII 
Lecithin:cholesterol acyltransferase 
Lipoprotein lipase 
Apolipoprotein E 
Apolipoprotein (a) 
t indicates increased; ~, decreased; VLDL, very-low-density lipoprotein; and IDL, 
intermediate-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein. Adapted from (Dammerman & Breslow, 1995). 
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1.4.1 Lipoprotein lipase 
Lipoprotein lipase (LPL) is the enzyme responsible for hydrolysis of triglyceride of 
primary lipoproteins; chylomicrons and VLDL. Hydrolysis of triglyceride converts 
primary lipoproteins to core and surface remnants, that transfer to HDL and LDL. 
In 1943 Hahn (Hahn, 1943) was the first to note that injection of heparin resulted in a 
rapid diminution or clearance of the alimentary lipaemia in dogs. Later studies (Anderson 
& Fawcett, 1950) revealed that heparin was capable of causing the release of this 
"clearing factor" into the plasma. This "clearing reaction" provided evidence for the 
presence of a heparin-releasable "clearing factor" with enzymatic properties and then this 
factor had been identified as lipoprotein lipase in the 1950's (EC 3.1.1.34) (Korn, 1955). 
1.4.1.1 Distribution and properties of LPL 
1.4. 1. 1 i Distribution 
LPL is synthesized predominantly by parenchymal cells (primarily in adipose tissue and 
muscle) and transported to the capillary endothelium of those tissues which either utilize 
fatty acids for the provision of energy via oxidation (heart, lung skeletal muscle) (Ehnholm 
et al., 1977; Gal et al., 1982; Twu et al., 1976) or resynthesis into triglyceride for storage 
(adipose tissue, mammary gland) (Clegg, 1981; Jansen et al., 1978). Milk is a relatively 
abundant source of the enzyme from which it can readily be purified (Egelrud & 
Olivecrona, 1972). The enzyme is also expressed by a variety of isolated cell types 
including granulosa cells (Brannon et al., 1978), macrophages and ~upffer cells (Bates et 
Page 46 
Chapter 1 
al., 1984; Khoo et al., 1981), which may account for much of the activity observed in lung 
tissue and vascular smooth muscle cells (Okabe et al., 1984; Vance et al .. 1982). 
1.4. 1. 1 ii Properties 
LPL is thought to be bound to capillary endothelial cells via an ionic interaction with 
surface glycosaminoglycan polymers such as heparan SUlphate, which allows the LPL to be 
exposed to the plasma (Olivecrona et al., 1977). By administration of intravenous heparin, 
LPL can be displaced from the endothelial surface into plasma where enzyme activity can 
be measured. LPL has a monomeric molecular mass of about 60,000 daltons on SDS-PAGE 
and between 41,700 daltons and 48,400 daltons on sedimentation equilibrium 
ultracentrifugation (Olivecrona et al., 1982) and it contains about eight percent 
carbohydrate (lverius & Ostlund-Lindqvist, 1976). The enzyme exhibits a pH optimum of 
8.0-8.5, and is inhibited by fatty acids. Apolipoprotein cn is the obligatory serum activator 
of LPL and very significantly enhances the LPL activity for lipoprotein substrates (LaRosa 
et al., 1970). LPL activity may be modulated additionally by apolipoprotein ClII (Wang et 
aI., 1985; Windler et al., 1980). The active enzyme is predominantly in the dimeric form 
(lverius & Ostlund-Lindqvist, 1976), which is less susceptible to degradation than the 
monomeric enzyme that loses activity and ultimately is degraded by the liver (Osborne et 
al., 1985; Wallinder et al., 1984). The active monomeric enzyme exists in equilibrium with 
the dimeric form, with heparan sulphate helping to maintain the enzyme as a dimer. The 
predominant substrate of this enzyme is the triglyceride component of chylomicrons and 
VLDL, while lecithin is hydrolyzed at a slower rate. 
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1.4.1.2 Structure and function of LPL gene 
1.4.1.2.i Structure 
The human LPL gene is approximately 30 kb in length and contains 10 exons. The gene is 
located on chromosome 8p22 (Sparkes et af., 1987). Two messenger RNAs have been 
identified in human adipose tissue of about 3350 and 3750 nucleotides (Wion et af., 1987) 
arising from alternative sites of 3' terminal polyadenylation. It has been suggested that the 
multiple mRNA species reported for LPL are generated by differential utilisation of these 
signals (Kirchgessner et af., 1987; Senda et af., 1987). A high degree of homology exists 
between the genes for LPL, hepatic lipase and pancreatic lipase. The three-dimensional 
structure of pancreatic lipase has been determined by X -ray crystallography and based on 
the homology between LPL and pancreatic lipase, a similar structure for LPL has been 
proposed (Kirchgessner et af., 1989; Kirchgessner et af., 1987), (Fig 1.4-1). 
Fig 1.4-1: 
Exon 2 345 6 7 8 9 10 
5'-- -- 3' LPL gene 
Legend to Fig 1.4-1: Schematic representation of the LPL gene. 
The size of these individual exons of the LPL gene is: exon 1,276 bp; 2. 161 bp: 3, 180 bp~ 
4,112 bp; 5,234 bp; 6, 243 bp; 7,121 bp; 8,183 bp; 9,102 bp; 10,1948 bp. 
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The cDNA for the human enzyme is encoded in exon 1-9 and forms a mature protein of 448 
amino acids with a molecular mass of 50,394 daltons (Enerback & Gimble, 1993). The first 
exon, size 276 bp, encodes the 5' untranslated region and the region coding for the signal 
peptide (Deeb & Peng, 1989); exon two, size 161 bp, includes the N-Linked glycosylation 
site necessary for enzymatic activity (Luo et ai., 1989; Semenkovich et ai., 1989)~ exon 
four, 112bp, codes for the interfacial lipid binding domain and contains the conserved 
lipolytic active site sequence (Wion et ai., 1987); exon five, 234bp, contains a highly 
conserved structural domain, which is the catalytic site of enzyme (Kirchgessner et ai., 
1987; Senda et ai., 1987; Wion et ai., 1987); exon six, 243bp, codes for the heparin binding 
domain (Enerback et ai., 1987; Senda et ai., 1987); exon eight, 183bp, contains the coding 
sequence for the second N-glycosylation site described (Luo et ai., 1989) and exon 10, size 
1948bp, which is significantly larger than other exons, contains the entire 3' -untranslated 
region (Deeb & Peng, 1989). The size of these individual exons is highly conserved 
(Enerback & Gimble, 1993). Regulatory elements have been identified 5' to the gene and 
the transcriptional start site is placed at 188 or 185 bp 5' to the ATG initiation codon (Deeb 
& Peng, 1989; Kirchgessner et ai., 1989; Oka et ai., 1990). 
1.4.1.2.ii Functional Domains 
To date only the locations of the heparin binding domain and the active site can be assigned 
to defined sequences within the enzyme's polypeptide backbone with any degree of 
certainty, although there have been various suggestions concerning the possible apoCII 
binding sites as well as the binding sites for fatty acids which will be mentioned. Significant 
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insight concerning the distribution of these domains within the lipoprotein lipase molecule 
has been provided by use of proteolytic cleavage techniques (Ben-Avram et al., 1986; Ben-
Zeev et al., 1987). A number of cysteine double bonds appear to be important in the tertiary 
structure of LPL and Asn
43 
is an important site for N-linked glycosylation and enzyme 
activation (Yang et al., 1989). 
It has been suggested (Enerback et al., 1987) that LPL has at least five functional sites: 
a), a catalytic site. The N-terminal domain ofLPL contains the active site of the enzyme as 
a 'catalytic triad' shielded by a surface loop (Dugi et al., 1995; Dugi et al., 1992; 
Faustinella et al., 1992). The catalytic Ser 132 forms part of the catalytic triad with Asp156 
and His 241 of human LPL (Brault et al., 1992; Wong et al., 1994); 
b), site for interaction with apoCII; The apoCII binding site on LPL remains unknown, 
although it is confined to the C-terminal end of the protein (Wong et al., 1991); 
c), sites for binding to lipid/water interfaces and fatty acids. Ser132 is located in one of two 
proposed lipid-binding domains, which extends from residue 126-135 (Persson et al., 
1989). Thls other lipid-binding domain is involved residues 245-253 (Hide et al., 1992). A 
domain that might bind free fatty acids has been suggested to involve residues 257 to 274, 
which is similar to a region of intracellular fatty acid binding proteins (Cooper et al., 1989; 
Enerback & Bjursell, 1989); 
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d), site for binding to heparan sulphate. The heparin binding site is an arginine-lysine-rich 
region in Exon 6, particularly involving residues 292-304, and possibly residues 279 to 282 
(Bengtsson-Olivecrona et al., 1986); 
e), site for subunit-subunit interation. 
1.4.1.2.iii Role of LPL in Lipoprotein Metabolism 
LPL bound to the endothelial cell, in conjunction with apoCII, is a major focal point in the 
processing of lipoproteins. The role of LPL in clearing plasma triglyceride can be 
demonstrated in both fasted and fed states (Taskinen & Nikkila, 1987). Other known effects 
of the enzyme include apolipoprotein and phospholipid exchange between VLDL and HDL 
(Nikkila et al., 1978), thereby affecting HDL3 conversion to HDL2 and LDL generation 
derived from VLDL catabolism (Brinton et al., 1989; Magill et al., 1982). The efficacy of 
triglyceride clearance is positively correlated with HDL2 concentrations (Brunzell & Austin, 
1989; Patsch et al., 1987). Activation of LPL requires apoC-II at the lipid interface, which 
is present in chylomicrons, VLDL, and HDL. Thus, LPL functioning at an important 
junction in lipoprotein metabolism, regulates the distribution of energy in the form of tree 
fatty acids and the distribution of cholesterol to LDL and HDL. 
Aside from its enzymatic actions, LPL has been postulated to be a receptor ligand for 
lipoprotein removal. Felts et al. (1975) first postulated that LPL was a signal for hepatic 
removal of chylomicron remnants. Beisiegel et al. (1991) renewed this concept by showing 
that LPL is a ligand for the LDL receptor-related protein (LRP). Several laboratories have 
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confirmed this and have shown that the carboxyl terminal region of LPL is required for LPL 
to bind to LRP (Nykjaer et al., 1994; Williams et al., 1994; Willnow et al., 1992). More 
recently, it was reported that LPL is also a ligand for the VLDL receptor (Argraves ef al., 
1995). 
1.4.1.3 Genetic mutations of the lipoprotein lipase 
The characterisation of defects in lipoprotein lipase at the molecular level can be of 
assistance in assigning structure-function relationships. Patients with LPL deficiency can be 
divided into three broad subgroups using combined measurements of LPL mass and 
activity. All classes have defective catalytic activity (Auwerx et al., 1992). The class I 
defect represents the complete absence of immunoreactive lipoprotein lipase homodimer in 
pre- and post-heparin plasma indicative of a lack of synthesis or secretion of the enzyme. 
The class II defect is characterised by almost no lipoprotein lipase protein in pre-heparin 
plasma and an increase following heparin consistent with a dysfunctional catalytic site, 
apoC-II binding or lipid binding domain. The Class III defects show considerable amounts 
of lipoprotein lipase in pre-heparin plasma with little increase following heparin 
administration. This defect would be consistent with a dysfunctional heparin binding site 
and the presence of the inactive monomer. 
The clinical syndrome associated with lactescent plasma in childhood was first described 
in 1932 by Burger and Grutz in a young male offspring of a consanguineous marriage 
(Burger & Grutz, 1932). In 1960 Havel and Gordon (1960) demonstrated defective 
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clearance of triglyceride-rich lipoproteins in this disorder related to diminished lipolytic 
activity in plasma after LV. heparin. Harlan et al. (1967) found decreased LPL activity in 
adipose tissue to be associated with the decrease in postheparin plasma lipolytic activity 
in two patients. In 1974, Krauss et al. (1974) separated the postheparin plasma activities 
into LPL and hepatic lipase and noticed very low levels of LPL with normal levels of 
hepatic lipase in this disease, many of these patients have been noted to have a 
catalytically defective enzyme protein (Brunzell et al., 1986). In 1989 the first of many 
lipoprotein lipase structural gene defects was described (Langlois et al., 1989), which 
were reported in a young male who had neither LPL activity nor LPL immunoreactive 
mass in postheparin plasma. He was found to be a compound hetl0zygote with two major 
gene re-arrangements, one a 6- kb deletion involving exons 3 to 5, the other a 2-kb gene 
duplication involving exon 6, this patient, as might be expected, also had no detectable 
mRNA for LPL in adipose tissue (Devlin et al., 1990). 
Until now, over 60 additional structural mutations in the LPL gene have been reported 
(Table 1.4-2). Forty four missense mutations have been described and thirty-six of them, 
. . 9 d 291 S . d . h k dl includlng two common mutatlOns: Asp -Asn an Asn - er, are aSSOCiate WIt mar e y 
reduced or absent LPL activity. Nine single base-pair substitutions causing stop codons, 
including one common mutation Ser447 -ter, have been noted. In addition to the tirst 
described patient with two major gene re-arrangements described above (a 6 kb deletion and 
a 2 kb duplication ), two deletions (one 3kb and the other 2-kb) both involving exon 9, and 
five smaller insertion-deletion defects have been noted. Finally, two acceptor splice-site 
1)'1(1" ~ ') (.. c""- --
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defects and two donor splice-site defects, involving introns 1, 2 and 6, have been reported 
(Pimstone et ai., 1996). 
The insertion-deletion mutations, the splice-site defects, and the nonsense mutations 
presumably lead to absent or truncated LPL protein with defective catalytic activity. How 
the missense mutations, with single amino acid substitutions, cause deficiency of LPL 
activity is more speculative. The exact mechanism concerning these single-residue 
mutations will depend on the determination of the actual structure of the LPL protein. 
(Faustinella et ai., 1991; Ma et ai., 1992). 
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Table 1.4-2: Mutations in Human lipoprotein lipase gene. 
Mutation 
Missense 
G280~A 
A317~T 
A383~G 
C385~T 
G460~C 
A662~G 
G670~A 
G680~A 
G715~A 
G721~A 
A722~G 
C725~G 
C770~G 
G781~A 
C795~G 
C804~G 
G818~A 
T836~C 
Amino acid Exon Protein defect 
substitution 
9 Asp ~Asn 
21 Asp ~Val 
Asn43~Ser 
H· 44 T IS ~ yr 
Val69~ Leu 
75 Arg -Ser 
Trp86~Arg 
His136~Arg 
Gly139 ~Ser 
Gly142~Glu 
Gl/54~Ser 
156 Asp ~Asn 
Asp156~Gly 
Pro157 ~Arg 
Serl72~Cys 
Ala176~Thr 
Asp180~Glu 
His183 ~Gln 
Gly188~Glu 
Ile194~Thr 
2 
2 
2 
2 
3 
3 
3 
4 
4 
4 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
LPL activity.J.-
LPL activity ~ 
inactive enzyme 
LPL activity ~ 
LPL activity.J.-
LPL activity ~ 
inactive enzyme 
LPL activity.J.-
LPL activity.J.-
LPL activity .J.-
LPL activity.J.-
LPL activity.J.-
LPL activity.J.-
LPL activity.J.-
LPL activity.J.-
LPL activity.J.-, 
abnormal heparin 
affinity 
inactive enzyme 
inactive enzyme 
inactive enzyme 
inactive enzyme 
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Reference 
(Lohse et aL 1991: 
Rouis et al., 1996) 
(Gagne et al., 1994) 
(Kobayashi et al .. 1994) 
(Gagne et al., 1994) 
Hayden MR et aI., 1993 
(Bruin et al., 1994) 
(Wilson et al., 1993) 
(Ishimura-Oka e/ al., 
1992~ Reina et al .. 1992) 
(Reina et al., 1992) 
(Bijvoet et al., 1994~ 
Hayden et al., 1993) 
(Ameis et al., 1991) 
(Hayden et al .. 1993) 
(Ma et al., 1992) 
(Faustinella et al .. 1991) 
(Bruin et al .. 1992) 
(Ma et al., 1993) 
(Beg et al., 1990) 
(Haubenwallner et al .. 
1993) 
(Tenkanen et al .. 1994) 
(Monsalve et al .. 1990) 
(Henderson et al .. 1991) 
P 'lO" ~~ "- ~\o,... __ 
Table 1.4-2 continued. 
Mutation Amino acid Exon Protein defect 
G839 ~A 
C867~G 
T869~G 
C875~T 
G884~A 
T901~A 
T985~A 
GI003~A 
C l007 ~G 
TIOlO~G 
TI032~A 
GI036~A 
T1039 ~C 
Tll12 ~C 
A1127~G 
C1348~G 
substitution 
GlyI95_Glu 
Asp204~Glu 
ILe205 ~Ser 
Pro207 ~Leu 
Gly21O_Asp 
Cys216 ~Ser 
Ileu225 ~ Thr 
Ar 243 H· g ~ IS 
243 Arg ~Cys 
Ser244~Thr 
Asp250~Asn 
Ser25 I ~Cys 
Leu252~Arg 
Ser259~Arg 
Ali61~Thr 
Tyl62~His 
Leu286~Pro 
Asn291~Ser 
Ala334~Thr 
Thr361~Thr 
Leu365~Val 
5 
5 
5 
5 
5 
5 
5 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
7 
7 
8 
8 
inactive enzyme 
inactive enzyme 
inactive enzyme 
inactive enzyme 
ND 
LPL activity-!,., 
destroys SS 
bridge 
LPL activity-!,. 
inactive enzyme 
LPL activity-!,. 
inactive enzyme 
LPL activity-!,. 
LPL activity-!,.. 
inactive enzyme 
ND 
inactive enzyme 
LPL activity-!,.. 
ND 
inactive enzyme 
LPL activity ~ 
LPL activity-!,.. 
ND 
LPL activity-!,.. 
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Reference 
(Hata et al., 1992) 
(Gotodaetal., 1991) 
(Reina et al., 1992) 
(Ma et al., 1991: 
Normand et af.. 1992) 
(Calandra et al., 1996) 
(Ma et al., 1992) 
(Henderson et al., 1993) 
(Gotoda et al., 199 L Ma 
et al., 1994)] 
(Hayden et al., 1993; Ma 
et al., 1994) 
(Hata et al., 1990) 
(Ma et al., 1992) 
(Hayden et al., 1993) 
(Hayden et al., 1993) 
(Hayden et al., 1993) 
(Hayden et al., 1993) 
(Lohse etal., 1991) 
(Hayden et al., 1993) 
(Ma et al., 1994: 
Pimstone et af.. 1996: 
Reymer et al., 1995) 
(Galton et af.. 1996, in 
press) 
(Kobayashi et af.. 1993) 
(Zhang et af.. 1997 10 
press) 
(Pepe el af.. 1994) 
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Table 1.4-2 continued. 
Mutation Amino acid Exon Protein defect Reference 
Nonsense 
T438~A 
G446~A 
C474~A 
C571~T 
C829~T 
G916 d I . e etlOn 
C1161~A 
G 1401 deletion 
C1595~G 
Frameshift 
substitution 
Glu410~Val 
418 Cys ~Tyr 
Tyr61~Ter 
Trp64~Ter 
Tyr73~Ter 
Glnl06~Ter 
Argl92~Ter 
221 Ala ~Ter 
239 Cys ~Ter 
262 Tyr ~Ter 
Ty?02 ~Ter 
Trp382~Ter 
Ser447 ~Ter 
C558 ~ T +GGGC Thr102 ins 
T 
A942 ~[T AAA T Gly229 ins 
ATT] A 
Splicesite defect 
G~C 
AG~AA 
First base of 
intron 1 
Last base of 
intron :2 
8 
9 
3 
3 
3 
3 
5 
5 
6 
6 
6 
8 
9 
3 
5 
LPL activity1', (Previato et aL 1994) 
alter the stability 
of the LPL dimer 
LPL activity-L- (Henderson et aL 1996) 
inactive enzyme (Gotoda et al., 1992) 
LPL activity-L- (Sprecher et al., 1992) 
LPL activity-L- (Wilson et al., 1993) 
LPL activity-L- (Emi et al., 1990) 
ND (Galton et al., 1996, III 
press) 
LPL activity-L- (Gotoda et al., 1992: 
Takagi et al., 1992) 
LPL activity-L- (Takagi et al., 1994) 
LPL activity-L-, (Funke et al., 1990: 
reduced heparin Rouis et al., 1996) 
affinity 
inactive enzyme (Calandra et al., 1996) 
inactive enzyme (Gotoda et al., 1991) 
LPL activitYB (Hata et al., 1990; 
Kobayashi et al., 1992)., 
inactive enzyme (Henderson et al., 1990) 
inactive enzyme (Hayden et al., 1993) 
inactive enzyme (Chimienti et al .. 1992) 
inactive enzyme (Hata et al .. 1990) 
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Table 1.4-2 continued. 
Mutation Amino acid Exon Protein defect Reference 
substitution 
G~A First base of noLPL (Gotoda et al., 1991) 
intron 2 messenger RNA 
eAG~AAG -3 acceptor of inactive enzyme (Holzi et al., 1994) 
intron 6 
DNA 
rearrangement 
2-kb duplication 6 null allele (Devlin et al., 1990) 
6-kb deletion 3,4,5 null allele (Langlois et al., 1989) 
. 614 617 4-bp deletIOn (A eTA 4 LPL activityJ.. (Ma et al., 1993) 
Asn120) 
3-kb deletion 9 null allele (Benlian et al., 1991) 
2.136-kb deletion 9 null allele (Benlian et al., 1995) 
ND, not determined; ~, no change; '1', decreased; Ins, insertion. 
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LP L gene mutation and dyslipideamia 
Complete LPL deficiency results in the inability to process TG-rich particles, leading to 
massive elevations in plasma TG levels, deposition of lipids in various body sites. and 
recurrent bouts of pancreatitis. This disorder, Familial Chylomicronemia, is however rare, 
usually manifesting in childhood and is an autosomal recessive disorder occurring at an 
estimated frequency of LPL deficiency of about one in one million (carrier frequency 1 in 
500) in most western populations (Fredrickson et af., 1978: Nikkila, 1983). The frequency 
of LPL deficiency is higher in French Canadians (Bergeron et af., 1992) than in the rest of 
the world. Consanguinity is fairly common in patients presenting with LPL deficiency 
suggesting that the abnormal alleles for the defective LPL activity are rare. Affected sibs on 
average having a ratio of 1 :4, and equal involvement of both sexes are observations 
consistent with an autosomal recessive pattern of inheritance (Brunzel!. 1989; Fredrickson 
et af., 1978; Nikkila, 1983). 
Severe hyperlipid$lIlia (total cholesterol> 7.8 mM or 300 mg/dl, triglycerides > 5.6 mM 
or 500 mg/dl ) arising from hyperchylomicronaemia (type I lipaemia) occurs in childhood 
and is rare, it is caused by an inherited mutation in LPL or, more rarely, in apolipoprotein 
CII (Fojo & Brewer. 1992). In adults with severe hypertriglyceridaemia, VLDL also 
accumulates, but this is almost always combined with excess chylomicrons (type V 
lipaemia) and is not due to absolute LPL or apolipoprotein ClI deficiencies. There may be 
partial LPL deficiency, other inherited disorders, or secondary conditions leading to o\'cr-
Chapter 1 
synthesis of triglycerides. More moderate hypertriglyceridaemia (type IV lipaemia) is 
often found in relatives of severely affected adults. 
Some cases of hypertriglyceridemia may have genetic determinants, they may arise from 
the inheritance of LPL gene variants with altered catalytic activities or binding properties 
that may predispose to hypertriglyceridemia. This is supported by reports using restriction 
fragment length polymorphisms(RFLPs) as LPL gene markers: the HindIII RFLP (intron 8) 
with primary hypertriglyceridemia, hypercholesterolemia, decreased HDL levels and 
premature CAD (Chamberlain et al., 1989; Gotoda et al., 1992; Thorn et aL 1990); and the 
PvuII RFLP(intron 6) with primary hypertriglyceridemia (Chamberlain et al., 1989). These 
studies suggest the possibility that relatively common mutations at the LPL gene locus, in 
linkage disequilibrium with these RFLPs, are involved in common forms of 
hypertriglyceridemia with low HDL levels and thus contribute to premature CAD. 
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1.4.2 Apolipoprotein ell 
Apolipoprotein cn (Apo ClI) is one of a family of apolipoproteins in which the gene 
characteristically has four exons and three introns (Das et al., 1987). The gene for Apo 
CII is on chromosome 19 (Humphries et al., 1984) and is closely linked to the genes for 
Apo E and Apo CI. The similarity of gene structure for Apo AI, Apo ClIl and Apo AIV, 
which are present on chromosome 11, with the apolipoprotein genes on chromosome 19 
suggests a common ancestry for all of these apolipoproteins (Luo et al., 1986). The 
human Apo CII gene spans 3.3 kb (Wei et al., 1985), while the mRNA as deduced from 
cDNA sequence is 494 nucleotides in length. Messenger RNA for apo CII is found in the 
liver and intestine in humans and other primates, and in HepG2 cells, a liver-cell line. 
Pre-pro-apo cn contains 101 amino acids and undergoes intracellular removal of 22 
amino acids, leaving the 79 amino acid apo CII, which contains no carbohydrate. Amino 
acids 56-79 of apo CII may contain the lipoprotein lipase binding and activation domain, 
whilst amino acids 44 to 51 appear to contain the site for binding of VLDL and 
chylomicrons (Wang, 1991). Apo CII is present on HDL and is transferred to nascent 
chylomicrons and VLDL to act as an activator for lipoprotein lipase (Havel et al., 1973). 
Apo ClIl has been suggested to inhibit the activation of LPL by apo CII (Cardin e/ al., 
1982; McConathy et al., 1992). Apo AIV has been implicated as a 'facilitator of transfer' 
of apo CII from HDL to the triglyceride-rich lipoproteins (Goldberg et al., 1990). 
Apo CII deficiency can be inherited as an autosomal recessive disorder. The disorder 
appears to be less common than LPL deficiency. Several molecular defects resulting in 
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Apo CII deficiency have been described, with effects such as translational frame shifts, 
premature termination, substitutions of functional regions and reduced translation 
(Breckenridge et ai., 1982; Brunzell, 1989; Miller et ai., 1981; Santamarina-Fojo, 1992). 
So far, no single amino acid substitution leading to loss of function has been reported. 
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1.4.3 Hepatic triglyceride lipase 
Hepatic lipase (HL) is a lipolytic enzyme involved in the metabolism of plasma 
lipoproteins. It is synthesized by hepatocytes, secreted and subsequently bound to liver 
endothelium from where it can be released into the circulation by heparin. The HL gene 
maps to human chromosome lSq21 (Sparkes et al., 1987), contains nine exons and eight 
introns, and encodes a mature protein of 476 amino acids, molecular weight 64,000 daltons 
(Datta et al., 1988). Comparison of the sequences indicates that LPL and HL are members 
of a gene family (Deeb & Peng, 1989); HL mRNA has 46 percent homology for LPL 
mRNA. This homology between LPL and HL might represent similar catalytic, heparin-
and lipid-binding sites, while the apo C-II binding site of LPL might represent a domain of 
difference. The major function of HL is to hydrolyse the phospholipids and triglycerides of 
HDLb recycling this lipoprotein or converting it to HDL3 and catabolizing IDL; it does not 
require apoCII for activation (Patsch et al., 1987). 
In the three kindreds studied, deficiencies of HL were associated with increased plasma 
cholesterol and triglycerides, abnormal lipoprotein profiles, and premature atherosclerosis 
(Auwerx et al., 1990; Carlson et al., 1986; Connelly et al., 1990; Demant et al., 1988). In 
contrast with LPL-deficient patients, HL-deficient patients have elevated plasma HDL and 
~VLDL and increased concentration of triglycerides and phospholipids in the LOL and 
HDL (Breckenridge et al., 1982). A substitution of Mee83 for Thr was observed in two of 
the families with complete deficiency of HL (Hegele et al., 1992). Since the subjects were 
heterozygous for the Mee83 mutation, it has been postulated that a second mutation may 
also exist in the other allele which causes a complete absence of enzymatic activity. 
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1.4.4 Apolipoprotein Al-Cill-AIV gene cluster 
1.4.4.1 Structure and function 
1.4.4.1.i Apolipoprotein AI gene 
Extensive epidemiological studies have suggested that HDL serves a protective function 
in atherogenesis, an inverse relationship existing between plasma cholesterol levels of 
HDL-C and coronary atherosclerosis (Gordon et at., 1977; Miller, 1979). Apolipoprotein 
(apo) AI is the major protein of HDL, comprising about 70% of the total HDL proteins. 
This gene is located on the long arm of chromosome 11 in the region designated q23 
(Bruns et at., 1984; Cheung et at., 1984; Law et at., 1984) and is in a cluster with two 
other apolipoprotein genes, ApoCIII and ApoAIV (Karathanasis, 1985; Karathanasis et 
at., 1983). The gene order is ApoAI, ApoCIII and ApoAIV, with the apoClII gene 
oriented in the opposite direction to the other two genes. 
The apoAI gene is 1863 bp long and contains four exons and three introns (Karathanasis 
et at., 1983), and is mainly transcribed in human liver and intestine (Zannis et at., 1985). 
The mRNA transcribed is 893 nucleotides long and encodes a 267 amino acid primary 
transcript that includes an 18 amino acid prepeptide, a 6 amino acid propeptide of unusual 
sequence that is cleaved extracellularly and a 243 amino acid mature protein (Breslow et 
at., 1982; Zannis et at., 1983). The protein sequence consists mainly of 22 amino acid 
amphipathic alpha helices separated by helix-breaking proline residues. Each 22 amino 
acid helix consists of two 11 amino acid subunits (Barker & Dayhoil 1977: Fitch. 1977: 
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McLachlin, 1977). The apoAI protein contains eight complete 22 amino acid amphipathic 
alpha helices and two 11 amino acid subunits. The nonpolar face of the amphipathic 
alpha helix is thought to bind lipid, whereas the polar face interacts with the aqueous 
environment (Segrest et al., 1974). The amphipathic alpha helices have some similarity to 
each other at the amino acid and nucleic acid levels and constitute imperfect repeats. 
Similar repeats have been found in other apolipoproteins and constitute a common feature 
of this class of lipid-binding proteins (Cheung & Chan, 1983; Li et aL 1988). 
In addition to its role as the major HDL structural protein, apoAI may serve other 
important functions. ApoAI can activate LCAT. This effect may be owing to its ability to 
bind phospholipid, particularly lecithin, which is the substrate for the LCA T reaction. 
ApoAI can also serve as an acceptor for free cholesterol derived from cells in tissue 
culture. This property of apoAI would allow it to playa role in cholesterol efflux from 
cells, which is presumably the first step in reverse cholesterol transport. ApoAI may also 
be the ligand for an HDL receptor controling the selective uptake of HDL cholesterol 
esters by the liver and by steroid-hormone producing tissues such as the adrenal gland 
(Oram et al., 1987). 
1.4.4. 1. ii Apolipoprofein Gil I gene 
Apolipoprotein CIII (apoCIII) is synthesized mainly in the liver and to a lesser degree in 
the intestine and is an 87,000 daltons glycoprotein (79 amino acids). which is a 
. "') kb 
component of chylomicrons. VLDL and HDL (Gotto et 01 .. 1986). ApoCIII gene IS -'.-
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long, containing four exons and three introns; it is situated 2.6 kb from the 3' end of the 
apoAI gene and 6.5 kb from the 5' end of the apoAIV gene (Karathanasis. 1985). The 
direction of transcription of the gene is opposite to that of the ApoAI and ApoAIV genes. 
The ApoCIII mRNA encodes a 99 amino acid protein which contains a 20 residue signal 
peptide. ApoCIII has been postulated to be a modulator of the receptor-mediated 
clearance of TG-rich lipoproteins (Quarfordt et al., 1982~ Windler & Havel, 1985). In 
vitro, ApoCIII has been shown to inhibit the activities of both lipoprotein lipase (Brown 
& Baginsky, 1972) and hepatic lipase (Kinnunen et ai., 1982). In recent studies, the 
human Apo CIII gene was introduced into transgenic mice and resulted in 
hypertriglyceridemia (Ito et al., 1990). 
1.4.4. 1. iii Apolipoprotein A/V gene 
Apo AIV is synthesized primarily in the intestine (Green et ai., 1980: Karathanasis et ai., 
1986; Karathanasis et al., 1986) and represents a major glycoprotein (46,000 daltons) 
constituent of newly secreted intestinal triglyceride-rich lipoproteins, i.e. chylomicrons 
(Green et al., 1979). The ApoAIV gene is 2.8 kb long and contains three exons and two 
introns and encodes a protein of 396 amino acids, including a 20-amino acid signal 
peptide (Elshourbagy et ai., 1986; Karathanasis et ai., 1986; Karathanasis et ai., 1986). 
The intron-exon arrangement of the Apo AIV gene is different from that of the other 
small apolipoprotein genes, all of which contain four exons and three introns 
(Karathanasis, 1985; Karathanasis et ai., 1983). The human Apo Al-CIII-AIV gene 
cluster Inaps on the long arm of chromosome 1 L region 11q13~qter (Cheung ('/ ai .. 
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1984). The function of apo AIV is not well understood. The possible involvement of apo 
AIV in the activation of LCAT (Steinmetz & Utermann, 1985), and the influence of the 
LeA T reaction on the distribution of apo AIV among different lipoproteins (Delmatre et 
al., 1983) indicate that apo AIV may also have an important role in the metabolism of 
HDL (Weinberg & Patton, 1990). Although several sildies showed the apo AIV 
variations have minimal impact on lipoprotein or apolipoprotein levels (Hanis et aL 
1991; Kaprio et al., 1991), the polymorphisms of Apo AIV continue to be of interest (von 
Eckardstein et al., 1992; Weinberg et al., 1990). However, it will not be further studied in 
this thesis. 
1.4.4.2 Genetic Mutations of ApoAI-CIII-AIV gene cluster 
1.4.4.2. i DNA variants 
ApoAI variants 
Deficiencies of apoAI are known to be associated with abnormalities in lipoprotein 
metabolism, as manifested by low serum HDL-C levels (Assmann & Smootz, 1978). Low 
~ M··k 
serum apoAI levels have been reported as an independent risk factors.~ AD ( aCleJ 0 et 
al., 1983). The apoAI structural variations detected thus far are rare in the population, 
occurring with a cumulative frequency of less than 1 in 1000 persons (von Eckardstein et 
al., 1990). The first of these was described in an extensive Italian kindred from the village 
of Limone suI Garda (Franceschini et al., 1980; Weisgraber et al., 1980): individuals in 
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this kindred have low levels of HDL-C that cosegregate with an electrophoretic variant of 
ApoAI, which has been called apoAI Milano (Arg l73 -Cys). 
Thirty-three naturally occurring ApoAI gene mutations have been described (Table 1.4-
3), mostly found in heterozygous sUbjects. Thirteen of these variants were associated with 
reduced plasma HDL-C and apoAI concentrations (including one associated with only 
decreased apoAI levels) and nine of them were associated with reduced LCAT activity. 
Nine of these mutations were inversion, deletion, insertion and nonsense mutations 
(Assmann et al., 1993), atherosclerosis risk associations were clearly demonstrated in six 
cases, the other three did not appear to increase coronary risk (Deeb et al., 1991; Funke et 
al., 1991). Twenty four mutations involving single amino acid substitutions were noted, 
only nine of the residues substituted were located between the N-terminus and residue 
100, the remaining fifteen being located between residue 100 and the C-terminus. Most of 
these substitutions appear benign in their effects on lipid metabolism and it has been 
noted (von Eckardstein et al., 1990) that they were predominantly localized in areas that 
were little conserved during mammalian evolution and may thus represent areas of lesser 
importance for apoAI function. 
No doubt as additional variants of apoAI become available, more information will be 
gained with respect to the structure-function relationships of apoAI. As the lipid binding 
characteristics of apo AI are intimately connected with LCAT activation, an 
understanding of the former may well be required before conclusions can be drawn about 
the latter (De Loof et al., 1987). 
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Table l.4-3: Characteristics of previously described ApoAI variants 
Amino Acid HDL Apo- Apo- LCAT Clinical Reference 
Defect -C AI ClII Findings 
Reduced 
HDL 
AI-ClII A~ Planar (Norum et al., 1982) 
. . Xanthomas, InverSIon 
Corneal 
clouding, CHD 
AI-CIlI-AIV A~ Corneal (Schaefer et al., 1985) 
deletion clouding, CHD 
Codon3-5, C NR Planar (Schmitz et al., 1990) 
insertion, Xanthomas, 
frame shift, Corneal 
stop codon 33 clouding,CHD 
84 A~ CHD (Matsunaga et al., GIn -stop 
Tsukuba Xanthomas 1991) 
L 107 0 NR MB Premature (Tilly-Kiesi et al., ys -
Helsinki AB CHDin 1995) 
Kindred 
146 Glu -Arg 160 NR M~A~ Arcus senilis (Deeb et al., 1991) 
Seattle 
Thr202, G M~A~ Corneal (Funke et al., 1991) 
deletion,fram opacities 
eshift, stop 
codon 230 
Absence of NR ND Xanthelasmata, 
(Ng et al., 1994; Ng et 
ApoAI Gln[- Premature al., 1995) 
2]Ter CHD 
26 NR ND Systemic (Nichols et aL 1988) Gly -Arg 
Iowa 
Amy loidosis 
Glu12o-Asp NR NR 
Premature (Zannis et aL 1982) 
Tangier 
CHD 
Disease 
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TablelA-3 continued. 
Amino Acid HDL Apo- Apo- LCAT Clinical Reference 
Defect -c AI CIlI Findings 
P l5S A ro - rg t t NR At None (von Eckardstein et al .. 
1989) 
173 Arg -Cys ~ ~ M~A~ None (Franceschini et al .. 
(Milano) 1980) 
Normal 
HDL 
Pr03 -His ND NR ND None (Menzel et al .. 1984) 
Munster 
3 Pro -Arg NR ND None (von Eckardstein et al., 
1989) 
4 Pro -Arg ND NR ND None (von Eckardstein et al., 
1989) 
10 Arg -Leu NR ND None (Ladias et ai., 1990) 
Baltimore 
13 Asp -Tyr NR ND None (Takadaetal .. 1991) 
Yame 
14 ND ND NR ND ND (von Eckardstein et al., Glu -Val 
1990) 
60 Leu -Arg ND ND NR ND None (Soutar et ai .. 1992) 
89 ND ND NR ND ND (von Eckardstein et al .. Asp -Glu 
1990) 
103 ND NR ND None (von Eckardstein et ai., Asp -Asn 1989) 
L 107 0 ND NR A~ None (RaIl et ai., 1984) ys -
Marburg 
Lysl07_Met ND ND NR ND ND (von Eckardstein e1 al .. 1990) 
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Table 1.4-3 continued. 
Amino Acid HDL Apo Apo LCAT Clinical Reference 
Defect -C AI CIlI Findings 
GI 110 L u - ys B B NR AB None (Takada et al .. 1990) 
Fukuoka 
136 Glu -Lys NR AB None (Schamaun et at.. 
1983) 
Glul39_Gly ND ND NR ND ND (von Eckardstein et at.. 
1990) 
143 Pro -Arg NR A~ None (Utermann et al .. 
Giessen 1984) 
GIU147 -Val ND ND NR ND ND (von Eckardstein et al., 
1990) 
Ala158 -Glu ND ND NR ND NR (Mahley et al .. 1984) 
Glul69-Gln ND ND NR ND NR (von Eckardstein et al., 
1990) 
177 H· Arg - IS ND ND NR ND NR (Jabs et al., 1986) 
198 NR AB None (von Eckardstein et al., Glu -Lys 
1990) 
213 Asp -Gly ND ND NR ND NR (Mahley et al., 1984) 
M indicates mass; A, activity; ND, not determined; NR, not recorded; B. no change: 
~, decreased. 
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Apo elll variants 
To date, the role of genetic variation in ApoCIII for the regulation of lipid metabolism is 
not well understood. ApoCIII deficiency has been found only in association with 
deficiency of ApoAI (Karathanasis et al., 1987). Hence, the contribution of the lack of 
apoCIII to HDL deficiency and atherosclerosis in these patients is not known. Moreover, 
four structural variants of apoCIII have been described. One variant, designated apoCIII-
3, is caused by over-sialylation (Jabs & Assmann, 1987); in the second variant, apoCIII 
(Thr74-Ala), the 'attachment site' threonine was lost (Maeda et al., 1987); the third one, 
apoCIII (Asp45-Asn), resulted in the concentrations of the variant allele products were 
increased two-fold in VLDL and slightly decreased both in LDL and in HDL relative to 
the concentration of the normal allele products, the disproportional distribution of the 
variant apoCIII isoproteins may indirectly indicates some impact on lipoprotein 
metabolism (Luttmann et al., 1994). These three apoCIII variants are not associated with 
dyslipidemia. The fourth variant, apoCIII (Lys58-Glu), however, was identified in two 
hyperalphalipoproteinemic woman with low plasma concentrations of apoCIII and 
atypically large HDL (von Eckardstein et al., 1991). 
In recent studies, the human Apo CIII gene was introduced into transgenic mice (Ito et 
al., 1990). Elevated apoCIII levels cause displacement of apoE from VLDL particles and 
decreased VLDL removal from plasma (Aalto-Setala et al., 1992), triglyceride levels 
were proportional to human ApoCIII gene expression, and as little as 500/0 extra ApoCIII 
caused demonstrable hypertriglyceridemia and even resulted III severe 
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hypertriglycerideamia with fasting triglyceride levels exceeding 950mg/dl or 10.7 mM. 
This work suggests that ApoCIII gene overexpression on either a primary or secondary 
basis may underly some types of hypertriglyceridemia. It remains to be proven whether 
increased apoCIII is a common cause of hyperlipidemia in humans. 
1.4.4.2.ii DNA polymorphisms 
The genes for Apo AI, ApoCIII and ApoAIV are in a cluster, spanning 12kb of DNA. 
More than 12 common RFLPs have been detected within this gene cluster~ RFLPs were 
detected with the enzymes Xmn I, Pst I, Sst I, Msp I, Pvu II, Apa I, Xba I and Taq 1. All of 
the polymorphisms in the ApoAI-CIII-AIV gene cluster are caused by sequence changes 
outside the coding regions of the genes and/or in promoter region, and therefore do not in 
themselves, alter the amino acid sequences of any of the proteins (Dammerman et al., 
1993; Humphries, 1988). 
DNA polymorphisms and Hyperlipidaemia 
It is most likely that the mutations associated with these RFLPs effect the level of 
expression or function of one of the apolipoproteins in the cluster. At the present time, the 
mutation or mutations in this gene cluster causing hypertriglyceridaemia are unknown. Of 
the three genes known to be within this region, the gene for ApoCIII would appear to be 
the most likely candidate for being involved in causing hypertriglyceridaemia, from 
studies carried out to date. 
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In 1983, the first study described an Sst I RFLP, C3175_G substitution in the 3' 
untranslated region of the apoCIlI gene. It was reported that the rare allele (designated 
S2) was present in a higher frequency in a group of patients with hypertriglyceridaemia 
(40%) than in the normal population (5%) (Rees et al., 1983), and could be involved in 
the development of coronary artery disease (Ferns et al., 1985). Similar results have been 
reported by many other groups (Hayden et al., 1987; Kessling et al., 1985; Shoulders et 
al., 1991; Tybjaerg-Hansen et al., 1993). However, the variant SstI site does not appear to 
alter the function of this protein or mRNA (Karathanasis et al., 1985). 
In the ApoClII promoter region, the polymorphic sites T-625 -deletion, C-482 -T, and Sst I 
RFLP in 3' Apo ClIl gene were observed as haplotypes (wildtype designated 1; mutant, 
2, for each site). Two Apo ClIl promoter/SstI haplotypes were observed to influence risk 
status for hypertriglyceridaemia. Carriers of the 2.1.1 haplotype were at decreased risk for 
hypertriglyceridaemia, with carriers of the 2.2.2 haplotype at increased risk (Dammerman 
et al., 1993); indicating that these haplotypes affect susceptibility to severe 
hypertriglyceridaemia. 
The C1100_T polymorphism in the ApoClIl gene is a new polymorphism (Xu et al .. 1994) 
which has been detected at a higher frequency in patients with familial combined 
hyperlipidaemia (FCH) compared to healthy controls. FCH is a dominantly inherited 
disorder with a frequency possibly as high as 1-2% that may cause at least 100/0 of 
premature coronary disease under the age of 60. Although defects in the ApoAI-CIII-AIV 
gene cluster are not the primary cause of FCH, this cluster has a specific modifying effect 
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on plasma triglyceride and LDL-cholesterollevels (Dallinga-Thie et al., 1996; Marcil et 
al., 1996; Peacock et al., 1994). 
Other studies have also reported an increased frequency of the Msp I RFLP (located in the 
third intron of the apoAI gene) in patients with hypertriglyceridaemia (Frossard et af., 
1987); and an increased frequency of the Xmn I polymorphism (2.5kb to the 5' end of the 
apoAI gene) in patients with hypertriglyceridaemia (Kessling et af., 1985) and familial 
combined hyperlipidaemia (Tybjaerg-Hansen et al., 1993). 
DNA polymorphisms and Coronary Atherosclerosis 
Several laboratories have reported that the allele frequencies of some of the above RFLPs 
in the Apo AI-CIII-AIV gene region are also altered in patients with CAD compared to 
groups of healthy individuals. This gives a clue that variation in this gene region is, in 
some way, involved in predisposing individuals to develop atherosclerosis, in addition to 
the involvement in the dyslipidaemia. 
Another possible mechanism for mutations in this gene cluster predisposing to CAD is 
through an effect on HDL levels. There has been a report of a population association 
between low levels of HDL and the Pst I RFLP (immediately 3' of the ApoAI gene) in 
patients with coronary artery disease (Ordovas et al., 1986). This suggests that a mutation 
in linkage disequilibrium with the Pst! polymorphic site, is predisposing individuals to 
develop CAD, by lowering levels of serum apoAI and HDL. 
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The G to A mutation at position -7Sbp in the promoter region of the apoAI gene does not 
directly affect HDL levels (Dallinga-Thie et ai., 1996; Needham et ai., 1994). Therefore, 
the increased HDL-C levels reported in other populations (Pagani et ai., 1990) must 
reflect linkage disequilibrium between the A allele and a putative HDL-raising allele. For 
the former, There were no evidence for association between the A allele and high HDL 
levels, it may indicate that this putative gene must occur at a low frequency in the 
population studied (Barre et ai., 1994). 
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CHAPTER 2 
AIMS OF THE THESIS 
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Genetic factors may contribute a major part to the aetiology of CHD. Many metabolic 
defects have been demonstrated in CHD, however, the distinction between inherited defects 
and defects secondary to metabolic abnormalities can be difficult to elucidate. The aims of 
my thesis are to analyse the possible role of several candidate genes in the genetic 
susceptibility to dyslipidamia and CHD. 
In particular, the aims are: 
(1) to investigate if some of the described genetic variants in the LPL gene (Asp9_Asn, 
Asn
29I
_Ser, Ser
447
_Ter mutations and Hind III RFLP) and the ApoAI-CIII-AIV gene cluster 
(MspI, XmnI, Pst! and SstI RFLPs) that have been related to the development of premature 
atherosclerosis are found at altered frequencies in subjects with dyslipidaemia/low HDL and 
CAD in a German population of patients with CAD and controls. 
(2) to determine if these genetic determinants that have been postulated to contribute to the 
atherogenic dyslipidaemia of raised plasma triglycerides/low HDL as described above differ 
between ethnic groups in patients with dyslipidaemia and/or CAD and to assess the relative 
incidence of each of these mutations in the occurrence of dyslipidaemia and CAD III 
different ethnic groups. 
(3) to explore the gene encoding a critical enzyme, lipoprotein lipase, for the clearance of 
plasma triglycerides in subjects with diabetes m, obesity and severe hypertriglyceridaemia; 
to see if mutations occur and their frequencies at the LPL locus. The studies were conducted 
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In a French group of severe diabetic lipaemia and a Chinese group of seyere 
hypertriglyceridemia by direct DNA sequencing; 
(4) to search for possible genetic markers or aetiological mutations in the ApoAI-CIII-AIV 
gene cluster that may influence plasma lipid levels and premature coronary atherosclerosis. 
A Finnish kindred with premature CHD was used for the study. 
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MATERIALS AND METHODS 
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3.1 GENERAL REAGENTS 
3.1.1 Chemicals and solutions 
All chemicals are ""Analar" grade and were purchased from British Drug Houses (BDH) 
Ltd., U.K., with the exception of: 
Agarose, bromophenol blue, xylene cyanole FF, DTT, BSA, glycerol, ethidium bromide, 
spermidine and mineral oil (light) which were purchased from Sigma Chemical 
Corporation, U.S.A. Ethanol (99.40/0) was purchased from James Burrows Ltd, London, 
U.K. 
3.1.2 DNA modifying enzymes 
All DNA modifying enzymes (including restriction endonucleases) were obtained from 
Gibco-Life Sciences, U.K. or NBL, U. K. Taq DNA polymerase was obtained from Gibco-
Life Sciences. 
3.1.3 Radioisotopes 
a_32p dCTP 800 Ci/m~) 0 mCi/ml in a stabilised aqueous solution was purchased from 
Amersham International, U. K. a_35S dATP 3000 Ci/mmol, 10 mCi/ml in a stabilised 
aqueous solution were purchased from ICN-Flow, U.S.A. 
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3.1.4 Nucleic acids and markers 
dATP, dCTP, dGTP, dTTP (lOOmM stabilised aqueous solutions), and lkb ladder markers 
were obtained from Gibco-Life Sciences, U.K. 
3.1.5 Electrophoretic materials 
Agarose were obtained from the Sigma Chemical Corporation, USA. Acrylamide solution. 
including bis-acrylamide, urea, TEMED and ammonium persulfate were purchased from 
National Diagnostics, U. S. A. 
3.1.6 Special reagent kits 
Sequenase ™ 2.0 DNA sequencing kits and Sequenase PCR product sequencing kits were 
obtained from Amersham Life Sciences, UK. Nucleon II kits were purchased from Scotlabs 
Ltd, UK. Dynabeads M-280 Streptavidin were purchased from Dynal A.S, Norway. 
3.2 GENERAL METHODS 
This section details the general methods for the molecular biological techniques that are part 
of the work presented in this thesis. The more specialised methodologies are described in 
the chapter of relevance. 
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3.2.1 Preparation of genomic DNA from human blood leukocytes 
Genomic DNA was isolated from fresh or frozen EDTA whole blood cells using a Nucleon 
II kit ( Scotlabs Ltd, UK) and resuspended in IxTE buffer (lOmM Tris-HCL. 1mM 
EDTANa2' pH 8.0) and stored at -20°C. 
3.2.2 Quantitation of genomic DNA 
DNA samples were quantified in one of two ways. 
3.2.2.i Ultraviolet Spectrophotometry 
Dilutions of the stock DNA samples were placed in ultraviolet (UV) light transparent 
Quartz cuvettes within an LKB Ultra Spec II spectrophotometer. TE was used as a blank 
and absorption values were obtained at 260 and 280nm. The ratio of the absorbance at these 
two wavelengths for each sample was calculated and samples demonstrating a 260/280 ratio 
of <1.8 were subjected to further purification. The concentration of each DNA sample was 
calculated using an absorption coefficient of IOD26o unit = 50/-lg/ml of double stranded 
DNA. 
3.2.2.ii Direct comparison to known standards in agarose gels 
This method was used when there was a possibility that the samples contained significant 
amounts of RNA or other contaminating chemicals which may interfere with the UV 
spectrophotometric method and also allowed the operator to assess the physical state of the 
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DNA sample at the same time. A small, known volume of the DNA sample (1-5111) was 
mixed with gel loading buffer and loaded into a well of an agarose mini-gel containing 
O.5J.lg/ml ethidium bromide. Three other wells were loaded with 1 J.lg of molecular \veight 
ladder, respectively. Electrophoresis was then allowed to occur until all DNA fragments 
were suitably separated, when the gel was visualised and photographed on a UV 
transilluminator. The fluorescence intensity of the bands in each DNA sample were then 
compared to those in the DNA ladder lane. In this way it was possible to estimate the 
quantity and size of any unknown DNA sample fairly accurately. 
3.2.3 Polymerase Chain Reaction (PCR) Amplification 
The polymerase chain reaction (peR) is a technique for the in vitro amplification of specific 
DNA sequences by the simultaneous primer extension of complementary strands of DNA 
(Mullis & Faloona, 1987; Saiki et ai., 1988). The reaction requires template DNA, synthetic 
oligonucleotide primers, deoxynucleotide triphosphates to provide both energy and 
nucleotides for DNA synthesis, DNA polymerase, and reaction buffer containing 
magnesium ions. It involves repeated cycles of denaturation of the double-stranded DNA, 
annealing of the primers to their complimentary sequences and extension of the annealed 
primers with DNA polymerase. The primers are designed to anneal to opposite strands of 
the DNA so that DNA synthesis by the polymerase proceeds across the region between the 
primers. The resultant copies are complementary and are capable of binding primers. they 
will themselves act as templates for further amplification. Thus successive cycles will 
theoretically double the amount of target DNA synthesised in the previous cycle. This 
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results in the exponential amplification of the specific target segment, approximately 2n , 
where n is the number of cycles of amplification completed. 
3.2.3.i Oligonucleotides: 
The design of primers for polymerase chain reaction is as follows: (1) Oligonucleotide 
primers are generally synthesised in the range of 18-30 bases in length. (2) There should be 
similar G+C content with a random base distribution in the primer sequences, (3) Primer 
should have minimal secondary structure (i.e. self-complementary) and low complementary 
to each other, particularly in the 3' region, thus avoiding primer-dimer artefacts. 
Primers were synthesized (IGI Ltd, UK) by standard ~-cyanoethyl phosphoramidite 
chemistry and purified on a Sephadex 0-25 column. The OD260 of each fraction was 
measured and the peak fraction pooled. To calculate the oligonucleotide concentration, the 
molar extinction coefficient (Em) was determined as follows: 
Equation 3.1: Em: (A x 16) + (G x 12) + (C x 7) + (T x 9.6); 
and the concentration with the formula: 
Equation 3.2: Conc. ul: (dilution x A260) x 1000 
(A x 16) + (0 x 12) + (C x 7) + (T x 9.6) 
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Oligonucletides were stored as 10uM (in lxTE buffer) working solutions. The primer 
sequences were derived from published data or were developed using DNA star PRIMER 
software. 
3.2.3.ii. Amplification of Genomic DNA 
All PCR reactions were performed on a Perkin-Elmer Cetus 480 thermal cycler. All PCRs 
were performed in a total volume of 25 ul using the same basic reaction condition as 
follows: 
The Reaction Mix: 
1) lOx PCR buffer: 
2) 10 x dNTPs: 
100 mM Tris-HCL (PH 8.3)~ 
500 mMKCL~ 
0.1 % gelatin, 
5M MgCl2 was added to a final [Mg2+] ofO.5mM to 5.0mM 
as appropriate 
2mmoi/L each of dA TP, dCTP, dGTP and dTTP~ 
3) 0.5 umol/L each primer (forward and reverse) 
4) Genomic DNA (0.2-0.5ug) 
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5) 2.5 U Taq DNA polymerase (GIBCO BRL). 
The mixture was overlaid with mineral oil. All tubes, tips and buffers were autoclaved and 
the reaction mixture was UV irradiated before addition of genomic DNA and Taq DNA 
polymerase to minize contamination (K wok & Higuchi, 1989). Blank controls containing 
no genomic DNA were run with each set of amplifications. 
The PCR Cycling Programmes: 
1) Denaturing File 5 mins 
2) Soak File whilst enzyme added 
3) Cycling program 1 min (denaturation) 
(32-35cycles) 48-630C I min (annealing) 
1 min (extension) 
4) Final extension 10 mins 
Several of the variables such as pnmer concentration, magneslUm IOn concentration, 
annealing temperature, duration of each temperature step and number of cycles, can be 
adjusted between the values stated to optimise the reaction efficiency. Following 
amplification, aliquots of the reaction were analysed in agarose gels as described following 
section -3.2.6.i. 
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Preventing contamination: 
peR is efficient and has the potential to produce 1 x 106 copies from a single copy of target 
DNA, there is a possibility of a contaminating DNA producing a false-positive 
amplification (Kwok et al., 1990). Under normal conditions the greatest risk comes from 
the introduction of previously amplified DNA into the new reaction. The following steps 
are taken to avoid contamination: 
(1) An area was designated for preparing peR reactions, which was located away from 
areas assigned for DNA extraction, and the handing ofPCR products. 
(2) Separate pipettes were designated solely for the preparation of PCR reagents, reactions 
and products. 
(3) Reagents and primers were aliquoted. 
(4) To minimise the handing of the solutions and reduce the number of pipetting steps, a 
master mix was prepared when several identical amplification reactions were to be 
performed. 
(5) at least one water control (no DNA) was run with every peR amplification to test for the 
presence of contamination. 
(6) Pipette tips, tubes and regents were sterilised by autoclaving. 
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3.2.4 Restriction enzyme digestion 
Restriction endonucleases are enzymes which cut DNA at a specific recognition sequence. 
They are used in restriction fragment length polymorphism (RFLP) analysis. 
DNA samples were restricted according to the enzyme manufacturers instructions with a 
few modifications. The restriction endonucleases used in the work were purchased from 
GIBCO-BRL and stored at -20°C. These restriction enzymes were generally supplied at a 
concentration of 5 to 10 units per ul. Unit definition varied according to the manufacturers, 
but was usually that enzyme activity which cleaved I ug DNA in 60 min at 37°C (or at 
65°C for TaqI) in total volume of 25 ul in the buffer conditions which are recommended by 
the manufacturers. For long incubation, a stabilizer such as: nuclease-free bovine serum 
albumin (BSA) was added at a final concentration of 100 ug/ml, usually 2.5ul of spermidine 
(lOOmM) was also added. Subsequently, the samples were electrophoresed in 1 x TBE 
buffer (89 mMTris-borate, 2mM EDTANa2 pH 8.3) in 2-30/0 agarose gels at 10V/cm for 1-
1.5 hrs. DNA was visualized by staining the gels with ethidium bromide (0.5 ug/ml) and 
transillumination with UV light (Fig 3.1). 
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Figure 3.1 
a b c d e f 
Legend to figure 3.1: 
Electrophoretic patterns of ApoAl gene PCR product before and after digestion with MspI. 
Lane a) negative control, b) 1kb ladder maker, c) ApoAl PCR fragment, d) digested 
homozygote, e) undigested homozygote, f) digested heterozygote. 
3.2.5 DNA Sequencing 
DNA sequencing was by the chain termination method using dideoxynucleotide analogues 
(Sanger & Coulson, 1978; Sanger et ai., 1977). All such sequencing was performed 
according to the manufacturer's instructions (United States Biochemical) using the 
SequenaseTM Version 2.0 DNA Sequencing Kit. 
3.2.5 i: Amplification of LPL or ApoAI gene exons (ref. 3.2.3.ii) 
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3.2.5 ii: Sequencing of peR Products 
PCR products were sequenced using the dideoxy chain termination method. The PCR 
products were pretreated by one of two methods. 
(1), peR products were incubated with streptavidin coated magnetic beads (Dynal Ltd. 
UK). After washing, the bound PCR product was denatured and the biotinylated strand 
recovered. The bound single stranded product was then sequenced using the Sequenase II 
kit (Amersham Life Sciences, UK) and the non biotinylated primer, 
(2), The peR product was sequenced directly after treatment with Exonuclease I and 
Shrimp Alkaline Phosphatase (Sequenase peR product sequencing kit, Amersham Life 
Sciences, UK). 
3.2.6 Gel electrophoresis 
DNAs were size fractionated by gel electrophoresis through either agarose or acrylamide 
matrices. 
3.2.6.i: Agarose electrophoresis: 
peR products or enzyme-digested products were resolved on agarose gels. Agarose at the 
appropriate concentration, depending on the size of the DNA fragments to be separated, was 
boiled in the appropriate volume of 1 xTBE, allowed to cool below 50°C and poured into a 
horizontal gel tray into which a comb with the relevant number and size of teeth had already 
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been inserted. The gel was allowed to set at room temperature for at least 30min. 
Approximately 0.2 vols of loading buffer (O.2S% bromophenol blue, 0.2S% xylene cyanole 
FF, 300/0 glycerol, 20mM Na2EDTA, pH8.0) was added to the DNA samples, which were 
then loaded into the wells in the gel. 1 ug of 1 Kb ladder maker was run in one lane. DNAs 
were visualised by the addition of SOJ.lgfml ethidium bromide to buffers or the gels 
immediately prior to pouring. After electrophoresis (l OV fcm, 1-1.S hrs), the gels were 
subjected to UV transillumination and photographed with Polaroid film. 
3.2.6.ii: Acrylamide electrophoresis 
DNA sequencing reaction products were resolved on 6 % acrylamide (19: 1), 7M urea gels 
in 1 x glycerol tolerant gel buffer. The gel mix (70ml) was poured between taped gel plates 
(one was silanised), after the addition of ammonium persulphate (600ul of 100/0 wfv 
solution) and TEMED (30 ul). After the gels had set they were prewarmed under current to 
SO°C prior to the loading of samples. The wells were rinsed with buffer to remove excess 
urea immediately before sample loading. Samples were electrophoresed at SOV fcm for 2-3 
hrs. Subsequent to electrophoresis, the silanised plate was removed and the gel ( attached to 
the non-silanised plate ) was immersed in 100/0 methanol, 10% acetic acid to fix for 30 
mins-l hr. The gels were transferred to 3 MM whatman paper and dried at 80°C for 2-3 hrs 
under vacuum prior to autoradiography. 
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3.2.7 Autoradiography 
Sequencing gels were visualised by autoradiography. The dry gels were placed in film 
cassettes, with or without intensification screens, with their DNA side facing up and were 
overlaid in a dark room by sheets of Hyperfilm MP (Amersham Life Sciences. UK). The 
cassettes were allowed to expose for between 24 and 72 hours at room temperature. The 
films were developed in an automatic X-ray film developer (X-Ograph X4) and the 
sequence read off the developed autoradiograph. 
3.2.8 Single-Strand Conformation Polymorph isms (SSCP) 
Single-Strand Conformation Polymorphisms (SSCP) analysis (Orita et al., 1989) is a 
method for the detection of sequence variations. SSCP is based on the principle that single 
stranded DNA of different sequences exhibit different mobilities when electrophoresed in 
non-denaturing polyacrylamide gels. To perform SSCP analysis, the DNA fragment of 
interest is amplified using PCR. The double stranded DNA is denatured by heating it to 
9S0C in formamide dye, the sample is then loaded onto a non-denaturing polyacrylamide 
gel (60/0 to I 00/0) and electrophoresed in 1 xTBE buffer. After electrophoresis the gel is 
stained with silver nitrate or, if using Hot-PCR, transferred to 3MM whatman paper and 
dried at 80°C for 2-3 hour under vacuum prior to autoradiography. The mutations in the 
DNA appear as shifts in one or more of the single strand DNA bands. as compared to the 
wild-type sequence.The schematic illustration of the SSCP technique is shown in fig 3.2. 
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Legend to Figure 3.2: Principle of SSCP analysis. The star (*) indicates the point 
mutation. 
3.2.9 Solid-Phase Minisequencing Assay 
Point mutations in amplified DNA were detected by the solid-phase mini sequencing assay 
(Syvanen et at., 1990; Syvanen et at., 1991), which is based on primer-guided nucleotide 
incorporation by a DNA polymerase. The method gives the results as numeric values that 
reflect directly the proportions of two sequences present in the original sample. The 
principle of the technique is illustrated in figure 3-3. 
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Legend to Figure 3-3: Principle of the solid-phase mini sequencing method. 
peR is carried out with one biotinylated primer, and the biotinylated PCR product is 
captured into a streptavidin-coated microtiter well and denatured. In the minisequencing 
reaction a primer hybridizing adjacent to the site of the mutation is elongated with a 3H_ 
labelled test nucleotide by Taq DNA polymerase. The primer is released and the 
incorporated label is measured in a liquid scintillation counter. 
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3.2.10 Statistical Analysis 
The data were entered into a SPSS database system using double entry and validation 
routines. Analyses were performed using SPSS for Windows 6.1 statistical packages. A 
level of p < 0.05 was taken as being statistically significant throughout these studies. 
The frequencies of polymorphic sites were estimated as both genotypes and alleles in cases 
and controls. The main statistical analysis are follows: 
(1) The Chi-squared (X2) test 
Genotype distributions between the study groups and after biochemical traits were divided 
into tertiles were assessed using this analysis. Differences in proportions or frequencies 
were evaluated by this test where samples sizes were sufficient to allow this. 
(2) Fisher's exact test 
An exact distribution method is used when the sample sizes had expected values <= 5 or 
observed frequency 0 or 1. 
(3) One-way Anova and Analysis of Covariance 
Variations in the biochemical traits with respect to genotypes were analyzed by performing 
these analyses. The association of each of the environmental cardiovascular risk factors 
with genotypes were tested by univariate analysis amongst the groups. If any associations 
were found to be significant, multivariate analysis was performed to assess their 
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independence from other variables. Probabilities were adjusted for the number of 
comparisons made. 
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CHAPTER 4 
DIABETIC LIPAEMIA AND MUTATIONS AT THE LIPOPROTEIN 
LIPASE (LPL) GENE LOCUS IN FRENCH SUBJECTS 
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4.1 INTRODUCTION 
Untreated non-insulin dependent diabetics frequently have abnormal fasting lipid profiles 
with elevation of plasma triglycerides greater than 2.8 mmolll and reduced HDL cholesterol 
to less than 0.9 mmolll in more than 250/0 of cases (Stem et aI., 1989). Factors responsible 
for this may be the increased flow of free fatty acids to the liver that augments hepatic 
synthesis and secretion of triglyceride-rich lipoprotein combined with a clearance defect of 
triglyceride-rich lipoproteins in the periphery by muscle and adipose tissue by impaired 
action of lipoprotein lipase (Brunzell, 1989). However, some non-insulin dependent 
diabetics develop a severe lipaemia with fasting plasma triglycerides greater than 20 mM 
suggesting that additional factors are operating. 
As previous mentioned, more than sixty mutations of lipoprotein lipase have been described 
including large insertions and deletions, frameshift mutations, splicing defects, nonsense 
and missense mutations (Pimstone et al., 1996). In the homozygous state these can impair 
the activity of the enzyme leading to a Type I chylomicronaemia syndrome associated with 
eruptive xanthomata, episodes of acute pancreatitis, and lipaemia retinalis (Durrington et 
al., 1981). Presumptive carriers for these mutations can also show severely abnormal lipid 
profiles when factors such as obesity, pregnancy, or exposure to oral contraceptives are 
present (Ma et al., 1993). The possibility therefore arises that subjects with severe diabetic 
lipidaemia are carriers for such mutants and the interaction of the metabolic state of diabetes 
in the presence of mutants of lipoprotein lipase predisposes to the lipaemia (Thomas et al., 
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1988). We have Therefore examined 18 subjects with severe diabetic lipaemia (plasma 
triglycerides ranging from 20 to 80 mM). 
4.2 Subjects 
Eighteen obese subjects with known or recently diagnosed NIDDM (Type II diabetes m.) 
and severe hyperlipemia (fasting TG > 11.4 mM), were referred for admission to the 
collaborator - the Endocrinology Lipid Units of the H. Mondor Hospital between March 
1993 and February 1994 and were included in this study. The main clinical and metabolic 
features are outlined in Table 4-1. Five patients had eruptive xanthomata and six had 
symptoms of pancreatitis. Eleven patients were of French origin; 3 were North African; and 
the other 4 patients' origins were: Spain, Italy, China and Haiti. All patients received strict 
hypocaloric nutritional therapy on admission combined with several hypoglycaemic and/or 
hypolipidaemic drugs depending on clinical features. Additional therapies were: the insulin 
pump for patients 1,4,5,7,9,10,11,12,17 usually for 48 hours; combined oral hypoglycaemic 
therapy with metformin, sulphonylureas and/or fib rates for subjects 3,6,8,13,14.; and diet 
alone for subject 2 whose dietary record showed a daily caloric intake of 7200 KcaL the 
highest of all subjects studied. The different treatments the patients thus received during 
hospitalisation do not allow reliable conclusions about lipid responses to therapies. The 
diagnosis of NIDDM and hypertriglyceridaemia occurring together was responsible for the 
hospital admission of patients 4,5,7, 10, 12, 15, 16, 17. A family history ofNIDDM was 
present in 10 out of the 18 patients (1, 2, 3, 5, 6, 7, 8, 9, 10, 16 and 18; patients 6 and 1-1- had 
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Table 4-1. Clinical Data of the French Patients at Admission 
Patient Age BMI(Kg/mL) Sex Pl..Chol.(mM) PI. Tg. (mM) HDL-C(mM) HDL-C(mM) Fasting Alcohol intake Complications 
at entry at disch glucose(mM) (glwk) 
1 42 29.3 M 9.3 24.1 0.67 0.93 17.5 1050 liver seatosis 
2 39 36.3 M 6.3 13.3 0.49 0.67 9.5 0 liver seatosis 
3 41 39.7 M 1l.3 75.0 0.36 0.49 1l.7 0 eruptive xanthomatosis 
4 43 27.0 M 19.3 4l.2 0.65 19.5 175 eruptive xanthomatosis 
5 36 32.1 M 7.61 12.5 0.60 16.7 0 liver seatosis, pancreatitis 
6 45 33.5 M 14.7 14.7 0.72 7.2 350 liver seatosis 
7 28 32.0 F 23.0 76.0 0.39 0.85 1l.7 40 liver seatosis, pancreatitis 
8 42 42.9 F 9.0 18.9 0.60 13.7 0 
9 58 40.1 M 8.2 30.8 0.36 0.60 27.9 518 liver seatosis 
10 39 30.7 M 16.6 33.3 l.06 12.2 56 
1 1 46 25.7 M 5.6 44.9 0.26 0.31 12.8 0 liver seatosis 
12 58 30.9 M 14.0 Iff 0 0.39 19.5 pancreatiis 
13 72 28.0 M 3.6 20.5 0.75 0.57 17.2 liver seatosis, eruptive 
xanthomatosis, history of 
possible pancreatitis 
14 56 27.8 M 4.0 26.2 0.70 I l.0 280 liver seatosis 
15 36 28.1 M 8.0 28.0 0.52 19.5 230 liver seatosis, eruptive 
xanthomatosis 
16 47 29.4 M 8.0 79.0 0.49 16.1 140 liver seatosis, eruptive 
xanthomatosis. history of 
possible pancreatitis 
17 27 27.7 M 4.5 28.0 ~41 0.67 I I. I 70 pancreatitis 
18 58 32. I F 44.2 33.0 0.80 12.2 0 
Abbreviations used: PI. =Plasma; Cho\.. =Cholesterol; HDL. =High density lipoprotein; C -cholesterol. 
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a family history of dyslipidaemia). There were 15 men and 3 women and the mean results 
of the clinical data are in Table 4-2. 
Eighty one control subjects were recruited randomly from the Hospital Mondor with 
diabetes m. and no overt hyperlipidaemia. These were used to analyse the frequencies of the 
3 new mutants that we found in this study. 
Table 4-2: The Mean Results of Clinical Data of the Patients at Admission 
Patient No. Mean Age (yrs) MeanBMI Mean Fasting Mean Alcohol 
& range Kg/m 2 Blood Glucose intake 
mM gmlwk 
15 (male) 45.6 31 15.2 191 
(39-72) 
3 (female) 43 37 12.5 13 
4.3 MATERIALS AND METHODS 
DNA Extraction, sequencing of PCR products, acrylamide electrophoresis were carried 
out as described in chapter 3. 
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4.3.1 Specialized Methods 
4.3.1.1 Lipoprotein Analysis 
Total cholesterol, triglyceride and HDL-cholesterol ( after precipitation of ~-containing 
lipoproteins by phosphotungstic acid and magnesium chloride) were determined with an 
Abbot Diagnostics VP analyser using enzymatic reagents (Boehringer Mannheim, 
Germany). Apolipoproteins AI and apoB were measured by immunoturbidometric 
methods using Daichi kits ( Tokyo, Japan) 
4.3.1.2 Amplification of LPL gene exons 
Oligonucleotide primers were synthesised (lGI Ltd. UK) to allow the amplification of 
individual exons of the LPL gene. For each exon, flanking intronic DNA (sequence 
courtesy of K. Oka) was examined for potential PCR primer sites using PRIMER software 
and primer pairs identified. In each pair, one primer was biotinylated at the 5' end. Typical 
PCR reaction conditions were as follows: 50 ~ 100 ng DNA, 50 mM KCL 10 mM Tris-
HCI (PH 8.3), 2.0 mM MgC1 2. 0.001 % (w/v) gelatin, 200 ",M dNTPs, 100 nM each primer 
and 2 units Taq polymerase (Life Sciences, UK) in a 100 ul reaction. Amplification was 
achieved in a Perkin Elmer Cetus 480 thermal cycler using an initial denaturing step of 
940C for lInin and then 35 cycles of94 °c 30 secs, 60°C 1 min, 72°C Imin followed by a 
final elongation of 72°C for 10 min. Small aliquots were removed to test the PCR reactions 
on 1.50/0 agarose gels. 
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4.3.1.3 LPL Mutagenesis (performed in collaboration with Dr. M Hoffmann) 
Site-directed mutagenesis of the LPL cDNA (Hoffmann & Stoffel, 1996) was carried out 
by using the splicing overlap extension method (Higuchi et al., 1988). The 
oligonucleotide primers (LPL Phe351 _Leu sense: 5'- GAG AAC ATC CCA TTG ACT 
CTG -3'; LPL Phe351 _Leu antisense: 5'- AAC TTC AGG CAG AGT CAA TGG -3 ') 
used for mutagenesis (MWG, Ebersberg, Germany) contained the substitution TTC 
(Phe351 ) by a TTG (Leu). The mutant LPL cDNA was confirmed by sequencing. For 
expression in HEK293 cells, the wild type and mutant cDNAs were cloned into the 
BamHI/EcoRI site of the expression vector pCDNA3 (Invitrogen), which contains the 
CMV promotor. 
4.3.1.4 Expression studies (performed in collaboration with Dr. M Hoffmann) 
DNA transfection was performed by electroporaion (Electroporator II: Invitrogen). 
Subconfluent HEK293 cells were harvested by tf)fSinisation and resuspended in DMEM. 
0.5 ml of a suspension containing 5 x 106 cells and 1 ~g plasmid DNA were loaded into a 
0.4 cm electroporation cuvette. after 10 min on ice, the cuvette was pulsed at 71 
~Fa/500n. The cells were then seeded in four 100 mm cell culture dishes and selected 
with DMEM, 10% (v/v) fetal bovine serum, containing 500 ~g/ml G418. After two 
weeks, positive clones were picked and characterized by Northern blotting, enzyme 
immunoassay, and assays for lipase activity. 
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4.3.1.5 Quantification of lipase activity and mass (performed in collaboration with Dr. M 
Hoffmann) 
Lipolytic activities in culture medium and cell extracts were determined by usmg 
radiolabelled trioleine (Amersham) as substrate as described by Hoffmann et al. LPL 
mass was determined three times by a sandwich enzyme immunoassay (MARKIT-F LPL: 
Dainippon Pharmaceutical). 
4.4 RESULTS 
4.4.1 Mutation Detected 
The mutations in the lipoprotein lipase gene revealed by DNA sequence analysis are shown 
in Table 4-3, and nine of the eighteen subjects carried mutants in the heterozygous state. 
Three previously unpublished mutations were found. No mutations were found in the 
I · . d ( 'd A 156 H' 241 S 132) b hr f h' d . cata ytlC tna reSI ues sp - IS - er ,ut t ee 0 t e mutatIOns occurre m exons 
3 and 5 which code for protein domains flanking the catalytic cleft of the enzyme. With 
regard to the most severely lipaemic subjects at presentation (patients 16, 3 and 11. with 
plasma triglycerides of 79, 76 and 45 mmol/l respectively). no mutations were detected at 
the LPL locus. Possibly regulatory sequences of the LPL gene or other genetic loci may be 
involved in their predisposition to develop a severe dyslipidaemia. The mean plasma 
triglycerides of the patients carrying the LPL mutants after treatment was 5.0±2.3 (n=8) 
mM compared to 7.9±5.5 (n=10) mM of the others. The numbers studied are too small to 
draw conclusions regarding the impact of these mutants on effects of therapy. 
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Table 4-3. Lipoprotein lipase gene mutations in French diabetic hyperlipidaemic individuals 
Exon Nucleotide aa residue individuals Publication information 
3 G579 _ A Val108 - Val 17, 18 in literature + 
GTG~GTA 
5 G818 _ A Glyl88 - Glu 13, 17 in literature + 
GGG~GAG 
C829 _ T 192 Arg - Ter 12 This study 
CGA~TGA 
6 Al127 _ G Asn 291 - Ser 6,9 in literature + 
AAT~AGT 
7 C1308 _ G 351 Phe - Leu 8 This study 
TTC::::>TTG 
8 C1338 _ A Thr361 - Thr 9, 14 This study 
ACC::::>ACA 
9 C1595 _ G Ser 447 - Ter 12, 13 in literature + 
TCA::::>TGA 
-0 
0' 
+ see revic\v ref (Monsalve et aL 1990; Reymer et at., 1995; Hata et at., 1990) for further details. 
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4.4.2 The New Mutations 
The DNA sequence gels showing the Arg192 and Phe351 mutations are presented in Figure 
4-1 and 4-2. Sequence analysis reveals that both subjects (numbers 8 and 12) are 
heterozygous for the C1308_G and C829_T substitutions respectively. The first mutation 
results in an amino-acid substitution of phenylalanine (TTC) for leucine (TTG) at residue 
351, site directed mutagenesis for this variant was performed and the DNA transfected into 
HEK293 cells. Lipase activity and mass was measured in culture medium and cell extracts. 
LPL specific activities were shown in Table 4 -4. 
Table 4 -4: LPL activity and mass of wildtype and mutant Phe351 in media of HEK293 
cells 
LPLcDNAs 
Wildtype LPL 
(n=6) 
Phe351Leu 
(n=6) 
LPL mass 
(ng/ml) 
173±29 
167±10 
Comparisons show no significant difference. 
LPL specific activity 
(~mol/h*~g LPL) 
23.74±2.01 
23.88±1.70 
The second mutation results in a substitution of arginine (CGA) at residue 192 by a stop 
codon (TGA). PCR amplifications of exons 5 and 7 and subsequent DNA sequencing on 
I . s .cor both coding and non-coding strands were performed to confirm the severa occaSIOn l~ 
presence of these two new mutations. 
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Legend to Figure 4-1: Autoradiograph of DNA gel sequences of Arg192_Ter mutation of the LPL gene. 
Nucleotide sequence of the non-coding strand for the mutant and normal exon 5 showing a C-T transversion at nucleotide 829 resulting 
in the substitution of arginine for a stop codon at position 192. 
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Figure 4-2 
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Legend to Figure 4-2: Autoradiograph of DNA gel sequences of Phe351 _Leu mutation of the LPL gene. 
Nucleotide sequence of the non-coding strand for the mutant and normal exon 7 showing a C-G transversion at nucleotide 1308 that 
results in the substitution of phenylalanine for leucine at codon 351. 
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Th ·1 t d . 1338 . 
e Sl en co on mutatIOn of C -A at threorune 361 ( sequence gels not presented) \\'ould 
not be expected to have any functional effects on the activity of lipoprotein lipase but could 
be used as a bi-allelic disease marker. 
4.4.3 The Allele Frequencies 
The Arg 192 varl·ant b I I d b PCR l·fi· f was su sequent y ana yse y amp 1 lcatIOn 0 exon 5 and 
digestion with Taq I because the mutation abolishes the Taq I site. This produces bands for 
the common allele of 123 bp and 140 bp; and for the variant of a 263 bp band on gel 
electrophoresis (Fig 4-3a). The Phe351 variant was further analysed by using a modified 
5'amplimer (-CGA GAG TGA GAA CAT CCC GTT-) that introduced an additional 
mutation (A-G) at nucleotide 1305 into the amplification product and created a Hinc II site 
in the presence of the mutant allele. That produces a band of 108 bp for the common allele 
and three bands of 108, 90 and 18 bp for the mutant allele (Fig4-3b). 
The Thr361 mutation was analysed by using a modified 5' amplimer (-GCC TGA AGT TTC 
CAC AAA TAA GGC-) where an additional mutation (A-ill was introduced at nucleotide 
1336 into the amplification product. Thus a novel HaeIII restriction site was created as the 
enzyme has the recognition sequence of GGCC. Amplification followed by digestion with 
HaeIII yielded bands of 214 and 23 bp for the common allele; and as the Thr 361 mutation 
abolishes the HaeIII site yielding three bands of 237 bp., 214 and 23 bp. for the rare 
heterozygote (Fig 4-3c). The frequencies of these three new variants in 81 subjects tested 
are presented in Table 4-5. 
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_ 108bp 
- 90bp 
Legend to Figure 4-3: RFLP analysis of the novel mutations of the LPL gene: 
(a) the C829_T mutation underlying Arg l92-Ter at the exon 5; (b) the C1308_G mutation 
underlying Phe35l -Leu at the exon 7; (c) the C1338_A mutation underlying Thr36 l_Thr 
at the exon 8. Numbers above the lanes denote genotypes. " 1" denotes the common 
allele; "2", the rare allele. 
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Table 4-5: Frequencies of novel mutations of lipoprotein lipase in diabetic hyper- and 
normolipidaemic subjects 
Location in LPL Nucleotide Codon Change Allele Frequency 
Control Subject 
Exon 5 C829_T A 192 T rg - er 0(162) 0.027 (36) 
Exon 7 C I308_G 351 Phe -Leu o (162) 0.027 (36) 
Exon 8 C1338 -A Thr361 _Thr 0.12(162) 0.055 (36) 
Numbers in brackets (n) represent chromosomes scored. 
4.5 DISCUSSION 
It is surprizing to be able to identify three new mutations of the lipoprotein lipase gene by 
DNA analysis of 18 patients with marked diabetic lipaemia. One of these in exon 5 predicts 
termination of the enzyme protein at amino-acid 192. This would be expected to abolish 
catalytic activity of the enzyme since it is known that carboxyl terminal truncation at 
residue 382 reduces catalytic activity by about 850/0 (Kozaki et ai., 1993). The heterozygous 
state may be unaffected or show a mild lipaemia; but when associated with diabetes m, a 
condition that predisposes to hypertriglyceridaemia, the mutant could lead to a severe 
lipaemia. The other newly described variant (Phe351 _Leu) may have some effect on enzyme 
function due to steric differences between the 2 amino-acids although both residues are 
hydrophobic~ however, this mutant did not show any significant differences from wildtype 
enzyme by site-directed mutagenesis and expression by transfection into HEK 293 cells. It 
is of interest however that the severity of the lipaemia in this case (fasting plasma 
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triglycerides of 19 mM at presentation) was similar to the lipaemia with the truncated 
mutant (18.9 mM). The severity of the diabetes at presentation was also similar (fasting 
blood glucoses of 13 mM and 19.5 mM respectively), so a second mutation may be 
expected to exist in regulatory region or the other genetic loci to cause reduced activity. The 
third newly described mutation ( C1338 -A) is conservative and does not change the amino-
acid sequence of the protein product. Its possible use is as a bi-allelic marker for the locus 
therefore I am not investigating this further. However, three new variants were revealed 
suggesting that there is much more genetic diversity at this locus than was previously 
recognised. 
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CHAPTER 5 
GENETIC VARIANTS OF THE LIPOPROTEIN LIPASE AND THE 
APOAI-CIII-AIV GENE CLUSTER IN GERMAN SUBJECTS 
Page 114 
Chapter 5 
5.1 INTRODUCTION 
Studies of concordance rates in monozygotic twins with premature coronary artery disease 
have emphasised the importance of family history and demonstrate that genetic risk factors 
contribute to the susceptibility of individuals to the disease (Berg, 1984). Several genetic 
loci have already been implicated in the development of premature coronary atherosclerosis. 
Possible candidates include the genes encoding proteins involved in lipoprotein catabolism 
and transport, e.g. the variants at the apolipoprotein AIICIIII AIV gene cluster (Chamberlain 
et al., 1991), the variants at lipoprotein lipase and hepatic triglyceride lipase (Galton & 
F ems, 1989). 
The present study has investigated these mutations at the LPL gene and Apo AI-CIII-AIV 
gene cluster for possible relationships with disorders of lipid transport and premature 
coronary atherosclerosis. 
5.2 SUBJECTS 
323 male subjects were recruited serially from the collaborator - physicians' and cardiac 
clinics of the Wolfgang Goethe-University Hospital in Frankfurt, Germany. 238 had 
angiographically proven coronary artery disease and some of these had additional 
peripheral vascular disease. Coronary artery disease was defined angiographically as 
patients having at least 500/0 stenosis or more in at least one of the major coronary vessels 
(right coronary artery, right circumflex, or left anterior descending arteries). Controls 
(n=85), had valve disease with no significant CAD (defined as less than 200/0 stenosis in 
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left main anterior and descending coronary arteries). Hypertension was defined as blood 
pressures> 140/>90 mmHg. Out of the 323 subjects studied, 81 had never smoked, 194 
were ex-smokers and 48 were current smokers. Further details of smoking habits are 
presented in Table 5-1. Regarding medication, of the total number of subjects (323) 
recruited, 34 subjects (i.e. 10.5%) were on drugs that may alter plasma lipids ( mainly 
nitrates, calcium antagonists, aspirin, diuretics and selective beta-1 betablockers) at the 
time of sampling for lipid estimations. 
Table 5-1: Clinical Features of Male Patients with Arterial Disease and Male Control 
Subjects 
Arterial Disease Controls P 
(n=238) (n=85) 
Age (years) 58±7 50±13 <0.0001 * 
Weight(Kg) 80.1±10A 79.3±13.0 NS* 
BMI 26A9±2.96 25.54±3.85 <0.05* 
Diabetes mellitus(no 31(13.0%) 2(2A%) <0.006 
&%) 
Hypertension(no & 0/0) 108(45.3%) 31(36.5%) NS 
Smokers(no & %) 185(77.7%) 57(67.10/0) <0.05 
Cigarettes( no & %): 
<14 cigs/day 36(19.5%) 11(19.3%) NS 
> 15 cigs/day 149(80.5%) 46(80.70/0) 
Arterial disease comprises coronary heart disease(n=215) and peripheral vascular 
disease(n=23); Controls comprise valve disease without significant CAD; BMI indicates 
body mass index. P values were analysed by Chi-square tests (2x2 contingency tables). 
* P values were analysed by Independent two samples T -Tests. 
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5.3 MATERIALS AND METHODS 
DNA extraction, PCR amplification, restriction enzyme digestion and electrophoresis 
were carried out as described in chapter 3. Primer sets for this study were as follows: 
LPL gene: 
ASp9 -Asn mutation (TaqI RFLP): 
5 '-upstream, 5 '-AAAATCAAGCAACCCTCCAG-3 , 
3 '-downstream, 5'-TAGGGCAAATTTACTTGCGA-3' 
Asn291 -Ser: mutation (RsaI RFLP): 
5' -upstream, 5' -TCTGCCGAGATACAATCTTGG-3' 
3' -downstream 
5'_ATAATATAAAATATAAATACTGCTTCTTTTGGCTCTGACTGTA-3' 
Hind III RFLP: 
5 '-upstream, 5'-GATGTCTACCTGGAT AA TCAAAG-3 
3 '-downstream, 5'-CTTCAGCTAGACATTGCTAGTGT -3' 
447 . Ser -Ter mutatIOn: 
a). Hinft RFLP 
5' -upstream, 5'-TATCCATTTTCTTCCACAGGG-3' 
3' -downstream, 5'-TAGCCCAGAATGCTCACCAGACT -3' 
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b) MnlIRFLP 
5 '-upstream, 5'-CATCCATTTTCTTCCACAGGG-3' 
3 '-downstream, 5'-AGTCTGGTGAGCATTCTGGGCTA-3 
HL gene: 
MspIRFLP: 
5'-upstream, 5'-CCCGCGT AACCCTT ACCCCT -3' 
3' -downstream 5' -GCTCCCGGCCCA TGACTTC-3' 
ApoAI-CIII-AIV gene cluster: 
MspIRFLP: 
5 '-upstream , 5 '-ATGTGCTCAAAGACAGCGG-3 , 
3 '-downstream, 5'-AGCAGAGGAGGTGGTGAAGA-3' 
Pst IRFLP: 
5 '-upstream, 5'_GAGCGCTCTCGAGGAGTACAC-3' 
3'-downstream 5'_GACTGGCTTCCACTGCTGTGC-3' 
Sst IRFLP: 
5 '-upstream, 5'_CACTCATAGCAGCTTCTTGTCC -3' 
3 '-downstream, 5'_TACAGAGGAGTTCTCATGCCC-3' 
Chapter 5 
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XmnIRFLP: 
5 '-upstream, 5'-TGCCAGACCTAGCAGGGGACA-3' 
3 '-downstream, 5'-GCATCTTACCAAGCAGGCAGTTTC-3' 
There are two primer sets for detecting the Ser 447 -Ter mutation of the LPL gene: one 
including 3' -modified amplimer for HinjI digestion and the other for Mnll digestion. Both 
primer sets were used for this chapter and just the primer set for Mnll digestion was used 
for chapter 6 because the Ser 447 - Ter mutation created a MnlI site and could be detected by 
MnlI directly and the results from the MnlI digestion after PCR were better than that from 
the HinjI digestion. 
5.3.1 Specialized methods 
5.3.1.1 Lipoprotein analyses 
Plasma cholesterol, triglyceride, and lipoproteins were determined by enzymatic methods 
with commercially available kits (Boehringer Mannheim and Beckman Array Protein 
System, Beckamn Instruments Brea, CA.). Lp(a) was measured by an enzyme-linked 
sorbent immunoassay (ELISA) using polyclonal antibodies raised against purified Lp(a), 
Mercodia Diagnostics, Uppsala, Sweden. HDL-C was measured after precipitation of 
apolipoprotein B containing lipoproteins and LDL-cholesterol calculated according to the 
Friedewald formula. 
5.3.1.2 Statistical Analysis 
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Genotype distributions between the study groups and other biochemical traits that were 
divided into tertiles were assessed using Chi-square analysis. Variations in the 
biochemical traits with respect to genotypes were analyzed by performing analysis of 
covariance, as described in chapter 3. 
5.4 STUDY I : GENETIC VARIANTS OF THE LIPOPROTEIN LIPASE GENE 
Over the past several years numerous rare sequence variants of the LPL gene have been 
found that lead to synthesis of non-functional enzyme and when an individual inherits two 
such defective alleles cause Familial Chylomicronaemia (Type I hyperlipidaemia) (Reymer 
et al., 1995; Santamarina-Fojo, 1992). Some individuals who are heterozygotes for such 
mutations may be predisposed to develop familial combined hyperlipidaemia and be at risk 
of early atherosclerosis. By contrast, three relatively common coding sequence mutations of 
population frequencies of > 1 % within exons 2, 6 and 9 of the LPL gene were recently 
reported (Gagne et al., 1994; Hata et al., 1990; Hayden et al., 1993; Stocks et al., 1992). 
One, 635bp downstream from a polymorphic Hind III RFLP (intron 8), involves a Ser447_ 
Ter (C 1S95_G transversion) mutation in exon 9 that converts serine447 codon to a premature 
termination codon producing a truncated protein lacking the two carboxyl-terminal amino 
acids that are normally present (Hata et al., 1990; Stocks et al., 1992); the second mutation 
is the substitution of Asp9 - Asn ( G280 -A transition) in ex on 2 which creates a Taq I 
) h h· d . h b" fA 291 S (A II27 polymorphic site (Gagne et a/., 1994 ,t e t Ir one IS t e su stltutlOn 0 sn - er -
G transition) in exon 6 which creates a Rsa I polymorphic site by using 3' modified 
amplimer (Hayden et al., 1993~ Ma et ai., 1994; Reymer et ai., 1995). 
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The present study has investigated these three coding sequence mutations ( Ser 44 7 -Tee 
Asp9 -Asn and Asn261 _Ser variants) for possible relationships with disorders of lipid 
transport and premature coronary atherosclerosis. 
5.4.1 results 
5.4.1.1 Clinical and Biochemical Characteristics of Study Groups 
Table 5-1 and 5-2 summarizes the clinical features and biochemical characteristics of the 
study groups. As expected, the mean levels of cholesterol, triglycerides, LDL-cholesterol, 
ApoB and Lp(a) were significantly higher in the arterial disease group versus controls. HDL 
levels were lower in the patient group. 
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Table 5-2. Biochemical Characteristics (Adjusted for Age and BMI) of Male Patients 
with Arterial Disease and Male Control Subjects 
Arterial Disease Controls p 
(n=238) (n=85) 
Cholesterol, mg/dl 238.79+ 47.61 213.06+ 53.56 <0.0001 
Triglycerides, mg/dl 215.30+ 134.01 183.04+119.28 0.008 
LDL-C, mg/dl 158.20+ 39.03 139.23+ 39.14 0.002 
VLDL, mg/dl 33.43+ 17.59 30.56+ 19.75 <0.03 
HDL, mg/dl 38.92+ 9.14 42.20+ 11.29 0.009 
ApoAI, mg/ dl 125.82+ 21.03 130.00+ 21.04 <0.08(NS) 
ApoB, mg/dl 145.73+ 33.77 125.02+ 35.67 <0.0001 
Lp(a), mg/dl# 44.80 28.46 <0.0001 
(0.51-214.19) (0.17-145.01) 
Arterial disease compnses coronary artery disease and peripheral vascular disease~ 
Controls comprise valve disease without significant CAD; BMI indicates body mass 
index. P values were analysed by Analysis of Covariances and triglycerides, VLDL and 
Lp(a) were log10 transformed before analysis. # Mean values and unadjusted range. 
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5.4.1.2 Genotyping 
The map in the Figure 5-1 represents the region of exons 2, 6, 8 and 9 of the LPL gene 
showing the positions of the ASp9 -Asn coding sequence mutation (TaqI RFLP), the Asn291 _ 
Ser coding sequence mutation (RsaI RFLP), the HindIII RFLP and the Ser447_Ter coding 
sequence mutation (HinjI RFLP). Previous genetic mapping of the LPL gene has revealed 
th . . f h A 9 A . . 291 e posItIOns 0 t e sp - sn vanant In exon 2, the Asn -Ser variant in exon 6, the 
HindIII RFLP in intron 8 and the Ser447_Ter mutation in ex on 9. The C-G transversion at 
nucleotide 1595 of the LPL exon 9 was identified by using a modified 3' amplimer, an 
additional mutation (G-T) is introduced at nucleotide 1598 into the amplification product. 
Thus, a novel HinjI restriction site is created solely in the presence of the G allele (Ser 447_ 
Ter variant), as the enzyme has the recognition sequence GA(N)TC. Similarly, the A 1127_ 
G transition of the LPL exon 6 was identified by using a modified 3' amplimer with an 
additional mutation (A 1130 -C), therefore, a novel RsaI restriction site is created in the 
presence of the Asn291 -Ser mutation. Conversely no modification of the primer sequence 
is necessary to detect the G~A change at nucleotide 280 that destroys a TaqI site in exon 
2. However the presence of a closely flanking nonvariant TaqI site ( position 284-287) 
necessitates the use of a modified reverse primer with a mismatch by introducing T-G 
transversion at nucleotide 287 that destroys this non-variant TaqI site that otherwise 
obscures detection of the variant site as the recognition sequence of TaqI is TCGA. The 
technique and genotype scoring have been detailed in Figures 5-1 and 5-2. Presence of 
the restriction sites are denoted by T2 (TaqI), R2 (RsaI), H2 (HindIII), and G (Hin/I). 
Page 123 
t-J 
+-
Figure 5-1 
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A schematic diagram of sections of the lipoprotein lipase gene. Shown is the region between exon 2, 6, 8 and 9 with the Asp9-Asn, 
Asn291 _Ser mutations, HindUI restriction fragment length polymorphisms and Ser 447 -Ter mutation. PCR indicates polymerase Chain 
reaction. 
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(a) the G280_A mutation underlying Asp9-Asn at the exon 2; (b) the A 1127 -G mutation underlying Asn291 -Ser at the 
exon 6; (c) the T-G mutation Hind III RFLP underlying Hind III RFLP at the intron 8; (d) and (e) the C1595_G 
mutation underlying Ser447-Ter at the exon 9; (f) the G-C mutation underlying Thr202-Thr at the exon 5 of the HL 
gene. Numbers above the lanes denote genotypes. "1" denotes the common allele; "2", the rare allele. 
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5.4.1.3 LPL genotypes and biochemical traits 
Comparisons of lipid, lipoprotein and apolipoprotein levels between genotypes are 
presented in Table 5-3. Plasma triglycerides and VLDL-triglycerides were lower in 
subjects (n=63) possessing the Serine447-Ter mutation (p=0.06 and <0.05 respectively). 
ASp9 -Asn variants 
There was no homozygote (Tl Tl) with the Asp9-Asn variant. The mean ApoAI levels were 
significantly lower between the subjects with the genotype Tl T2 (n=ll, 114.54 mg/dl) 
versus the alternative ones with genotype T2T2 (n=309, 127.51 mg/dl), p<0.05. No other 
differences were observed in the presence or absence of this mutation. 
Ser447 - Ter variants 
There were only three homozygotes with the Ser447 -Ter mutation(GG), so they were 
pooled with the other heterozygotes(CG). The homozygotes and heterozygotes (CG+GG, 
n=63) had significantly lower mean VLDL levels than the wild-type homozygotes (CC, 
n=257, 29.66 v 33.55 mg/dl, p<0.05). There was a similar trend with total plasma 
triglycerides but did not reach statistical significance. 
There were no significant differences in biochemical traits relating to these genetic 
markers: HindIII RFLP in LPL gene and MspI RFLP in HL gene. 
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Table 5-3. Biochemical characteristics (adjusted for age and BMI) of the study samples with lipoprotein lipase genotypes 
Asp9-Asn (TaqI) Ser447 - Ter (HinjI) 
Cholesterol, mg/dl 
Triglycerides, mg/dl 
HDL, mg/dl 
LDL-C, mg/dl 
VLDL, mg/dl 
ApoAI, mg/dl 
ApoB, mg/dl 
Lp(a), mg/dlll 
T2T2 
(n=309) 
232.74+ 50.82 
208.45+131.47 
39.92+9.79 
153.50+ 40.06 
33.03+ 18.25 
127.51+ 2l.00 
140.70+ 35.59 
40.34 
(0.17-214.19) 
T1T2 
(n=ll) 
218.55+ 41.53 
182.45+ 126.35 
36.54+8.04 
149.82+ 35.02 
26.03+ 17.02 
114.54+ 17.28# 
132.06+ 28.20 
45.70 
(l.47-158.86) 
CC 
(n=257) 
234.32+ 50.34 
213.34+ 135.98 
39.77+9.62 
154.93+ 40.38 
33.55+ 18.45 
127.30+ 2l.38 
142.00+ 35.70 
40.60 
(0.17 -212.59) 
CG+GG 
(n=63) 
223.81 + 50.91 
183.94+ 107.25* 
39.96+ 10.31 
146.99+ 37.27 
29.66+ 17.10$ 
126.08+ 19.48 
133.80+ 33.40 
40.28 
(0.28-214.19) 
BMI indicates body mass index. Triglycerides, VLDL and Lp(a) were log10 transformed before statistical analysis. 
#Genotypes TI T1 vs T1 T2, p<0.05(Analysis of Covariance). *Genotypes CC vs CG+GG, p=0.06(Analysis of Covariance). 
~ $Genotypes CC vs CG+GG,p<O.05(Analysis of Covariance). II Mean values and unadjusted range. 
Table 5-4 Lipid and lipoprotein tertiles and lipoprotein lipase genotypes in the study samples 
Table 5-4 Lipid and Lipoprotein Tertiles and Lipoprotein Lipase Genotypes in the Study Samples 
No. of subjects represented by genotypes 
Asp9-Asn(TaqI) Ser447-Ter (HinjI) 
T2T2 T1T2 P CC CG+GG P 
Triglycerides 
lower tertile( < 13 9. Omgl dl) 104 4 78 30 
higher tertile(>226.0mg/dl) 106 2 NS 92 16 <0.02 
VLDL 
lower tertile( <22.2mg/dl) 100 6 77 29 
higher tertile(>35.3mg/dl) 106 2 NS 91 17 <0.04 
ApoAI 
lower tertile«117.0mg/dl) 101 6 85 22 
higher tertile(> 13 3. 8mgl dl) 105 1 =0.05 88 18 NS 
TG/HDL 
lower tertile«3.371) 104 3 77 30 
higher tertile(>6.263) 105 2 NS 91 16 <0.02 
-t-J 
00 
P \'alues were analysed by Chi-square tests (2x2 contingency tables) and Fisher's exact test where appropriate. 
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5.4.1.4 LPL genotypes and lipid and lipoprotein tertiles 
When the lipid distributions were analysed by tertiles, the Ser447 -Ter mutation was 
significantly less frequent in the highest tertiles for triglycerides (p<0.02), and VLDL 
(p<0.04), (Table 5-4). 
The triglyceride/HDL ratios, when divided by tertiles, also showed differences in the 
.h . f h S 447 T . 9 lrequencles 0 t e er - er mutatlOn (p<0.02, Table 5-4 ). The Asp -Asn substitution 
was found more frequently in the lowest tertiles for ApoAI (p=0.05). Furthermore, There 
is a trend that the Asn261 _Ser mutation was found more frequently in the higher tertiles for 
the triglyceride/HDL ratios (p=0.063), but this does not quite reach significance. 
5.4.1.5 LPL genotypes in CAD and controls 
Case-control analyses of genotypic distributions between the two groups with or without 
arterial disease did not show any significant differences. However, there is a trend towards 
increased number of genotypes containing the Asn261 -Ser variant in the arterial disease as 
compared with the normal controls (data not shown), this does not quite reach 
significance. The genotype frequencies in the CAD patients versus controls for the Ser 44
7
_ 
ter mutation are: CC, 80.50/0; CG, 19.1 %~ GG, 0.50/0 for cases; and for controls 79.1 %. 
19.80/0 and 1.20/0 . For the Asp9-Asn mutation: T1 T1 95.9%, T1 T2 4.10/0, T2T2 0% for 
cases; and for controls 97.70/0, 2.30/0 and 0%. For Asn261-Ser mutation: R1R1 93.7%, 
R1R2 6.30/0, R2R2 0% for cases, and for controls 95.30/0, 4.70/0 and 00/0. 
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5.4.2 Discussion of study I 
The Serine 447 - Ter variant is the first observed common coding sequence mutation at the 
LPL gene locus that appears to have beneficial effects on plasma lipid profiles. The 
functional significance of the carboxyl terminal region of the LPL remains uncertain but it 
is highly conserved in the known mammalian species (human, mouse, bovine and guinea 
pig) and may provide an anchor for the attachment of the enzyme to endothelial cell 
surfaces. 
Our data show that the truncated enzyme is found much more frequently in the lowest 
tertiles of the triglyceride or VLDL distributions of our sample population. There was also 
a trend for the truncation (in hetero- and homozygous- states) to be associated with lower 
plasma triglycerides (p=0.06) or lower VLDL-triglycerides (p<0.05). The Ser447 -Ter 
mutation appears to relate to the intermediate phenotype for coronary atherosclerosis, but 
the study perhaps is too small to show effects on the end stage phenotype of atherosclerosis. 
A site-directed mutagesis experi ment (Stocks et al., 1992) and a larger epidemiological 
study (n=1273) all had similar results and did have the power to reveal differences in allele 
frequencies between subjects with CAD (n=42l) and control (n=852), (Galton et al., 1996). 
With regard to the Asp9-Asn mutation, no associations were found with plasma lipid levels, 
although there were weakly significant associations with apolipoprotein A-I levels, when 
analysed by tertiles. Further work is needed to clarify this by study of other groups. 
Hypertriglyceridaemia (with low HDL) is an established independent risk factor for the 
development of coronary artery disease, our observation suggests the decreased ApoAl 
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levels in subjects with the Asp9-Asn mutation may cause a decreased number of HDL 
particles and then may, at least in part, lead to the decreased HDL-C levels. 
5.5 STUDY II: GENETIC VARIANTS OF the APOAI-Cill-AIV GENE CLUSTER 
Extensive epidemiological studies have suggested that decreased plasma HDL-C and 
increased LDL-C are major risk factors for atherosclerosis (Assmann et al., 1991; Austin, 
1989; Carlson et al., 1979; Gordon et al., 1977). The major apoproteins of HDL are 
apoAI and apoAlI. ApoAI comprises 75% of the apoprotein component of an HDL 
particle and is thought to serve the function of a co-factor for the LCAT. In addition, low 
serum apoAI levels have been also reported as an independent risk factor in CAD 
(Assmann et al., 1978; Fielding et al., 1972; Maciejko et al., 1983). 
The genes coding for apoAI, ClII and AIV are clustered within a 15 kb DNA segment on 
the long arm of human chromosome 11q23 (Bruns et al., 1984; Karathanasis, 1985). 
Several common DNA polymorphisms have been identified in this gene cluster (Cohen et 
al., 1986; Coleman et al., 1986; Peacock et al., 1994), some of which may be involved in 
combined hyperlipidemia or hypertriglyceridemia: the rare allele (P-) of PstI RFLP 
immediately 314 bp 3' to the polyadenylation signal of the apoAI gene has been found to 
be associated with low concentrations of HDL-C and also with angiographically detected 
premature CAD and familial hypoalphalipoproteinemia (Kessling et aL 1985; Ordovas et 
al., 1986); the rare allele (X+) of the XmnI RFLP approximately 2.6kb to 5' of apoAI 
gene has been associated with familial combined hyperlipidemia (Kessling et aL 1985; 
Kessling et al., 1988; Marcil et al., 1996; Rees et al., 1985). and more recently has been 
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reported to segregate with familial combined hyperlipidemia in some families (Pauhyeber 
et af., 1988; Wile et af., 1989); furthermore, the rare allele (S+) of the SstI RFLP in the 3' 
non-coding region of apoCIII gene (Ferns et af., 1985; Marcil et af., 1996; Rees et af., 
1985) and the rare allele (M-) of MspI RFLP in the third intron of apo AI gene have been 
found to associate with hypertriglyceridemia (Frossard et af., 1987; Tybjaerg-Hansen et 
af., 1993). 
In the German group, we have studied genetic variation in the apoAI-CIII-AIV gene 
complex in relation to lipid, lipoprotein levels and atherosclerosis. 
5.5.1 Results 
5.5.1.1 Genotyping 
The Figure 5-2 is map of the apoAI-CIII-AIV gene cluster showing the polymorphisms 
sites by digestion with the restriction enzymes MspI, PstI, XmnI and Sst!. Presence of the 
restriction site is denoted by M+ (MspI), P+ (PstI), X + (XmnI) and S+ (SstI). 
5.5.1.2 Apoproteins genotypes and biochemical traits 
Comparisons of lipid, lipoprotein and apolipoprotein levels between genotypes are 
presented in Table 5-5. 
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Table 5-5. Biochemical characteristics for PstI RFLP of Apo AI-CHI-AIV gene cluster in all subjects (n=323) 
PstI 
p-p- & p+p- p+p+ p* 
(n=45) (n-275) 
Cholesterol, mg/dl 238.42+ 47.39 231.24+51.05 NS 
Triglycerides,mg/dl 266.31+157.74 197.93+ 124.03 0.001 
HDL, mg/dl 38.50+ 8.51 40.02+9.93 NS 
LDL-C, mg/dl 155.18+ 32.30 153.07+41.02 NS 
VLDL, mg/dl 38.82+ 17.78 31.80+ 18.14 <0.02 
ApoAI, mg/ dl 126.81 + 20.36 127.11+21.14 NS 
ApoB, mg/dl 148.56+ 27.37 139.07+36.35 <0.09(NS) 
Lp(a), mg/dl# 40.58 40.68 NS 
(0.17-161.23) (0.17-214.19) 
TGIHDL 7.47+5.14 5.57+4.83 <0.04 
# Mean values and unadjusted range. *p values were analysed by One-Way Anova. 
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PstI RFLP 
The mean triglycerides levels were significantly higher among the pooled subjects with 
the heterozygote and homozygote (P+P-and P-P-, n=45, 266.31 mg/dl) versus the wild-
type homozygote (P+P+, n=275, 197.93 mg/dl), p=O.OOl. Similarly, levels of VLDL and 
TG/HDL ratio were significantly higher in subjects with PstI variant (P-P- and P-P+, 
38.82 mg/dl versus P+P+, 3l.80 mg/dl, p<0.02; and 7.47 versus 5.57, p<0.04 
respectively). There was only one homozygote (P-P-) in the group. 
There were no significant differences in biochemical traits relating to these genetic 
markers: XmnI and MspI RFLPs in ApoAI gene and Sst! RFLP in ApoCIII gene. 
5.5.1.3 Apopropteins genotypes and biochemical tertiles 
The rare genotypes (P-P- and P-P+) of PstI RFLP were significantly more frequent in the 
highest tertiles for triglycerides (p<0.003), VLDL (p<0.02), TG/HDL (p<0.006) and 
apoB (p<0.03), Table 5-6. 
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Table 5-6. Biochemical Tertiles for PstI RFLP of Apo AI-CIII-AIV gene cluster in subjects 
from Arterial disease and control groups 
Triglycerides 
lower tertile( <139.0 mg/dl) 
higher tertile(>226.0 mg/dl) 
VLDL 
lower tertile( <22.2 mg/dl) 
higher tertile(>35.3 mg/dl) 
ApoB 
lower tertile( <124.0 mg/dl) 
higher tertile(> 153.0 mg/dl) 
TG/HDL 
lower tertile«3.371) 
higher tertile(>6.623) 
No.of subjects represented by genotypes 
p+p+ p+p-& p-p- p* 
101 
86 
98 
87 
99 
87 
98 
86 
7 
22 
8 
21 
8 
19 
7 
21 
<0.003 
<0.02 
<0.03 
<0.006 
Arterial disease compnses coronary artery disease and peripheral vascular disease~ 
Controls, valve disease without significant CAD. *p values were analysed by Chi-square 
tests (2x2 contingency tables). 
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5.5.2 Discussion of study II 
The development of significant atherosclerotic lesions depends on the interaction of 
environmental and genetic risk factors. High levels of LDL-C and low levels of HDL-C 
have been identified as independent risk factors for coronary artery disease. Furthermore, 
deficiencies of ApoAI are known to be associated with abnormalities in lipoprotein 
metabolism, as manifested by low plasma HDL-C levels (Humphries, 1988; Monsalve et 
al., 1989). 
Our results confirm the association between high triglyceride, VLDL levels, TG/HDL 
ratio and the Pst! RFLP at the ApoAI gene, this is similar to that seen in the earlier work 
of our laboratory (Chamberlain & Galton, 1990, Chamberlain, 1991 .). In particular, 
the PstI polymorphism is associated with the higher tertiles levels of ApoB, which is a 
principal apolipoprotein component in LDL and VLDL respectively. Consequently, the 
increased ApoB levels in the higher terti Ie may be due to the increased VLDL and LDL 
levels. 
In conclusion, our observations suggest that variations In the LPL and the 
apolipoproteinAI-CIII-AIV gene cluster may not make major contribution to the 
development of atherosclerosis, but variations associated with some of the genetic m~kers 
and common mutations may be involved in determining plasma levels of lipid, lipoproteins 
and apolipoproteins in this group of German individuals. 
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CHAPTERS 
GENETIC VARIANTS OF THE LIPOPROTEIN LIPASE GENE AND 
THE APOAI-CIII~V GENE CLUSTER IN CHINESE SUBJECTS 
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6.1 INTRODUCTION 
The dyslipidaemic syndrome of raised plasma triglycerides and low HDL occurs 
commonly in European populations at frequencies of greater than 5% and is a well 
established risk factor for premature coronary heart disease (Assmann et al., 1991 ~ 
Austin, 1989; Carlson et al., 1979). Several common genetic variants have been detected 
that associate with this dyslipidaemia and in some cases may constitute genetic 
d . +. h d· . F I 3175 etermlnants lor t e con It1on. or examp e, a common G -C transversion that is 
transcribed but not translated in exon 4 of the ApoCIII gene on chromosome 11 p21 has 
been found in association (Rees et al., 1983; Rees et al., 1985) and pedigree studies 
(Wojciechowski et al., 1991) to link with dys1ipidaemia; two ApoCIII promoter 
mutations at position C-482 - T and T-455 -C have also been found to associate with 
hypertriglyceridaemia (Dammerman & Breslow, 1995). In addition several common 
mutations in the gene encoding lipoprotein lipase on chromosome 8p have also been 
found to relate to this dyslipidaemia. For example, a C1595 - G transversion that converts 
Ser447 to a stop codon thereby prematurely truncating the enzyme protein by 2 amino-
acids has been shown to relate to low levels of plasma triglycerides and elevated levels of 
HDL in several studies (Stocks et al., 1992; Zhang et al., 1995). Two other common 
mutations at lipoprotein lipase, namely ASp9_ Asn and ASp291_ Ser have also been shown 
to associate with dyslipidaemia (Ma et al., 1994; Mailly et al., 1995) and in vitro 
transfection studies show a decreased activity of both mutant enzymes. 
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There are large ethnic differences in the prevalence of coronary artery disease manifesting 
before the age of 60 years between Western Europe and China. For example, the UK 
standardized mortality rates in men aged 35-64 for coronary heart disease is 
approximately 3501100,000 compared to 30/100,000 in rural China and 601100,000 in 
urban China for men aged 35-74 years (Tao, 1993). Part of this difference may be due to 
differences in the frequencies of risk factors such as diabetes m. hyperlipidaemia, 
hypertension and smoking habits. but all these cardiovascular risk factors occur 
commonly in China (diabetes m. (NIDDM) 2.50/0, hyperlipidaemia 20%, and 
hypertension 11.6%), (Pan, 1996; Wang et at., 1996; Wu et at., 1995). It is therefore of 
great interest to compare frequencies of the common genetic variants of the AI-CIII-AIV 
gene cluster and lipoprotein lipase genes that have been postulated to contribute to the 
atherogenic dyslipidaemia of raised plasma triglycerides/low HDL in Chinese and 
European populations to see if genetic factors may account for such ethnic differences. 
6.2. SUBJECTS 
881 subjects under the age of sixty-five years were selected randomly from the staff 
members of Hong Guang Electron Tube Factory and four Universities in the Chengdu 
area. Those with hepatic, renal and thyroid diseases were excluded from this study. The 
subjects were asked to fast 12-14 hours before venous blood was taken. From this survey 
69 subjects were identified with fasting plasma triglycerides >204 mg/dl and selected for 
further study. None of them were taking medication known to affect levels of plasma 
lipids and they were considered to have a primary dyslipidaemia. Controls (n=74) came 
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from the same survey who had fasting plasma triglycerides <177 mg/dl. The presence of 
other related diseases ( diabetes m., coronary artery disease etc.) were established by a 
questionnaire. Full clinical details of the study groups are presented in Table 6-1. 
Table 6-1. Clinical characteristics of Chinese subjects with and without hyperlipideamia. 
Hyperlipideamia Controls p 
(n=69) (n=74) 
Age (yrs) 54.69±6.83 52.81±8.03 NS 
Sex (male+female; no & %) 64+5(92.80/0+ 7.2%) 68+6(91.9%+8.10/0) NS* 
Weight (Kg) 70.32±9.23 62.86±8.67 <0.001 
BMI (Kg/M2) 25.42±2.76 22.67±2.76 <0.001 
Diabetes mellitus (no & %) 5 (7.2%) 5 (6.8%) NS* 
Hypertension(> 130mmHg; 15 (21. 70/0) 10 (13.50/0) NS* 
no&%) 
BMI indicates body mass index. p values were analysed by Chi-square test* and One-way 
Anova. 
6.3 MATERIALS AND METHODS 
DNA extraction, PCR amplification, restriction enzyme digestion, direct DNA 
sequencing of PCR products, agrose and acrylamide electrophoresis were carried out as 
descri bed in chapter 3. 
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6.3.1 Specialized method 
6.3.1.1 Lipoprotein Analyses 
Total serum cholesterol and triglycerides were measured by the enzymatic method (kits, 
Zhong Sen Co., Beijing). HDL-C was determined after sodium phosphotungstate/ 
Magnesium Chloride precipitation. Serum apolipoprotein AI, An, B 1 00, cn, CIn and E 
were quantified by the radial-immunodiffusion kits developed by Apolipoprotein 
Research Laboratory in West China University of Medical Sciences, China (Liu, 1995). 
6.3.2 Statistical Analysis 
Genotype distributions between the study groups and after biochemical traits were 
divided into tertiles were assessed USIng Chi-square analysis. Variations in the 
biochemical traits with respect to genotypes were analyzed by performing analysis of 
covariance, as described in chapter 3. 
6.4 STUDY I: POPULATION ASSOCIATION STUDY 
6.4.1 Results 
The clinical and biochemical characteristics of the Chinese group are presented in Table 
6-1 and Table 6-2. The hypertriglyceridaemic Chinese group had raised plasma levels of 
apoB, cn, CIn and E due probably to the increased circulating levels of triglyceride rich 
lipoproteins compared to Chinese controls. They also had decreased levels of apoAI and 
All and HDL. 
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Table 6-2. Biochemical characteristics (adjusted for age and BMI) of Chinese subjects 
with and without hyperlipideamia. 
Hyperlipideamia Controls p 
(n=69) (n=74) 
Blood Glucose, mg/dl 101.64+19.30 98.94±30.42 NS 
Triglycerides, mg/dl 440.16±363.16 125.55+29.81 <0.0001 
Cholesterol, mg/dl 227.83±223.80 184.70±34.30 NS 
HDL-C, mg/dl 36.58±9.52 50.58+ 10.21 <0.0001 
ApoAI, mg/dl 108.05±14.86 117.43±19.85 0.004 
ApoAII, mg/dl 23.40±5.16 27.04±3.41 <0.0001 
ApoB, mg/dl 117.92+29.56 93.67±23.50 <0.0001 
ApoCII, mg/dl 6.89±3.10 3.46±1.07 <0.0001 
ApoCIII, mg/dl 18.95±10.83 9.13±2.44 <0.0001 
ApoE, mgdl 7.20±5.19 3.97±0.82 <0.0001 
TG/HDL 13.54±16.68 2.62±0.91 <0.0001 
BMI indicates body mass index. p values were analysed by Analysis of Covariance and 
triglycerides were log 10 transformed before analysis. 
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6.4.1 1 Allele Frequencies 
With regard to allele frequencies of common genetic variants that have been reported in 
European populations to relate to the hypertriglyceridaemic/low HDL syndrome. the 
Asn
291
_ Ser and ASp9 - Asn variants of lipoprotein lipase were not detected in the Chinese 
control group (n=74). The Serine447-Ter variant and the HindIII restriction length 
polymorphism in intron 8 of the LPL gene were found at similar frequencies to European 
groups (Table 6-3.). 
The two disease related restriction length polymorphisms of the ApoAI gene (detected 
with Msp I and Xmn I) were also significantly different in frequencies between Chinese 
. 1 317~ control and CaucasIan contro groups (p<0.0006 and p<0.004); as was the ApoCIII G -_ 
C variant (p<0.003), (Table 6-3). The electrophoretic patterns of PCR products of the 
ApoAI -CIII gene loci were shown in Fig. 6-1. 
6.4.1.2 Disease Associations 
Apo/ipoproteins AIICIII variants 
The ApoAIICIII variants (the ApoAI MspI and ApoCIII polymorphisms) that have 
shown disease relationships in European studies also appear in the Chinese group (Table 
6-4). Thus the rare ApoCIII variant (G3175_ C) is found more frequently in the upper 
tertile for plasma apoCIII and TG/HDL ratios (both p=0.05). The Apo AI MspI rare 
variant is also found more frequently in the upper tertile for plasma TG/HDL ratio 
(p<0.04). The similar results found with plasma apoE tertiles probably reflect the 
increased amounts of apoE carried on VLDL in lipaemic plasma. 
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Table 6-3. Observed distribution of allele frequencies for the LPL gene, HL gene and ApoAI-CIII gene mutations 
compared between Chinese and Caucasian controls 
Chinese Caucasian 
(n=74) (n=54) 
Gene allele frequencies p 
common allele rare allele common allele rare allele 
LPL 
9 Asp -Asn 1.000(140) 0.000(0) 0.991(107) 0.009(1) NS 
291 Asn -Ser 1.000(140) 0.000(0) 0.963(104) 0.037(4) <0.03 
447 Ser -Ter 0.893(125) 0.107(15) 0.880(95) 0.120(13) NS 
LPL-HindIII 0.771 ((1 08) 0.229(32) 0.704(76) 0.296(32) NS 
Thr361 _ Thr (HaeIII) 0.886(124) 0.114(16) 0.870(94) 0.130(14) NS 
HL 
Thr202 -Thr (MspI) 0.943(132) 0.057(8) 0.500(54) 0.500(54) <0.0001 
ApoAI 
AI-MspI 0.707(99) 0.293(41) 0.889(96) 0.111(12) <0.0006 
AI-XmnI 0.714(100) 0.286(40) 0.870(94) 0.130(14) <0.004 
AI-PstI 0.929(130) 0.071(10) 0.954(103) 0.046(5) NS 
ApoCIII 
CIII-SstI 0.721(101 ) 0.279(39) 0.880(95) 0.120(13) <0.003 
The number of observed alleles are presented in parentheses. Values for Caucasian controls are taken from our previous 
publication (Zhang 1995) 
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Figure 6-1 
12 11 22 
11 12 22 
- 522bp 
- 739bp 
(a) - 409bp (b) 
- 399bp 
- l13bp - 340bp 
ApoAI-Xmn I 
ApoAl-Pst I 
11 22 12 11 22 12 
(c) 342bp (d) - 363bp 
203bp 
139bp - 212bp 
- 151bp 
ApoAI-MspI ApoCIIl-Sst I 
Legend to Figure 6-1: RFLP analysis of the Apo AI-ClII gene complex: 
(a) the point mutation underlyingXmn I RFLP at 2.5kb upstream 5' of the ApoAI gene; (b) the 
G-C mutation underlying Pst I RFLP immediately at 3' of the ApoAI gene; (c) C-G mutation 
underlying Msp I RFLP at the intron 3 of the ApoAl gene; (d) the C3175_G mutation underlying 
Sst I RFLP at the exon 4 of the ApoCnI gene. Numbers above the lanes denote genotypes. 
Numbers above the lanes denote genotypes. " 1" denotes the common allele; 2', the rare 
allele . 
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Table 6-4. Lipid and lipoprotein tertiles related to ApoAI-CIII genotypes 
No. of Subjects Represented by Genotypes 
ApoAI-MspI ApoCIII -SstI 
MIM2 MIM2 M2M2 p SISI S1S2 S2S2 p 
Blood Glucose 
lower terti Ie «90.00mg/dl) 19 26 3 NS 20 25 3 <0.04 
higher terti Ie (>98.53mg/dl) 27 15 6 (0.07) 29 13 6 
ApoCIII 
lower terti Ie «9.72mg/dl) 26 17 4 NS 28 16 3 0.05 
higher tertile (> 13.90mg/dl) 25 14 11 25 13 12 
ApoE 
lower terti Ie «3.75mg/dl) 20 24 6 <0.03 20 24 6 <0.03 
higher terti Ie (>5. 15mg/dl) 31 11 8 31 11 8 
TG/HDL 
lower terti Ie «3.06) 23 22 2 <0.04 25 20 2 0.05 
higher terti Ie (>7.08) 25 15 10 25 15 10 
p Values were analysed by Chi-Square Tests (2x2 contingency tables) and Fisher's exact test where appropriate. 
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Lipoprotein Lipase Mutations 
The frequencies of LPL mutants in Chinese hyperlipidaemic subjects are presented in 
Table 6-5. The Ala261 _Thr variant was found more frequently in Chinese lipaemic 
subjects than controls, and the Serine 447 - Ter variant showed a tendency to be found at 
lower frequencies in the lipaemic subjects, but both did not reach statistical significance 
possibly because of small samples. None of the other common variants showed 
significant differences. 
6.4 2 Discussion 
The question whether genetic variants at loci involved in lipid transport could in part 
account for differences in mortality rates from coronary heart disease between Chinese 
and European populations has been considered in this study. In support of this hypothesis, 
we have found that two common disease related mutants of lipoprotein lipase in 
Caucasian groups do not occur in our Chinese samples. However, the Chinese group is 
small (n=143) and a larger study is warranted to substantiate these result. If confirmed the 
data may indicate that these mutations are of recent evolutionary origin, or that they have 
been exposed to positive selection pressures (possibly nutritional) in Caucasian 
populations. 
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Table 6-5: Observed distribution of allele frequencies for the LPL gene, HL gene and ApoAI-CIII 
gene mutations compared between Chinese hyperlipidaemic patients and controls 
Controls Patients 
(n=74) (n=69) 
Gene allele frequencies 
common allele rare allele common allele rare allele 
LPL 
9 Asp -Asn 1.000(140) 0.000(0) 1.000(136) 0.000(0) 
Ala261 _Thr 1.000(140) 0.000(0) 0.993(135) 0.007(1) 
291 Asn -Ser 1.000(140) 0.000(0) 1.000(136) 0.000(0) 
447 Ser -Ter 0.893(125) 0.107(15) 0.926(126) 0.074 (10) 
LPL-HindIII 0.771((108) 0.229(32) 0.824(112) 0.176(24) 
Thr361 _ Thr (HaeIII) 0.886(124) 0.114(16) 0.904(123) 0.096(13) 
HL 
Thr202 - Thr (MspI) 0.943(132) 0.057(8) 0.904(123) 0.096(13) 
ApoAI 
AI-MspI 0.707(99) 0.293(41) 0.647(88) 0.353(48) 
AI-XmnI 0.714(100) 0.286(40) 0.721(98) 0.279(38) 
AI-PstI 0.929(130) 0.071(10) 0.949(129) 0.051(7) 
ApoCIII 
CIII-SstI 0.721(101) 0.279(39) 0.647(88) 0.353(48) 
The observed alleles are presented in parentheses. Comparisons show no significant difference. 
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No ethnic differences were found in other reported LPL variants ( Ser447_Ter. or the 
HindUI RFLP); and no differences in allelic frequencies were found within the Chinese 
sample (n=143) between upper and lower tertiles for plasma triglyceride, or HDL. This, 
however, is a small sample and statistical significance may have been lost. 
With regard to the ApoAI-CIII-AIV gene cluster the common ApoCIII variant ( G3175 -C ) 
was found at higher frequencies in the upper tertiles for plasma triglyceridelHDL ratios 
and ApoCIII levels in the Chinese sample. This ApoCIII variant has been consistently 
found at higher frequencies in Caucasian subjects with hypertriglyceridaemia (Aalto-
Setala et al., 1987; Jowett et al., 1984; Stocks et al., 1987), Familial combined 
hyperlipidaemia (Hayden et al., 1987), and other dyslipidaemias. It has also been 
observed at increased frequencies in Caucasian subjects with premature coronary artery 
disease (Ferns & Galton, 1986; Rees et al .. 1985). The same relationship appears to hold 
for Chinese subjects with hypertriglyceridaemiallow HDL. However the observation that 
the ApoCIII variant occurs more commonly in a normolipidaemic Chinese group 
suggests that the variant is not directly involved as an aetiological factor, but is probably 
acting as a genetic marker for an aetiological mutant with which it is in linkage 
disequilibrium. 
6.5 STUDY II: DIRECT DNA SEQUENCING 
6.5.1 Results 
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6.5.1.1 Mutations detected 
Eleven of the most lipaemic Chinese subjects (fasting plasma triglycerides >700 mg/dl) 
were analysed for DNA sequence variation in the lipoprotein lipase genes (Table 6-6) to see 
if "non-European" mutants occur in this population. Analysis of the 9 coding sequence 
exons revealed two published mutations at Ali61 -Thr in exon 6 and Ser447_Ter in exon 9, 
and only one novel mutation where C 1338 is substituted by A; this is a silent mutation at 
Thr
361
_ Thr in exon 8 (Table 6-7), which was also found in French subjects with diabetic 
lipaemia recently (for reference to see chapter 4). Four of the eleven subjects carried these 
mutants in the heterozygous state. The gel sequences for detection of the novel mutation are 
presented in Figure 6-2. No mutations were found in the catalytic triad (residues ASplS6_ 
His241_Ser132) but one of the mutations occurred in exons 6 that code for binding the enzyme 
to heparan sulphate. 
6.5.1.2 The Allele Frequencies 
The Ala261 , Ser 447 and Thr361 variants were subsequently analysed by PCR amplification 
of exon 6, 9 and 8, and digestion with HaeIII, MnlI and HaeIII respectively. The 
frequencies of these three variants in 74 Chinese controls tested are presented in Table 6-
7. The Ali61 _Thr variant was not found in the control group. The Serine-+47-Ter variant and 
the silent mutation at Thr361 showed at frequencies 0.1 07 and 0.114 in Chinese controls 
respectively. 
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Table 6-6: Clinical data of the Chinese hyperlipidaemic patients analysed by DNA sequence variation 
Patient Age Sex BMI Fasting Pl.Chol Pl.Tg HDL-C ApoAI ApoAII ApoB ApoCII 
(yrs) 2 (kg/m) glucose (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) 
(mg/dl) 
1 50 M 27.5 87 223 725 27 101.0 21.0 96 11.8 
2 54 M 17.8 150 433 2711 20 117.0 32.3 105 17.2 
3 56 M 22.3 106 177 787 25 109.5 18.9 84 4.5 
4 61 M 21.3 97 217 863 30 87.0 14.3 100 11.4 
5 55 M 23.5 112 221 776 32 101.0 11.3 112 10.2 
6 55 F 22.9 102 221 684 30 101.0 24.8 96 12.3 
7 57 M 27.0 98 165 764 29 101.0 19.5 96 12.8 
8 64 M 31.2 99 233 1192 28 117.0 32.3 118 12.1 
9 49 F 28.4 123 300 1453 84 117.0 15.8 105 17.2 
10 59 M 23.2 81 184 726 37 100.5 21.0 110 8.2 
11 50 F 29.2 94 232 760 32 115.5 19.5 286 9.5 
Abbreviations used: PI. = plasma; TG. = triglyceride; Chol. or C = cholesterol; HDL = high density lipoprotein. 
ApoCIII ApoE 
(mg/dl) (mg/dl) 
34.3 13.3 
84.0 40.1 
24.8 13.8 
24.8 10.5 
24.8 8.5 
26.3 10.5 
35.5 4.2 
34.7 12.3 
40.0 23.3 
23.1 8.1 
20.5 8.8 
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Figure 6-2 
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Legend to Figure 6-2: Autoradiograph of DNA gel sequences of Thr361 silent mutation of LPL gene. 
Nucleotide sequence of the coding strand for the mutant and normal exon 8 of the LPL gene showing a 
C-A transversion at nucleotide 1338 that results in a silent mutation at Thr36 1 . 
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Table 6-7. Lipoprotein lipase gene mutations found in eleven Chinese seyerely 
hyperlipideamic subjects (plasma triglycerides > 700 mg/dl). 
Location 
in LPL 
gene 
Exon6 
Exon 8 
Exon 9 
Nucleotide 
Change 
C1595 -G 
Code Change 
Ali6L -Thr 
GCC=>ACC 
Thr361 _Thr 
ACC=>ACA 
447 Ser -Ter 
TCA=>TGA 
Individuals Allele 
frequencies 
in controls 
(n=74) 
3 0.000(0) 
2 0.107(15) 
9, 10 0.114(16) 
The number of observed alleles are presented in parentheses. 
6.5.2 Discussion 
Information 
Ma et at., 
1994 
this study 
Stocks et 
at., 1992 
We have found three mutations of the lipoprotein lipase gene by DNA analysis of 11 
patients with severe hyperlipideamia, which presented in the heterozygous state. Two 
already published mutations were Ala261 _ Thr in exon 6, which is a rare mutation and 
resulted in a mutant LPL protein with approximately 32-360/0 of normal LPL activity in 
vitro mutagenesis (Ma et at., 1994), and Ser447 -Ter in exon 9 (Stocks et at., 1992), which is 
a common mutation with normal LPL activity. The newly described mutation (C1338_A) is 
conservative. As discussed in chapter 4, it does not change the amino-acid sequence of the 
protein product and would not be expected to have any functional effects on the activity of 
lipoprotein lipase but could be used as a bi-allelic disease marker for the locus. Possibly 
regulatory sequences of the LPL gene or other genetic loci may be involved in their 
predisposition of these Chinese subjects to develop a dyslipidaemia. 
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7.1 INTRODUCTION 
Decreased plasma HDL-C levels have been associated with premature CHD (Gordon et 
al., 1989). ApoAI is the major protein of HDL, and with apoAII accounts for about 85% 
of the protein within HDL (Eisenberg, 1984; Patsch & Gotto, 1987). In some studies 
(Avogaro et al., 1979; Maciejko et al., 1983) plasma apoAI concentrations provide more 
information about CHD risk than do HDL-C levels. The protective role of HDL against 
CHD has been related to its function in the transport of cholesterol from peripheral cells 
to the liver for excretion, the so called "reverse cholesterol transport process" (Glomset, 
1968; Norum et al., 1989). Two distinct populations of HDL particles, lipoprotein 
containing apoAI and both apoAI and apoAII (LpAI and LpAI:AII), have been isolated 
(Atmeh et al., 1983; Cheung & Albers, 1982). Recently it has been noted that reduced 
LpAI but not LpAI:AII levels account for the decreased HDL-C concentrations in 
patients with CHD (Puchois et al., 1987). In other studies a reduced HDL-C level in CHD 
patients was associated with decreases in both types of particles (Genest et al., 1991; 
Parra et al., 1992). 
Some HDL-deficient syndromes, such as Tangier disease or familial ApoAI-CIII or 
ApoAI-CIII-AIV deficiency states, are characterized by premature CAD (Norum et al., 
1982; Ordovas et al., 1989~ Schaefer, 1984). In contrast, apoAI variants, including 
ApoAI · ApoAI band ApoAI1owa have not been associated with premature CHD milano' mar urg' , 
(Franceschini et al., 1980~ Rader et al., 1992; Utermann et al., 1982). 
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This chapter described a new deletion mutation in the human apoAI gene associated with 
low serum HDL-C and decreased apoAI and apoAII concentrations in a kindred with a 
high incidence of CHD. It has been characterised that the association of this ApoAI 
variant on different lipoproteins and their subclasses, on lipoprotein particle size and 
density distribution, and on the activities of the major enzymes involved in lipoprotein 
metabolism. 
7.2. SUBJECTS 
A 51-year-old woman (A.U.T) from South Finland was referred to the Lipid Research 
Clinic, Helsinki University Central Hospital (HUCH), due to her low HDL-C 
concentration (0.24 mM[9mg/dl]). She had significant obesity (BMI, 38.9 kg/m2) and had 
received medication for essential hypertension for 14 years. For the last three years, she 
had no history of angina pectoris or other vascular disease and had never smoked. There 
were no abnomal finding on her physical examination and laboratory tests about thyroid, 
liver and renal function. Her fasting blood glucose and glycosylated haemoglobin levels 
were normal. 
Altogether 25 relatives of the proband's family, from southern Finland, participated in the 
study. According to medical records: the proband's father had received medication for 
anginal symptoms for 3 years and died of cerebral haemorrhage at the age of 69 years: 
one aunt was diagnosed as having ischemic heart disease based on symptoms and 
electrocardio-graphic findings, who received medication for CHD symptoms and died 
suddenly at age 48 years; the other aunt had died at the age of 66 years of heart failure 
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after she had three prior admissions to HUCH for acute MI; an uncle had died of his 
fourth acute MI in HUCH at age of 54 years, the autopsy confirmed coronary 
atherosclerosis; another uncle had died of MI at age of 63 years, the autopsy confirmed 
substantial atherosclerotic changes in the coronary arteries and abdominal aorta; other 
two uncles died of CHD at 63 and 66 years, respectively, the latter uncle suffered the first 
MI at age 53 years; there were no HDL-C values in their medical records of the proband's 
aunts or uncles. In addition, three of the proband's cousins had died of CHD between the 
ages of 46 and 62 years, one of them died after receiving a heart transplantation at 
HUCH, his HDL-C level (measured on several occasions) was below the normal range 
(0.80 mM[31mg/dl]); other two of her cousins (T.M.A. and D.E.D.) had suffered an MI. 
The other family members had no clinical symptoms of CHD except two unaffected 
subjects (P.E.K. and R.E.K.) were diagnosed as having non-insulin-dependent diabetes 
mellitus according to the results of laboratory tests. A pedigree of the family is presented 
in Fig 7-1. 
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Figure 7-1 
* * 
** ** 
* 
I PEK I 
* 
= Heterozygotes 
= Heterozygotes 
* * = Premature CHD 
* =CHD 
-... = Proband 
Legend to figure 7-1: 
Pedigree of the family having the apoAI (Lys l07 -L1) deletion. Affected family members were all heterozygous for the defect. Squares 
indicate men; circles, women; and diagonal line, deceased. 
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7.3 MATERIALS AND METHODS 
7.3.1 DNA Preparation 
Genomic DNA was isolated from frozen whole blood of the proband, her family 
members, and a series of normal control subjects (Higuchi, 1989). 
7.3.2 Amplification of DNA 
Oligodeoxynucleotide pnmers used in amplification and sequencIng were chosen 
according to the published apoAI gene structure (Karathanasis et al., 1983) and 
synthesized on an Applied Biosystems model 381A DNA synthesizer. The sequences and 
positions of these primers are shown in Table 7-1. Six fragments of the apoAI gene of the 
subjects were amplified by using PCR with genomic DNA as a template. The PCR was 
performed in a reaction mixture containing 1 /-lM of primers, 0.2 mM each dA TP, dCTP, 
dGTP and dTTP, 50 mM Tris-HCI (pH 8.8), 1.5 mM MgCI2, 15 mM (NH4hS04' 0.1% 
Triton X-I 00, 0.1 mg/ml gelatin, and 2.5 U Taq DNA polymerase (Promega Corp) In a 
final volume of 100 ul. The reaction conditions on a programmable heating block (M] 
Research Inc) were as follows: 95°C 1 minute, 58°C to 63°C for 1 minute, and 72°C for 
2.5 minutes, 30 cycles. 
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Table 7-1: Sequence and position of oligodeoxynucleotide primers 
pnmer Sequence 5' position 
1 5' -CACCCGGAGACCTGCAAGC-3' -256 
2 5' -AGTGACCGGGGCAGGCAGCA-3' +26 
3 5' -GCTGGCTGCTT AGAGACTGC-3' -12 
4 5' -CGATGGTTGGCTCCCTAGGT -3' +293 
5 5' -GGCTCAGATCTCAGCCCACA-3' +408 
6 5' -CATCATCCCACAGGCCTCTG-3' +660 
7 5' -CTGA T A GGCTGGGGCGCTGG-3 ' + 1153 
8 5' -AGCGGCTCCACCTTCTGGCG-3' +1426 
9 5' -GGCAGGAGGAGATGGAGGCTC-3' +1403 
10 5' -CCGCCGTTCTCCTTGAGAGC-3' +1618 
1 1 5' -GAGGCTCTCAAGGAGAACGG-3' +1615 
12 5' -GAAGCTGCTTCCCACTTTGG-3' +1858 
13 5' -GGGCCTGAGGCAGGA-3' +1320 
14 5' _GGGCCTGAGGCAGGAGATGA-3' +1320 
15 5' -CA TCTCCTCCTGCCACTTCT -3 ' +1397 
Primers 1-13 were used for PCR and sequencing. Primers 8, 14 and 15 were used for 
mini sequencing. Primer 14 was biotinylated and primer 15 was used as a detection primer 
for the mutation. The 5' position indicates the position of the 5' end of the primer on 
apoaI gene ( + 1 is the first base of exonl). 
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7.3.3 SSCP analysis 
Six fragments of the apoAI gene of the subjects were amplified by PCR following the 
reaction conditions above and 2-3 /-ll of [a_32p] dATP or dCTP (3000 Ci/mM, 
Amersham) was added to each tube. The peR product was diluted 1: 1.5 with 0.1 % SDS, 
lOmM EDTA pH 8.0, denatured and loaded on neutral 5% polyacrylamide gel for 
mobility shift electrophoresis (Orita et al., 1989). Autoradiography was carried out with 
an intensifying screen using Kodak X-Omat film at room temperature for 24-72 hours. 
7.3.4 Direct DNA Sequencing 
The peR products were purified by Qiaex (Diagen GmbH) and directly sequenced with 
the dideoxy chain-termination reaction by using a sequenase kit ( US Biochemical Corp). 
For sequencing of the fourth exon, an additional primer, No.13, which is located 76 
nucleotides 5' of the mutation point, was used. 
7.3.5 Solid-phase minisequencing 
The solid-phase mini sequencing and the preparation of the batches of pooled leukocyte 
DNA were performed as described by Syvanen et al (Syvanen et al., 1992). The 127 bp 
fragment located at 111 nucleotides downstream of the 5' end of ApoAI gene exon 4 was 
amplified for minisequencing. The peR reaction mixture and condition were mentioned 
above except that the primers used were 2 /-lM biotinylated primer No. 14 and 10 pM of 
the primer No.8 and the annealing temperature was 60"C. The reaction mixture. which 
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consisted of 0.2 !J.M detection pnmer No. 15, 0.4 !J.M eH] dTTP (l16Ci/mmoL 
Amersham) to detect the wildtype, or 0.4 !J.M eH] dGTP (34 Ci/mmol, Amersham) to 
detect the mutated type and 1 U Taq DNA polymerase in 50 !J.l of PCR buffer, was added 
to each well. The radioactivity was measured in a liquid scintillation counter (1210 
Ultrobeta, LKB). 
7.3.6 ApoAI isoform analysis 
The ApoAI isoforms of the subjects were determined by isoelectric focusing and 
immunoblotting (Ehnholm et al., 1986). 
7.3.7 Lipid and lipoproteins 
Blood samples were obtained in the mornIng after a 12 hr fast. Cholesterol, free 
cholesterol, phospholipid, and triglyceride levels were analyzed by uSIng enzymatic 
colorimetric methods with a Cobas Mira analyzer (Hoffmann-Ia Roche) and reagent kits 
(Hoffmann-Ia Roche, Boehringer Mannheim GmbH Diagnostica, and Wako Chemicals 
GmbH). Serum apoAI, apoAII and apoB concentrations were measured by using an 
immunoturbidometric assay (Orion Diagnostica). Serum lipoproteins were isolated by 
sequential ultracentrifugation in a Beckman L8-70 ultracentrifuge (Beckman Instruments) 
(Havel et al., 1955). Density-gradient ultracentrifugation of lipoproteins, LDL gradient 
gel electrophoresis, HDL gradient gel electrophoresis, measurement of CETP and LCA T 
activity, measurement of LpAI and LpAI:AII concentrations and statistical analyses were 
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performed in collaboration with Dr. Marju Tilly-Kiesi et al (for reference to see 
publication 2). 
7.4 RESULTS 
7.4.1 Analysis of the apoAI variant 
Isoelectric focusing of the plasma of the proband (A.U.T.) and nine family members 
(K.K.K., R.O.K. K.P.V., T.M.A., O.E.O., P.P.V., M.V., R.K., and L.S.T.) revealed a 
variant apoAI isoprotein that had a decrease of one positive charge compared with normal 
mature apoAI (Fig 7-2). The relative plasma concentrations of the variant apoAI isoform 
and normal apoAI were similar as judged from the isoelectric focusing pattern. 
7.4.2 Mutation detected 
To localize the mutation that caused the net charge change of the variant isoprotein, all 
exons of the apoAI genes of the propositus and her relatives were amplified by PCR and 
subjected to SSCP analysis. Fig 7-3 shows the first fragment of exon 4 of the apoAI gene 
of the proband and some of the affected family members. Compared with the DNA 
migration pattern of control subjects, they had two additional bands with faster mobility. 
Pane 164 b 
Chapter 7 
Figure 7-2 
-
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Legend to figure 7-2 
Isoelectric focusing of apoAI. Lane 1, control apoAI; lane 2, apoAI (Lysl07_~). Arrow 
indicates shift mobility caused by mutation. 
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Legend to figure 7-3: PCR-SSCP analysis of exon 4 of apoAI. 
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Genomic DNA from leukocytes was subjected to PCR-SSCP amplification by using a 
pair of primers in exon 4 of apoAI. Amplified DNA from the proband (lane 1), her 
brother (lane 2) and her brother's son (lane 4) was used; lanes 3, 6 and 7 show control 
DNA. Lane 5 contains a mixture of normal and mutated DNA. Electrophoresis was 
performed in nondenaturing 50/0 polyacrylamide gels containing 10% glycerol at room 
temperature for 12 hours. 
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Direct sequencing of the coding region of the apoAI gene revealed that the proband and 
the nine other affected family members (Fig 7-1 ) were heterozygous for a 3 bp deletion 
in exon 4 from nucleotides 1396 through 1398, removing the codon (AAG) for Lys107 of 
the mature apolipoprotein. Exon 4 of the apoAI gene contains six 66 bp long homologous 
tandem repeats that code for six 22 amino acid segments. The 3 bp deletion described 
above occurred within repeat number one. The rest of the apoAI gene sequence was 
normal. 
7.4.3 Solid-phase minisequencing analysis 
The 3 bp deletion in the apoAI DNA of the proband and affected family members was 
further confirmed by using solid-phase mini sequencing, in which a 3' - detection primer 
(5'--------A CTT CT-3'), annealing immediately adjacent to the mutation site, is 
elongated by a DNA polymerase with a single dNTP corresponding to the nucleotide at 
the site of the mutation. To identify the normal sequence (5'-CAG AAG AAG T-3') and 
the sequence including the 3 bp deletion (5' -CAG --- AAG T-3 '), eH]dTTP is included 
in one mini sequencing reaction and eH] dGTP in another reaction. The ratio between the 
incorporated nucleotides directly reflects the ratio between the two sequences present in 
the PCR product. DNA samples from the proband (A.V.T.), her two brothers (K.K.K. and 
R.O.K.) and her son (K.P.V.) as well as DNA samples from two unaffected family 
members (K.K. and K.A.P.) and two unrelated control subjects were analyzed by solid-
phase minisequencing. The presence of the mutation resulted in a significant 
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incorporation of eH] dGTP, leading to a T/G ratio of about L while this ratio In 
unaffected family members and control subjects was >10 (Table 7-2). 
To determine the prevalence of the mutation apoAI (Lys l07 -~) in the Finnish population, 
solid-phase minisequencing of pooled DNA from Finnish subjects was performed. Three 
separate pools containing DNA from 921, 189 and 180 individuals, respectively, were 
analysed. In these population samples no subjects with the apoAI (Lys l07 -~) mutation 
could be identified (Table 7-2). 
Table 7-2. Determination and quantification of the 3 bp deletion causing removal of 
Lysl07 of apoAI DNA in affected and control individuals by solid-phase mini sequencing 
Sample 
K.K.K (brother 1) 
R.O.K (brother 2) 
K.K (mother) 
A.U.T (proband) 
K.P.V (son) 
K.A.P (sister) 
Normal subj ect 1 
Normal subj ect 2 
Pooled DNA 
A (n=921) 
B (n=189) 
C (n=180) 
G, cpm 
1428 
1324 
26 
2018 
1754 
80 
70 
16 
36 
34 
36 
Incorporated radioactivity 
T, cpm 
1306 
1276 
3514 
1944 
1706 
3090 
1522 
2544 
1052 
1072 
1502 
T/G,cpm 
0.90 
0.96 
135.00 
0.96 
0.97 
38.60 
21.70 
15.90 
29.00 
32.00 
42.00 
In the solid-phase mini sequencing reaction, T/G cpm was> 1 0 for normal, 0.1-10 for 
heterozygous, and <0.1 for homozygous individuals. n indicates number of individuals 
(ref. Chapter 3.2.9). 
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7.4.4 Serum lipoprotein and apolipoprotein levels and enzyme activities 
(performed in collaboration with Dr. Tilly-Kiesi et al ) 
The clinical characteristics and lipid values measured in subjects of the pedigree are 
presented in Table 7-3. The mean serum HDL-C concentration of the affected family 
members was clearly below the normal range and was reduced by 360/0 compared with 
the mean HDL-C value of the unaffected family members. Total serum cholesterol, LDL 
cholesterol and triglyceride concentrations were similar in apoAI (Lys l07 -~) affected and 
unaffected subjects. The proband had moderately increased serum triglycerides, while the 
rest of the apoAI (Lys107 -~) heterozygotes were normotriglyceridemic. The fasting blood 
glucose, glycosylated haemoglobin and serum insulin values were within the normal 
ranges for all affected subjects (data not shown). 
The mean serum apoAI concentration of heterozygotes was reduced by 18.30/0 and the 
apoAII concentration by 22.2% compared with unaffected family members (p<O.05 and 
p<O.OI, respectively). In heterozygotes the mean concentration of LpAI:AII was 310/0 
lower than in those with normal apoAI (p<O.Ol), while the mean level of LpAI was 
similar in the two groups (Table 7-3). The mean apoCII and apoCIII concentrations of 
heterozygotes were within the normal ranges and were similar to unaffected family 
members (data not shown). 
The mean plasma LCAT activity in carriers of the mutant apoAI gene did not differ from 
the LCA T activity of unaffected family members. In vitro no defect was observed in the 
LCA T activation properties of the isolated mutant apoAI. HoweveL the mean CETP 
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activity was reduced by 250/0 in affected family members compared with unaffected 
family members (p<0.05, Table 7-3). The mean CETP activity of the unaffected family 
members was similar to the level measured in the same laboratory for healthy control 
subjects. 
HDL density-gradient ultracentrifugation showed a lack of HDL2 and small dense HDL3 
in heterozygotes compared with unaffected family members. The HDL particle size 
distribution, as analyzed by nondenaturing gradient gel electrophoresis of heterozygotes, 
revealed one major peak at 8.0 to 9.7 nm, a minor peak at 7.8 to 8.5 nm and an absence of 
HDL2b and HDL2a peaks. These latter peaks were observed in unaffected family 
members. Serum levels of LDL cholesterol, triglycerides, VLDL, IDL and LDL 
subclasses were similar in the two groups (data not shown). However, in heterozygotes 
the cholesterol-to-triglyceride ratios in VLDL2, LDLb LDL3, HDL2b, HDL2a and HDL3a 
were 80/0 to 54% lower than in unaffected family members (p<0.05) (ref. Tilly-kiesi M, 
Zhang Q et aI., 1995). 
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Table 7-3. Clinical characteristic, lipid, lipoprotein, apolipoprotein, LpAI and LpAI:AII, and LCAT and CETP activities of family members with (n=lO) and 
without (n= 15) the apoAI (Lysl07 -0) mutation 
sex 
A.U.T.** F 
K.K.K.* M 
R.O.K.* M 
K.P.V.* M 
T.M.A.* F 
O.E.O.* M 
P.P.V.* M 
M.V.* F 
R.K.* M 
L.S.T.* F 
M.lV. M 
K.A.P. F 
K.K. F 
A.A.S. F 
A.K.S. F 
A.K.U. F 
P.E.K. M 
P.M.K. F 
P.K.B. M 
R.E.K. M 
R.T.K. M 
R.E.N. F 
R.A.T.K. F 
R.E.O.K. M 
1.K. M 
Mean±SD 
age,y 
51 
55 
40 
27 
68 
63 
49 
56 
35 
33 
32 
59 
79 
84 
49 
52 
64 
59 
48 
55 
58 
56 
41 
46 
11 
BMI, 
Kg/m2 
38.9 
27.7 
25.6 
26.9 
39.3 
32.2 
26.8 
28.1 
22.1 
21.9 
28.8 
28.3 
25.8 
36.3 
29.4 
31.0 
45.6 
24.3 
34.9 
31.3 
22.9 
43.4 
31.0 
27.7 
16.1 
TC, 
mM 
5.98 
4.50 
3.64 
5.39 
4.75 
6.81 
5.54 
2.97 
6.49 
3.99 
5.51 
4.99 
5.56 
5.50 
4.76 
5.05 
6.44 
7.70 
5.55 
6.69 
6.36 
5.65 
4.36 
6.18 
3.07 
Tg, 
mM 
5.87 
1.13 
0.85 
1.27 
2.40 
2.49 
1.11 
2.22 
1.27 
0.81 
2.72 
0.95 
0.83 
1.57 
1.85 
0.73 
2.84 
1.10 
0.91 
3.16 
1.51 
1.42 
1.00 
1.18 
0.38 
HDL-C 
mM 
0.28 
0.67 
0.73 
1.02 
0.46 
0.99 
0.54 
0.60 
0.98 
0.67 
0.69 
0.67 
1.51 
0.63 
0.76 
1.80 
0.76 
1.61 
1.15 
1.11 
1.18 
0.75 
1.07 
1.23 
1.07 
LDL-C 
mM 
3.57 
3.13 
2.33 
3.46 
2.75 
4.67 
4.31 
1.45 
3.32 
2.84 
3.90 
3.65 
3.55 
3.50 
2.71 
2.43 
3.85 
4.86 
3.44 
4.08 
3.37 
3.80 
2.80 
3.60 
ND 
apoAI 
mg% 
50 
105 
108 
132 
83 
151 
93 
113 
131 
108 
110 
100 
138 
98 
114 
173 
112 
170 
132 
160 
145 
114 
127 
141 
121 
apoAII 
mg% 
28 
26 
32 
42 
22 
31 
25 
20 
28 
23 
38 
33 
42 
30 
37 
37 
31 
42 
31 
40 
41 
26 
30 
39 
40 
LpAI 
mg% 
17 
51 
39 
63 
35 
57 
66 
51 
28 
24 
58 
29 
78 
40 
64 
46 
53 
66 
36 
43 
54 
LpAI:AII 
mg% 
33 
54 
64 
75 
44 
88 
58 
56 
65 
57 
82 
76 
80 
72 
85 
95 
72 
106 
86 
107 
79 
78 
84 
87 
82 
apoB 
mg% 
107 
91 
71 
97 
115 
156 
110 
70 
96 
74 
129 
91 
94 
III 
95 
70 
126 
124 
92 
157 
115 
114 
115 
1 1 1 
39 
LCAT 
M L-l h-l n .m . 
25.1 
41.4 
58.2 
55.4 
44.3 
36.8 
74.8 
45.0 
32.4 
46.0 
39.0 
42.2 
35.2 
35.7 
46.9 
42.5 
35.5 
33.7 
38.2 
42.5 
47.0 
52.2 
67.9 
41.8 
58.1 
CETP 
AU 
1.0 
1.1 
0.8 
1.2 
0.8 
0.8 
0.9 
0.7 
1.1 
1.1 
1.4 
1.7 
1.1 
1.7 
1.3 
1.0 
0.7 
1.2 
1.0 
0.8 
1.4 
1.5 
1.4 
1.4 
ND 
Mutation 47.7±13.5 29.0±6.1 5.01±1.26 1.94±1.51 0.69±0.25# 3.18±1.10 107±28# 28±6:;t: 48±14 59±15<D 99±26 45.9±14.1 0.9±0.2# 
No mutation 55.9± 13.7 31.5±6.6 5.74±0.87 1.56±0.80 1.07±0.38 3.54±1.42 131±25 36±5 46± 17 85± II 110±21 42.9+8.9 1.2+0.2 
8MI indicates body mass index; TC, total serum cholesterol: Tg,serum triglycerides; LDL-C, LDL cholesterol; AU, arbitrary unit and ND, not determinded. 
**Proband, *Subjects with the apoAI (Lys107_0) gene mutation. #p<0.05, :;t:p<O.OI, <Dp<O.OOI affected vs unaffected family members. 
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7.5 DISCUSSION 
This study reported an apoAI variant detected in a Finnish kindred. Isoelectric focusing of 
plasma from the proband and nine other family members revealed a variant apoAI 
isoprotein with a decrease of one positive charge compared with normal apoAI. PCR-
SSCP analysis, direct sequencing, and solid-phase mini sequencing analysis showed that 
the variant apoAI isoprotein was caused by a 3 bp deletion of nucleotides 1396 through 
1398 in exon 4 of the ApoAI gene, resulting in the lack of the codon for LysI07 ofapoAI. 
The mean HDL-C concentration of affected family members was reduced by one third 
compared with unaffected family members, while mean total and LDL cholesterol 
concentrations were similar in affected and unaffected subjects. An increased incidence of 
hypertriglyceridemia is typical of some apoAI variants (Funke et al., 1991; Utermann et 
al., 1982; Weisgraber et al., 1980), but the serum triglyceride concentrations of all the 
107 d h apoAI (Lys -,6.) heterozygotes except the proban were normal. T e proband had 
moderately increased serum triglycerides, possibly as a consequence of obesity and low 
lipoprotein lipase activity (Eckel, 1989; Taskinen & Nikkila, 1977). Concomitant 
moderate hypertriglyceridemia explains the proband's exceptionally low HDL-C 
concentration compared with the HDL-C levels of other affected family members 
(Nikkila, 1984). 
Heterozygous subjects had mean serum apoAI and apoAII concentrations that were 
reduced by a similar extent. The mean concentrations of LpAI particles were the same in 
affected and unaffected subjects, while affected family members had a 31 % lower mean 
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concentration of LpAI:AII particles than unaffected family members. Puchois et al (1987) 
and Barkia et al (1991) have shown that reduced concentrations of LpAI but not 
LpAI:AII are associated with coronary artery disease, and in vitro studies support the 
assumption that LpAI is cardioprotective (Barkia et al., 1991; Puchois et al .. 1987). In 
contrast, other studies have shown that LpAI and LpAI:AII are reduced to a similar 
degree in coronary artery disease or CHD patients (Genest et al., 1991; Montali et al., 
1994; Parra et al., 1992). 
An inverse correlation between the HDL-C level and the fractional catabolic rate of 
apoAI and apoAII has been demonstrated (Brinton et al., 1989; Brinton et al., 1991; 
Horowitz et al., 1993; Schaefer et al., 1982), and in heterozygous apoAI milano (Arg I73_ 
Cys) and apoAI Iowa (Gly26_Arg) subjects both the mutant and the normal apoAI are 
catabolized at an increased rate (Rader et al., 1992; Roma et al., 1990). In addition, 
apoAII levels are decreased in subjects with these mutations, which suggests that apoAII 
may be more rapidly catabolized in these subjects as well (Rader et al., 1992). However, 
apoAII kinetics have not been studied in subjects with apoAI variants, and no data have 
been reported on the metabolism of the two HDL particle populations in apoAI-variant 
subjects. On the basis of the normal concentration of LpAI particles and the decreased 
concentration of LpAI: All particles in apoAIHelsinki (LysI07_~) heterozygotes, it can be 
hypothesised that this mutation primarily affects the metabolism of HDL particles 
containing both apoAI and apoAII. The preliminary data from in vivo turnover studies in 
two apoAI (LysI07_~) heterozygotes show an increase in the fractional catabolic rate of 
both apoAI and apoAII (Tilly-Kiesi et al, unpublished data, 1995). 
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Several characteristic features of the HDL of heterozygotes were observed in comparison 
with the HDL of unaffected family members. Density-gradient ultracentrifugation studies 
demonstrated that the heterozygotes lacked HDL2, and more than two thirds of their total 
HDL was found in subfractions HDL3b and HDL3c' which have the highest density and 
the lowest cholesterol/protein ratio (Eisenberg, 1984; Patsch & Gotto, 1987). These data 
are consistent with the observation that these subjects have a greater percentage reduction 
in serum HDL-C levels than in apoAI and apoAII concentrations. HDL particle size 
distribution studies revealed that heterozygotes lacked HDL peaks in the particle size 
range> 9.7 nm, indicating a deficiency of larger HDL particles (Cheung et al., 1987). 
The LDL subclass concentrations, density distribution, and particle size of heterozygotes 
resembled those of unaffected family members. The concentrations and density 
distribution of VLDL and IDL were also similar in affected and unaffected family 
members. LPL and HL, which are related to the conversion of VLDL to IDL and LDL, 
are also involved in the conversion of large LDL to smaller LDL particles (Auwerx et al., 
1988; Connelly et al., 1990; Deckelbaum et al., 1982; Levy et al., 1990). Similar mean 
postheparin LPL and HL activities were found in affected and unaffected family members 
(data not shown), consistent with the similarity of VLDL, IDL and LDL subclass 
distributions in these two groups. 
136 ) . In Tangier homo zygotes and in subjects homozygous for the apoAI(Glu -Lys mutatIOn, 
the triglyceride levels in LDL is increased (Heinen et al., 1978; RaIl et al., 1986). In 
Lys l07 . k'-~ heterozygotes the cholesterol to triglyceride ratio was significantly HelslJ1 'I ' 
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reduced in VLDL2, LDLJ, LDL3, HDL2b, HDL2a and HDL3a, and in all other lipoprotein 
subclasses, a similar trend was noted. An imbalance in the amounts of donor (HDL) and 
acceptor (VLDL, LDL) particles for cholesteryl ester transfer may account for the 
diminished cholesterol-to-triglyceride ratio in the plasma lipoproteins of heterozygotes 
(Chait et al., 1984; Gambert et al., 1990). The reduced CETP activity of heterozygotes 
compared with unaffected family members may be a compensatory alteration to increase 
the HDLiHDL3 ratio and to correct the HDL composition (Inazu et al., 1990). 
ApoAI is an important activator of the LCAT enzyme (Cheung et al., 1988; Cheung et 
al., 1986). As reviewed in chapter 1.4.4, partial LCAT deficiency due to reduced LCAT 
mass or to reduced ability of the variant apoAI to activate LCA T is associated with apoAI 
. 173 202 )..16 160 . 
vanants such as apoAI (Cys -Arg), apoAI (Thr -L1), apoAI(Glu -Arg ) deletIOn, 
apoAI(Lys I07_L1) and apoAI(Pro I43-Arg) (Deeb et al., 1991~ Franceschini et al., 1990; 
Funke et al., 1991; Utermann et al., 1984). The mutant apoAI (Lys 107_L1) was isolated 
from our proband and studied the interaction of mutant apoAI with LCAT in vitro. No 
defect in the LCAT activating properties of the mutant apoAI was observed. In addition, 
the mean plasma LCAT activity of affected subjects was similar to that found in 
unaffected subjects. 
HDL deficiency due to Tangier disease or apoAIIapoCIII or apoAI/apoCIIIIapoAIV 
deficiency syndromes has been associated with premature CHD (Norum et al., 1982; 
Ordovas et al., 1989; Schaefer, 1984). In addition, apoAI gene mutations causing a 
84 . d truncated apoAI protein (GIn -stop) and an absence of apoAI (Gln[ -2]Ter) are aSSOCIate 
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with xanthomas and premature CHD (Matsunaga et al., 1991; Ng et al., 1994). The 
majority of apoAI variants have not been associated with low HDL-C levels or premature 
CHD, only one third are clearly associated with reduced plasma HDL-C and apoAI 
concentrations, and the mean age of those subjects was 33 years, a very low age to make 
accurate estimations of any association with CHD. Interestingly, in three apoAI variants 
(C 173 Ar Thr202 146 160. . . ys - g, -~ and Glu -Arg ) causIng HDL deficIency, the abIlity of variant 
apoAI to activate LCAT and lor the plasma concentration of LCAT is markedly reduced 
(Deeb et al., 1991; Franceschini et al., 1990; Funke et al., 1991). In contrast, apoAlhelsinki 
(Lys107_~) heterozygotes had HDL deficiency and normal LCAT activity. It should be 
noted that markedly premature CHD has not been observed in LCA T deficiency or fish-
eye disease despite strikingly low levels of HDL-C (Norum et al., 1989). Therefore, 
normal LCA T activity may be necessary for low HDL-C to be a CHD risk factor. 
In Kindred studies it is hard to actually assess associations of mutations with CHD 
because of the limited number of subjects and the strong association of CHD with age 
and gender. Pedigree analysis indicated that the proband received the mutation from her 
father. Medical-record review revealed that the father and six of his siblings had CHD; in 
four of these siblings, CHD was present before the age of 55 years. These six siblings 
died of CHD, while the father died of cerebral haemorrhage. The mean age of death in 
these seven subjects at 61 years is earlier than that observed in the normal population. 
The one remaining sibling of the father was an unaffected subject and healthy at age of 84 
years. Among the seven heterozygotes ( mean age, 56 years) of the proband and her 
generation, two (T.M.A. and O.E.O) had CHD at age 65 and 63 years. respecti\'ely. 
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without any other risk factors except for a low HDL-C level. In addition, three other 
subjects of this generation, including T.M.A. 's sister and brother, had died of CHD at the 
ages of 45, 55 and 62 years. It was not possible to determine whether they \\"ere 
heterozygotes. None of the unaffected family members had symptoms or signs ofCHD. 
The combined data indicate that the apoAIHelsinki mutation (Lys 107 -i1) results in decreased 
serum HDL-C, apoAI, apoAII and LpAI:AII levels, reduced CETP activity, normal 
lipolytic enzyme and LCAT activities and may be associated with premature CHD. 
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GENERAL DISCUSSION AND CONCLUSION 
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The work presented in this thesis aimed to study the possible role of several candidate 
genes in the genetic susceptibility to dyslipidaemia and premature CAD. Association 
studies by PCR-RFLPs, SSCP and direct DNA sequencing were the methods used in 
these studies. 
The candidate genes were selected from the pathophysiological data available on 
dyslipidaemia and CAD, which indicate a possible primary role for genes encoding 
proteins and enzymes involved in lipid transport. These include the LPL gene and the 
ApoAI-CIII-AIV gene cluster. 
Firstly, the role of the LPL gene and the ApoAI-CIII-AIV gene cluster were examined by 
association studies in both German and Chinese populations of controls and dyslipidaemics 
and! or patients with arterial disease (coronary artery disease and! or peripheral artery 
disease). As possible pitfalls of association studies are: small sample sizes; disease 
heterogeneity; cases vesus controls of different ethnic origins and population differences, to 
avoid these problems in this study, the sample size were based on our previous publications 
in the field showing that subject groups of greater than 75 persons were required to 
undertake a satisfactory statistical analysis given the power of the currently available 
methods; the same criteria was used to define patients and controls in German and Chinese 
populations; controls were matched with patients from the same ethnic origin. Secondly, the 
role of the LPL gene has been investigated respectively by direct DNA sequencing in 
French subjects with severe diabetic lipaemia and Chinese subjects with severe 
hyperlipidaemia; the studies for gene frequencies of new detected mutations are warranted, 
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thirdly, the role of the ApoAI gene has been studied in a Finnish kindred with premature 
CHD. 
The expected benefits from identifying such genetic factors would be: 
(i), the possibility of early identification and treatment of high risk individuals who possess 
a susceptibility genotype. 
(ii), a better understanding of the pathogenesis of the premature types of atherosclerosis and 
providing means of risk prediction at both the population and individual based levels. 
(iii), the possibility of the identification of critical environmental factors that interact with 
the genotype before development of the disease occurs. Identifying such key environmental 
factors from knowledge of the genes involved may aid in disease prevention both at the 
population and individual based levels. 
(iv), the possibility of suggesting newer forms of therapies by either replacing or blocking 
the gene products when the defective genes have been identified. 
8.1 GOALS ATTAINED IN THIS STUDY 
8.1.1 The LPL gene 
The role of the LPL gene was examined by association studies in both German and Chinese 
populations of dyslipidaemic, arteriopaths (coronary artery disease and/or peripheral artery 
disease) and controls. Its role has also been investigated by direct DNA sequencing in 
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French subjects with severe diabetic lipaemia and Chinese subjects with severe 
hyperlipidaemia. 
More than 60 disease related mutations of lipoprotein lipase have been noticed as discussed 
in chapter 1.4.1. The majority of these appear to be rare, occurring at frequencies of less 
than 1: 1000. However four common population polymorphisms (frequencies of> 1 0/0) at the 
LPL locus have been documented that show disease relationships. The first to be published 
was the bi-allelic marker in intron 8 at a HindIII restriction site (Chamberlain et at., 1989), 
whose alleles showed asymmetric frequencies in subjects with dyslipidaemia compared to 
controls (Chamberlain et at., 1989; Heizmann et at., 1991; Peacock et at., 1992) and in 
subjects with premature coronary artery disease (Thorn et at., 1990). These effects were 
subsequently attributed to linkage disequilibrium to a common premature termination 
mutation, Ser447_Ter, in exon 9,635 base pairs downstream of the HindIII site (Hata et at., 
1990; Stocks et at., 1992). This variant truncates the mature protein by two amino-acids, 
which has beneficial effects on lipid profiles, and has been found to show associations with 
decreased dyslipidaemia (Mattu et at., 1994). Other common polymorphic variants 
(population frequencies of>l%) at LPL have been found Asp9-Asn at exon 2 (Gagne et at., 
1994) and Asn291 -Ser at ex on 6 (Reymer et at., 1995). These have been reported to be 
associated with increased dyslipidaemia (Pimstone et at., 1995; Reymer et at., 1995). 
Pag~ 181 
Chapter 8 
8.1. 1. 1 Association studies 
Case-control analyses of these three allelic distributions, ASp9 -Asn, Asn291 _Ser and Ser 447_ 
Ter, of the LPL gene between the two groups with or without dyslipidaemia or arterial 
disease did not show any significant differences in the German and Chinese populations 
studied. However, with regard to the common mutations and biochemical characteristics 
, 
the following observations were made: 
S . 447 T t t· erme - I er mu a Ion 
In German groups (n=323), Plasma triglycerides and VLDL-triglycerides were lower in 
subjects possessing the Serine447-Ter mutation. When the lipid distributions were analysed 
by tertiles, the Ser447 -Ter mutation was significantly less frequent in the highest tertiles for 
triglycerides (Zhang et at., 1995). The Ser447_Ter variant was also found at lower 
frequencies in the Chinese lipaemic subjects, which is consistent with previous publications 
(Mattu et at., 1994). 
The Ser 447 - Ter variant is the first common coding sequence mutation at the LPL gene locus 
that appears to have beneficial effects on plasma lipid profiles. The functional significance 
of the carboxyl terminal region of the LPL remains uncertain, and may provide an anchor 
for the attachment of the enzyme to endothelial cell surfaces. Studies on the deletion of the 
terminal two residues (serine-glycine) of LPL have resulted in cont1icting reports of the 
kinetic properties of the truncated enzyme. In one study (Kobayashi el aI., 1992), after 
transient transfection of wild type and mutant cDNA's into COS-1 cells, the mutant enzyme 
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hydrolysed much less Triton-X 100 triolein than wild type enzyme; in another study no 
differences were found in either secreted enzyme mass or specific activity (Faustinella et 
al., 1991); and in a third study (Kozaki et al., 1993) which specifically set out to study the 
effects of carboxyl-terminal truncation, the mutant enzyme showed greater mean specific 
activities than control (185%) enzyme, which was repeated in nine separate experiments. 
Successive truncations after residue 446 resulted in the expected progressive loss in specific 
activity of the enzyme. Discrepancies between these results may be due to variations in 
tertiary structure (e.g. glycosylation) of enzymes secreted by different COS-cell lines; or to 
the differences in properties of the substrates used to measure enzymatic activities. A study 
of the kinetic properties of the native enzyme purified from plasma of subjects homozygous 
for the rare or common alleles using a variety of substrates (chylomicra; intralipid; triton-
triolein; and gum arabic-triolein) found that the Km and Vmax of the native and variant 
enzymes were similar, but that heparin appeared to more readily release the variant enzyme 
from endothelial binding sites (Previato et al., 1994). 
In summary, the Ser447 -Ter mutation may be one of many variants that counteracts the 
effects of cardiovascular risk factors such as the dyslipidaemias. The presence of such 
beneficial mutations may account for the clinical variability in the natural history of 
atherosclerosis in subjects with well-defined cardiovascular risk factors. Further work is 
required to identify such putative protective variants and elucidate the mechanisms of their 
possible beneficial effects on lipoprotein profiles. 
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A 9 291 . sp -Asn and Asn -Ser MutatIons 
In this study, two European disease-related genetic variants, Asp9-Asn and Asn291 _Ser. were 
not found in the Chinese group (Zhang et al., 1997 in press). However. in German 
population, we found the ASp9 -Asn substitution was significantly more frequent in the 
lowest tertiles for ApoAI, and a trend towards increased number of genotypes containing 
the Asn261 -Ser in the arterial disease group as compared with the German controls, but 
this does not quite reach statistical significance. 
Humphries et al (unpublished data, 1995) found the frequency for the Asp9-Asn mutation 
was between 2-30/0 in the general population in the UK, Sweden and Holland, which is 
equivalent to that found in the German group. Post-heparin LPL activity was in the lower 
tertiles, and plasma triglyceride levels above the mean in the majority of individuals with 
this mutation. In patients with combined hyperlipidaemia, the frequency of the mutation 
was 5-70/0, and the majority of these individuals had significantly reduced levels of post-
heparin LPL activity. In addition, the ASp9 -Asn variant (Mailly et al., 1995) lowers 
lipoprotein lipase expression by about 25-30% and is found at higher frequencies in 
patients with hypertriglyceridaemia than in healthy controls. Healthy carriers of the 
mutation also have plasma triglyceride levels 25-300/0 higher than non-carriers: and 
survivors of myocardial infarction, who were both obese and carriers, were found to have 
higher plasma triglyceride levels than non-carriers. 
The Asn291-Ser mutant (Reymer et al., 1995) is found at an increased frequency in 
Caucasian male patients with premature atherosclerosis who have 10\\ 1e\'els of lIDt. 
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This variant results in a significant decrease in LPL catalytic activity and in yitro 
expression studies confirm that this variant shows a significant reduction in LPL activity 
compared to wildtype. 
It appears that the Asp9-Asn and Asn291 _Ser mutations are relatively common mutations 
which may predispose individuals to develop hypertriglyceridaemia (HTG) and CAD in 
Caucasian population via reduction in LPL activity. The fact that these mutations were not 
observed in the Chinese group may add weight to the hypothesis that they have an impact 
on the development of coronary heart disease. 
8.1.1.2 Direct DNA sequencing 
Diabetes m., obesity, and hypertriglyceridaemia are commonly found together and this 
association has led to the postulation of a metabolic syndrome, called Syndrome X. The 
basic pathology of this syndrome has been proposed to be due to insulin resistance with a 
possible underlying genetic basis to account for its familial associations. However insulin 
resistance is a complex concept and may be due to many different factors including: the 
presence of circulating insulin antibodies; insulin receptor antibodies; insulin receptor 
mutants; defects in the intracellular signal transduction pathway for insulin~ and raised 
plasma levels of free fatty acids or triglycerides. 
As defects in the plasma transport of triglyceride or fatty acids could be pnmary 
determinants for this syndrome, we have investigated the gene encoding LPL, a critical 
enzyme in the clearance of plasma triglycerides, in eighteen French subjects with diabetes 
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m., obesity, and severe hypertriglyceridaemia. Eight of the subjects were found to possess 
genetic variants, all in heterozygous state, at the LPL gene locus (Galton et ai., 1996. in 
press; Zhang et ai., Submitted to Europ J Clin Invest). Variants found were: 
(b) Gly188 -Glu (G818 -A), (c) Arg I92 -Ter (C829 - T); 
(d) Asn291 _Ser (A1I27_G), 
Three of these, (c), (e ),and (f) have not hitherto been described. (f) appears to be a silent 
population polymorphism, whose allele frequency in eighty one of normolipidaemic 
diabetics was found to be 0.12. The two others, Arg I92_Ter in exon5 and Phe35I _Leu in exon 
7, are all rare at frequencies of <0.01 and may contribute to the phenotype by impairing 
clearance of plasma triglycerides. The heterozygous state of these two rare mutations may 
be unaffected or show a mild lipaemia; but when associated with diabetes m, a condition 
that predisposes to hypertriglyceridaemia, the mutant could lead to a severe lipaemia. 
However, a second mutation may occur in regulatory regions or the other genetic loci to 
cause reduced the LPL activity. 
Three new variants came to light suggesting that there is much more genetic diversity at this 
locus than was previously recognised. It can be postulated that with this degree of locus 
heterogeneity, there is unlikely to be a single aetiological factor to account for this 
syndrome; and conclude that genetic variants at the lipoprotein lipase locus occur 
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commonly in subjects with this syndrome and may affect the individual's response to 
obesity and diabetes m. for the development of lipaemia. 
Direct DNA sequencmg analysis of 11 Chinese patients with severe hyperlipideamia 
identified three mutations in the LPL gene, which were present in the heterozygous state. 
The two previously published disease-related mutations were Ala 261_ Thr in exon 6, and 
Ser 447 _ Ter in exon 9 as previously discussed (Stocks et al., 1992). The third mutation (C 1338_ 
A) is conservative, also found in the French diabetic lipaemic subjects as discussed above. 
The Ali61 -Thr variant was not found in the Chinese control group (n=74), which is also a 
rare mutation in Caucasian population. The Serine 447 -Ter variant and the silent mutation at 
Thr361 showed at frequencies 0.107 and 0.114 in the controls (n=74) respectively. 
447 . b h A 9 d A 261 .c. d' Ch' In summary, the Ser vanant ut not t e sp an sn mutants were loun m mese 
subjects and it suggests that these genetic differences between Chinese and Europeans may 
partially account for the differential prevalence of coronary artery risk factors involved in 
lipid transport between the two populations (Zhang et al., 1997 in press). 
8.1.2 The ApoAI-CIII-AIV gene cluster 
The role of the ApoAI -CIII -AIV gene cluster was examined by association studies in both 
German and Chinese populations of dyslipidaemic, arteriopaths (coronary artery disease 
and/or peripheral artery disease) and controls. Its role has also been investigated by direct 
DNA sequencing in a Finnish family with premature CHD and decreased HDL cholesterol 
levels. 
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Case-control analyses of these four genotypic distributions, MspI, PstI, XmnI and SstI 
RFLPs, of the ApoAI-CIII-AIV gene cluster carried out between the two groups with or 
without dyslipidaemia or arterial disease did not show any significant differences in the 
German and Chinese populations studied. However, in the German group, the results 
showed the association between high triglyceride, VLDL, TG/HDL ratio and PstI RFLP 
at the ApoAI gene, which is similar to results seen in the earlier work of our laboratory 
(Chamberlain & Galton, 1991). High levels of LDL-C and low levels of HDL-C have 
been identified as independent risk factors for coronary artery disease. In addition, 
deficiencies of ApoAI are known to be associated with abnormalities in lipoprotein 
metabolism, manifesting as low plasma HDL-C levels (Humphries, 1988; Monsalve et 
al., 1989). Therefore, these variations in lipoprotein metabolism may predispose to the 
development of atherosclerosis. 
In the Chinese group, the rare alleles of the Apo CIII -SstI RPLP and the apo AI MspI 
polymorphic variant were both found more frequently in the upper tertile distributions for 
apolipoprotein CIII levels and plasma triglyceridelHDL ratios. The ApoCIII variant has 
been consistently found at higher frequencies in Caucasian subjects with 
hypertriglyceridaemia (Aalto-Setala et al., 1987; Jowett et al., 1984; Stocks et al., 1987), 
familial combined hyperlipidaemia (Hayden et al., 1987) and premature coronary artery 
disease (Ferns & Galton, 1986; Rees et al., 1985); the ApoAI MspI is also associated with 
hypertriglyceridemia (Frossard et al., 1987) in Caucasian subjects. The same 
relationships appear to hold for Chinese subjects with hypertriglyceridaemiallow HDL. 
However the observation that the Apo CIII variant occurs more commonly In a 
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normolipidaemic Chinese group than European group suggests that the variant is not 
directly involved as an aetiological factor, but is probably acting as a genetic marker for 
an aetiological mutant with which it is in linkage disequilibrium in both group. 
A Finnish kindred with premature CHD and decreased HDL cholesterol levels was 
identified as having an apoAI variant (Lysl07-~), caused by a 3 bp deletion of 
nucleotides 1396 through 1398 in exon 4 of the ApoAI gene (Tilly-Kiesi & Zhang et al., 
1995). Ten family members were heterozygous for this mutation. CETP in heterozygotes 
was reduced by 25% compared with unaffected family members, while the plasma LCA T 
activity did not differ between heterozygotes and unaffected family members. The ability 
of isolated variant apoAI to serve as a cofactor for LCA T in vitro did not differ from that 
of normal apoAI. On the basis of the normal concentration of LpAI particles and the 
decreased concentration of LpAI:AII particles in apoAIHelsinki (Lys107 -~) heterozygotes, It 
can be concluded that this mutation primarily affects the metabolism of HDL particles 
containing both apoAI and apoAII. The reduced CETP activity of heterozygotes may be a 
compensatory alteration to increase the HDL2/HDL3 ratio and to correct the HDL 
composition, and normal LCAT activity may be necessary for low HDL-C to be a CHD 
risk factor. This data are consistent with the concept that the apoAI Helsinki 
mutation(Lysl07~~) having normal LCAT activity is a consequence of decreased 
concentration of LpAI:AII particles and of a smaller size and reduced cholesterol content 
of HDL particles. The combined data indicate that the apoAIHelsinki mutation (Ll's 107 -~) 
results in decreased serum HDL-C, apoAI, apoAII and LpAI:AII levels, reduced (,ETP 
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activity, normal LPL, HL and LCAT activities and may be associated with premature 
CHD. 
The development of significant atherosclerotic lesions depends on the interaction of 
haemodynamic, environmental and genetic risk factors. The data so far suggest that the 
LPL gene and the ApoAI-CIII-AIV gene cluster play important roles in the genetic 
susceptibility to dyslipidaemia and CHD; and the strong possibility that individuals who are 
carriers for different mutations in the LPL gene and the ApoAI-CIII-AIV gene cluster may 
benefit from an early identification, followed by appropriate counselling on life-style 
changes that would help them to reduce their subsequent risk of developing arterial disease. 
8.2 FUTURE STUDIES 
Although studied for several decades, mechanisms of regulation of lipolysis by lipases 
and apolipoproteins are still incompletely understood. Continued studies of the naturally 
occurring LPL and apolipoprotein mutations could provide new insights into the structure 
and function of LPL and apolipoproteins. This information can be refined further by in 
vitro site-directed mutagenesis of the LPL gene and apolipoprotein genes; and 
structure/function analysis of the mutant proteins. The elucidation of the three-
dimensional structure of LPL and apolipoprot2lns could provide the answer to how and 
why specific amino acid substitutions affect the function(s) of the proteins. Finally, 
because of the genetic complexity of the heritable lipoprotein phenotypes associated with 
coronary heart disease, the important advances are likely to result from the development 
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of new animal models based on transgenic techniques, where individual risk variables can 
be assessed independently. 
8.2.1 Transgenic animal models 
The mouse has been used as an experimental model for atherosclerosis research for only a 
short time; however, the genetics of this species has already allowed a number of 
innovative approaches to studying the complex physiological and pathological processes 
in vivo that are not possible with other animal models. Lipoprotein transport genes have 
either been added to the germ line of mice by transgenic techniques or knocked out by 
homologous recombination in embryonic stem cells to further probe their physiological 
functions. The resultant over- or underexpression of these genes has resulted in new 
insights about how these genes function in the body and their role in lipoprotein 
metabolism, e. g. human Apo crn gene was introduced into transgenic mice and resulted 
in hypertriglyceridemia (Ito et al., 1990). Either singly or in combination, these genetic 
modifications can be used to engineer the mouse to make it a better model for human 
lipoprotein disorders and atherosclerosis (Breslow, 1993). More importantly, the newer 
genetic technologies such as quantitative trait-loci mapping (e.g. identifying rodent genes 
controlling quantitative traits such as plasma cholesterol and triglycerides) transgenic 
mice, and gene-targeted mice are likely to lead to the identification of corresponding 
human genes. Improved understanding of the genetic processes underlying lipoprotein 
disorders will suggest new interventions to inhibit or reverse these processes. (Paigen et 
al., 1994; Willnow & Herz, 1995). 
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Gene targeting allows precise, predetermined changes to be made in a chosen gene in the 
mouse genome. To date, targeting has been used most often for generation of animals 
completely lacking the product of a gene of interest. Models of several human genetic 
diseases have been produced by targeting--including Gaucher's disease, Cystic fibrosis. 
These diseases are primarily determined by defects in single genes, and their modes of 
inheritance are well understood. When the disease under study has a complex aetiology 
with multiple genetic and environmental components, the generation of animal models 
becomes more difficult but no less valuable. The problems associated with dissecting out 
the individual genetic factors also increases substantially and the distinction between 
causation and correlation is often difficult. To prove causation in a complex system 
requires rigorous adherence to the principle that the experiments must allow detection of 
the effects of changing only a single variable at one time. Gene targeting experiments, 
when properly designed, can test the effects of a precise genetic change completely free 
from the effects of differences in any other genes (linked or unlinked to the test gene). 
They therefore allow proofs of causation (Smithies & Maeda, 1995). 
Further metabolic and genetic studies indicate that some of these loci of lipoprotein 
transport genes harbour significant, but as yet undefined, genetic variation. Additional 
candidate gene loci might be those coding for genes involved in intracellular cholesterol 
metabolism, cholesterol absorption, or insulin resistance. A more complete understanding 
of the genetics of atherosclerosis susceptibility will probably also entail the identification 
of variants at genetic loci that control both the response of the blood vessel wall to 
atherogenic lipoproteins and the thrombosis system. Investigation of the genetic basis of 
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coronary heart disease susceptibility remains a worthwhile and intriguing field. with 
important clinical and public health ramifications. 
8.2.2 Gene therapy 
Over the last 10 years, the explosion of molecular biology and molecular genetic 
techniques have allowed major advances in the diagnosis and management of a wide 
variety of human disorders. These range from accurate and simple screening for carriers 
of thalassemia (Old et al., 1990) to the use of preimplantation diagnosis of embryos at 
risk for untreatable congenital defects (Monk & Holding, 1990) and the development of 
gene therapy for treatment of disorders such as adenosine deaminase deficiency (Sharp, 
1991). Gene therapy is the introduction of new genetic material into somatic or germ 1 ine 
cells to synthesise missing or defective proteins. Efficient methods for the introduction of 
genetic material into cells are available, both in vitro and in vivo. These strategies involve 
chemical, physical, and viral-mediated mechanisms of gene transfer. Application of these 
gene transfer techniques has led to the development of potential gene-based treatment 
strategies that could combat vascular and myocardial disease. These molecular techniques 
have been applied to lipid disorders with some notable successes, both in their diagnosis 
and understanding of the mechanisms of the resulting pathology; in particular, the recent 
experiments (Wilson et al., 1992) that have led to treat homozygous familial 
hypercholesterolemia by transfer of LDL using gene replacement (Grossman et al .. 1994; 
Raper & Wilson, 1993). Gene therapy in the treatment of cardiovascular disease promises 
to alter atherosclerotic risk factors, prevent vascular thrombotic disease, retard 
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progression of disease in the peripheral vasculature, provide drug delivery systems, and 
prevent further myocardial infarction in patients with CAD. This technology may 
eventually become the intervention in the treatment of cardiovascular disease (Rowland 
et al., 1995). 
These exciting directions open new chapters in lipoprotein research which may permit the 
description of most of the diseases of lipoprotein metabolism at the molecular level and 
possibly suggest means for their treatment. 
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Two cO.mmon coding sequence mutations of lipo~rotein lipase (serine447 -ter. 
producmg a carboxy terminal truncation; and asp -asn variants) were studied 
in 329 Caucasian subjects, of whom 243 had angiographic features of prema-
ture atheroscelerosis (220 with coronary artery disease; 23 with coronary and • 
peripperal artery disease). As expected, the mean levels of cholesterol triQ:lvc-! 
erides, LDL-cholesterol, ApoB and Lp( a) were significantly higher in 'the '-arte-: . 
rial disease group than in the controls. HDL levels were lower in the patient 
group, With regard to the common mutations, plasma triglycerides a~d 
VLDL-triglycerides were lower in subjects possessing the Serine447 -Ter 
mutation (p=0.06 and <0.05, respectively). When the lipid distributions \,vere 
analysed by tertiles, the Ser447 -Ter mutation \V:lS significantly less frequent in 
the ~ighest tertiles for triglycerides Ip<0.02). and VLDL (p<0.04). The Asp'-l_ 
A~ substitution was signific::mIly more frequent in the lowest [ertiles for 
ApoAI (p=0.05). Case-control analyses of genotypic distributions between the , 
two groups with or without arterial disease did nO[ show any significant differ- ' 
i ences. The possible functional effects o( these common mutants .-)f lipoprotein 
lipase are discussed. 
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Studies of concordance rates in monozY'gotic twins 
with premature coronary artery disease have empha-
sised the importance of family history. Jnd d~mon­
strate that genetic risk factors contribute to the sus-
ceptibility of indi viduals to the disease (Berg 1 98...J.). 
Several genetic loci have already been implicated in 
the development of premature coronary atheroscle-
rosis. Possible candidates include the genes encod-
ing proteins involved in lipoprotein catabolism and 
transport, such as the apolipoprotein E \'ariants (Ut-
ermann 1987): variants at the apolipoprotein .-\ II 
C Ill! A I V aene cluster (Chamberlain & Galton 
1991) iind li~oprotein (a) (Berg et al. I 97...J.). Other 
candidates are genes coding for lipoprotein recep-
tors. and the lipolytic enzymes such ;,is lipoprotein 
lipase and hepatic triglyceride lipase (Galton L\.: 
teins from the cin:ulation (Pykalisto et al. 1987. 
Garfinkel & Schorz (987)' The enzyme participate:-, 
in the metabolism of HDL and as chylomicrons and 
VLDL are converted to remnant particle\. phosphol-
ipids, triglycerides and Jpolipoproteins Jre trans-
ferred to HDL a process ultimately rc\ulting in the 
formation of HDL2 particles. The efn .. :Jcy of tri-
glyceride clearance is pu\iti\cly correlated with 
HDL1 concentrations (Pat"ch d al. 19'<',7. Brunzell 
1989). Ml)re recent report" suggest th,ll LPL is able 
to complex to remnants and to enhance the uptake 
()f these particles by the LDL-rec:-ptor-related pro-
tein/alpha2-macroglobulin receptllr (\\'illianb et al. 
19l)...J. ). 
Ferns 1989). 
Lipoprotein lipase (LPL) is a rate-determining 
enzyme in the clearance of triglyceride-rich lipopro-
The gene encoding human lipoprotein lipase IS on 
chromosome 8p.2.2 and spans appro.\imatel~ .:,() kb 
(Sparkes et al. 19;;;'. Wion et al. IU:\7, Deeb & Peng 
1989). The first 9 of its l() c.\ons c,)de for a protein 
nf -1.'7) amino JCllb \\hich. after clea\ ~lgc ()f J leader 
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sequence. results in a mature molecule 60 000 dal-
ton (Deeb & Peng 1989, Olivecrona et al. 1985). 
In recent years numerous rare sequence variants 
of the LPL gene have been found that lead to syn-
thesis of non-functional enzymes. and when an indi-
vidual inherits two such defective alleles cause Fa-
milial Chylomicronaemia (Type I hyperlipidaemia), 
(Hayden et al. 1991, Santamarino-Fojo 1992). Some 
individuals who are heterozygotes for such muta-
tions may be predisposed to develop familial com-
bined hyperlipidaemia and be at risk of early athero-
sclerosis. By contrast, two relatively common cod-
ing sequence mutations of population frequencies of 
> 1 % within exons '2 and 9 of the LPL gene were re-
'-' 
cently reported (Hata et al. 1990. Stocks et al. 1992, 
Gagne et al. 1994). One, 635 bp downstream from a 
polymorphic HindUI RFLP Cintron 8), involves a 
Ser447 -Ter mutation in exon 9 that converts 
serine447 codon to a premature termination codon 
producing a truncated protein lacking the two car-
boxyl-terminal amino acids that are normally 
present (Hata et al. 1990. Stocks et al. 1992); an-
other mutation is the substitution of Asp9 - Asn in 
,exon 2. which creates a TaqI polymorphic site 
(Gagne et al. 1994). 
The present study has investi2:ated these two cod-
ing sequence mutations (Se(+-+I-Ter and Asp9-Asn 
variants) for possible relationships with disorders of 
lipid transport and premature coronary atherosclero-
SIS. 
Materials and methods 
Subjects 
Three hundred and twenty-nine subjects were 
recruited serially from the physicians' and cardiac 
clinics of the Wolfgang Goethe-Uni\ersit> Ho"pital 
in Frankfurt. Germany. Ot these patients. 2-+3 hacl 
angiographically proven coronary artery di"cJ,e. 
CAD+ (and some had aclclitional peripheral vascular 
disease). Coronary artery disea'le cases \vere deti ned 
angiographically as patients having at least )()Cr "te-
nosis or more in at least one of the major coronaf: 
vessels (right coronary artery. right circumtlex. Of 
left anterior descending arteries). Controls (C.-\D 
n=86) had valve disease with no significant CAD 
(defined as less than 2()7c' stenosis in the left main 
anterior and descending coronary arteries). H: per-
tension was defined as blood pressures> l-+()/>'-)() 
mmHg. Of the 329 subjects studied. 82 had ne\er 
smoked, 195 were ex-"mokers and 52 \\ere CUITent 
smokers. Further details of smoking habits are pre-
sented in Table I. Regarding medication. of the ((ILt! 
number of subjects recruited (329) 3-+ subjects (i.e. 
10.3%) were on drugs that may alter plasma lipid" 
(mainly nitrates. calcium antagonists. aspirin. diu-
retics and selective beta-\ betablockers) at the time 
of sampling for lipid estimations. 
Lipoprotein analyses 
Plasma cholesterol. triglyceride. and lipopruteins 
were determined by enzymatic methods with ((Im-
mercially available kits (Boehringer ~[annheim ancl 
Beckman Array Protein System, Beckman In''tru-
ments Brea. CA. l'S,-\). Lp(;l) was measured by an 
enzyme-linked immunosorbent assay (ELlSA) 
usi~g polyclonal antiboclie'l raised against purihed 
Lp(a) (Mercodia Diagnostics. Uppsala. Sweden l. 
HDL-C was measured after precipitation of apolipo-
protein B containin; lipoproteins and LDL-choles-
terol calculated ~lccording to the FrieJe\\~tld 
formula. 
Table 1. Clinical features of male patients with arterial disease and male control subjects 
Age (years I 
Weight (kgl 
BMI 
Diabetes rT'eliitus 
(no. & %) 
Hypertension (no. & %) 
Smokers I no. & %) 
Cigarettes I no & %) 
Arterial disease 
(n=238) 
58±7 
80.1::10.:\ 
26.49::,:296 
31 (130%) 
108 (45.3%) 
185 (777%) 
36 (19 5 % ) 
149 (80.5%) 
Controls 
In=851 
50±13 
79.3=13.0 
25.54::385 
2 (2.4°01 
31 (36.5%) 
57 (671°',) 
11(19.3°'0) 
46 (80.7%) <14 clgsday 
~15 cigs.day 
---
----------- -------
Art~rI;1 dISc;S'; ~'ompr~e;~-orona;y heart disease (n=215) and. peripheral vascular disease (n=23) 
Controls comprise valve disease Without Significant CAD. BMllndlcates body mass Index. 
P.values were analysed by Chi-square tests (2·2 contingency tables) . 
• P.values were analysed by Independent two samples t·tests. 
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p 
<00001 . 
NS' 
<005' 
<0006 
i ~S 
NS 
Genetic analyses 
DNA was isolated from fresh or frozen EDT~ whole 
blood cells using a spin column method (Diagen, 
Dusseldorf, Germany J. It was redissolved in double-
distilled water and stored at -20°C. Primers for the 
polymerase chain reaction were synthesized by 
standard B-cyanoethyl phosphoramidite chemistry 
using a Biotech BT 8500 DNA Synthesizer and puri-
fied on a Sephadex G-2S column. The primer 
sequences were derived from published data (Hata et 
a1. 1990, Stocks et a1. 1992) and our laboratory data. 
Amplification of genomic DNA 
Genomic DNA (0.2-0.5 ).1g) was amplified in 25-).11 
reaction mixtures containing 10 mmol/l Tris-HCI 
(pH 8.3); 50 mmolll KCl; 0.001% gelatin, 200 
).1molfl each of dATP, dCTP, dGTP and dTTP; 2-3.5 
mmoVl MgCI 2; 0.5 ).1molll each primer and 2.5 U 
Taq DNA polymerase (Gibco BRL). The mixture 
was overlaid with mineral oil. All tubes, tips and 
buffers were autoclaved and the reaction mixture 
was UV irradiated before addition of gc:nomic DNA 
and Taq DNA polymerase to minimize contamina-
tion tK wock & Higuchi 1989). B lank controls con-
taining no genomic DNA were run with each set of 
amplifications. The amplification cycle \vas per-
formed on a Perkin-Elmer Cetus .+80 Thermal 
cycler and entailed 5 min of denaturation of 96°C 
followed by 35 cycles of I min at 9J.:C. I min at 
.+a.-55°C and I min at 72°C. This was followed by 
10 min of extension at 72°C. 
Digestion and electrophoresis 
Five microliters of di~estion mixture containing the 
manufacturer's recon;mended restriction buffer and 
5 U restriction enzyme were added to the amplifica-
Common genetic variants of lipoprotein lipase 
tion product and incubated at 65~C for 3 h with Taq! 
(Gibco BRL) for the Asp9 -Asn mutation of the LPL 
gene or 37°C overnight: \\ ith HindIII (Gibco BRL) 
for the intron 8 RFLP and with Hintl (Gibco BRL) 
for the Ser-l,47 -Ter mutation of the LPL gene. Subse-
quently, the samples were electrophoresed in TBE 
buffer (89 mmolfTris-borate, .2 mmol/l EDT.--\. pH 
8.3) in 2-3% agarose gels at 150 V f()r I-\.5 h. 
DNA was visualized by staining the gels with ethid-
ium bromide (0.5 ).1g/ml) and transillumination with 
UV light. 
Statistical analysis 
Genotype distributions bet\veen the study groups 
were analysed by .2x2 contingency tables and Chi-
square analysis. Variations in the biochemical traib 
with respect to genotypes were analysed by analysis 
of covariance. Similar comparisons of genotype dis-
tribution were undertaken using Chi-square analysis 
after biochemical traits were divided into tertiles. 
Analyses were performed using \crsion 6 of SPSS 
programme for Windows statistical package (3.1 J. 
Results 
Clinical and biochemical characteristics of study groups 
Tables 1 and 2 summarise the clinical feature~ and bi-
ochemicai characteristics of the study groups .. -\s ex-
pected, the mean le\els of cholesterol. triglycerides. 
LDL-cholesteroL ApoB and Lp( a) \vere sig.nificantly 
higher in the arterial disea:-;e group \'ersus comrols, 
HDL levels were lower in the patient group. 
Genotyping 
Genetic mapping of the LPL gene has revealed the 
positions of the Asp9-.-\)n variant (TJljI RFLPI in 
Table 2, Biochemical characteristics (adjusted for age and 8MI) of male patients with artenal disease and male control sublec:s 
ChOlesterol, mg/100 ml 
Triglycerides, mg/100 ml 
LDL -C, mg/100 ml 
VLDL, mg/1 00 ml 
HDL, mg/100 ml 
ApoAI, mg/100 ml 
ApoB, mg/100 ml 
Lp (a), mg/1 00 mlJ 
Artenal disease 
(11=238) 
238.79=..\761 
215.30 134,01 
1582039.03 
3343±1759 
38.92::.9 1J 
12582=21.03 
1.+573::.33 ~-: 
.+..! 80 
1.051-21419) 
Controls 
(n=85) 
213.06±53,56 
183,04±11928 
139.23±391-+ 
3056:::1975 
'+2.20=11.29 
130.0±21.04 
12502±35.67 
28.46 
(017-1 4501) 
p 
<0001 
o iJOS 
0002 
<003 
OJC9 
<D03 ,:r3) 
<00001 
<0001 
--- --Arte-n~ld~~~~e~o~pnses-~~~~ary art~ry disea~e-;nd Penpher~1 vascula~-d~eas~, C~ntrol~~-~p-rlse valv;di-sease I'lithout siynlflcant ,:MJ 8:.11 :ndlcatos bod'.: 
;~~~ul;:~~re analysed by AnalysiS of Covariances and tnglvcerides VLDL and Lp (a) were IOg10 transformed before analvsls 
a Mean values and unadlusted range, 
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ex on 2, the HindIII RFLP in intron 8 and the 
Se(~·n -Ter mutation in exon 9. The C-G transver-
sion at nucleotide 1595 of the LPL exon 9 was 
identified by using a modified 3' amplimer; an addi-
tional mutation (G-T) is introduced at nucleotide 
1598 into the amplification product. Thus, a novel 
Hint1 restriction site is created solely in the pres-
ence of the G allele (Se(1-47 -Ter variant), as the 
enzyme has the recognition sequence GA(N)TC. 
Conversely, no modification of the primer sequence 
is necessary to detect the G~A change at nucle-
otide 280 that destroys a Taq 1 site in exon 2. How-
ever, the presence of a closely flanking nonvariant 
Tag I site (position 284-287) necessitates the use of 
a modified reverse primer with a mismatch that 
destroys this nonvariant Taq 1 site, that otherwise 
obscures detection of the variant site. The technique 
and genotype scoring have been detailed elsewhere 
(Patsch et al. 1987). Presence of the restriction sites 
is denoted by T2 (TagI), H2(HindIII), and 
G(Hindt1). 
LPL genotypes and biochemical traits 
,Comparisons of lipid, lipoprotein and apolipopro-
tein levels between genotypes are presented in Table 
~. Plasma triglycerides and VLDL-triglycerides 
1 . b' . h S . ..\....1.7 T were ower m su Jeets possessmg t e enne - er 
mutation (p=0.06 and 0.05, respectively). 
.... Asp9-Asn and Ser-+-+7 -Ter variants 
There was no homozygote (TIT 11 with the Asp9-
Asn vari:lllt. The mean ApoAr levds were signifi-
candy lower het\veen the subjects \vlth the :;enmype 
TIT2 (n=l1. 11-1-.5-1- mg/dl) versus the alternative 
ones with genotype T2T2 (n=309. 127.51 mg/JIJ. 
p<0.05. No other differences were observed in the 
presence or absence of this mutation. 
There were only three homozv~otes with the 
..\....1.7 .-Ser -Ter mutation (GG), so they were pooled with 
the heterozygotes (CG). The GG homozygotes anJ 
the heterozygotes (CG+GG, n=63) had significantl} 
lower mean VLDL levels than the \\ild-type ho-
mozygotes (29.66 v 33.55 mg/dl, p<O.051. There 
was a similar trend with respect to total plasma tri-
glycerides but it did not reach statistical signifi-
cance. 
LPL genotypes and lipid and lipoprotein tertiles 
When the lipid distributions \vere anal} sed by ter-
tiles, the Ser-+-+7-Ter mutation was significantly less 
frequent in the highest tertiles for triglycerides 
(p<0.02)' and VLDL (p<O.O-1-) (Table -1-). The trig-
lyceridelHDL ratios, when divided bv tertiles, also 
showed differences in the frequencies' of the Ser-+-+7 -
Ter mutation (p<O.02 Table -1-). The Asp9-Asn sub-
stitution was found more frequently in the lowest 
tertiles for ApoAr (p=0.05). 
LPL genotypes jn CAD and controls 
Case-control analysis of genotypic di~tributions 
between the two groups with or without arterial dis-
ease did not show any signincant differences. The 
genotype frequenci~,s7 in the CAD patients ve~sus 
controls for the Ser~'" -ter mutatIOn are: Cc. 80.Ylc: 
CG, 19.1 %: GG, O.SC.~(' for cases: and for controh 
79.1 %, 19.80"c and 1. 20'c. For the asp9-asn mutation: 
TITl 1)5.9S:, TIT2 -:'.111', T2T2 OC1c f(lr ;.:asc~: and 
for controls 97.7C:0. 2.39c and O!)c. 
Table 3. Biochemical characteristics (adjusted for age and BMI) of the study samples with lipoprotein lipase genotvpes 
------------_.- -- --------_._--
---- ----- -_. ----~--
Cholesterol, iTlgi100 ml 
Triglycerides, mg/l 00 ml 
HOl, mg/l00 ml 
lOl -C. mg/l00 ml 
VlOl, mg/l00 ml 
ApoAI, mg/100 ml 
ApoB, mg/l00 ml 
lp (a), mg/l00 mla 
Asp9-Asn (Taql) 
T2T2 
In=309) 
232.;- 4±5082 
208.!.5:,:131.47 
39.92±9.79 
153 30=4006 
3303=18.25 
12/51=21.00 
1-\0 ~0:::35.59 
-\034 
(0,,-21-\19) 
T1 T2 
(n=ll ) 
218.55=4153 
182.15=12635 
3654=3 ,]-\ 
1-\9.82=3502 
26.03=1/.02 
11-l5-\=1 ~ 28: 
13206=2820 
·15.70 
(1 -\~-158.86) 
CC 
(n=257) 
23-\32=50 2.1 
2133-\±i35JS 
3977:,:9.62 
15-\.93=4038 
33.55=18 J5 
127.30±213S 
142.00:t357,J 
40.60 
10.17-212591 
BMI indicat~~b~dy m~~sinde~T~;y~;rld-e~~viDLa~d LP~lJe~e log10 transformed before stastlstical anaivsls 
• Genotypes T1T1 vs T1T2, p<005 (AnalYSIS of Covanance) . 
. Genotypes CC vs CG+GG, p=0.06 (Analysis of Covanance). 
S Genotypes CC vs CG+GG, p<005 (Analysis of Covanance). 
J Mean values and unadlusted range 
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22331:::JI)91 
13334=107.25-
3996±1031 
1-1639-:::3727 
~9.66±17 ~ :JS 
12608:::19':3 
" 33.30±33 ..\0 
-1028 
(023-21.1 1?1 
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Table 4~~ and lipoprotein tertiles and lipoprotein lipase genotypes in the study samples 
No. of subjects represented by genotypes 
Asp9-Asn (TaQI) Ser~~'· Ter 
T2T2 T1T2 P CC CG+GG p 
Triglycerides 
Lower tertile «139.0 mg/100 ml) 104 4 78 30 Higher tertile (>226.0 mg/100 ml) 106 2 NS 92 16 VLDL <002 
Lower tertile «22.2 mg/100 ml) 100 6 77 29 
Higher tertile (>35.3 mg/100 ml) 106 2 NS 91 17 Apo AI <o.o~ 
Lower tertile «1170 mg/100 ml) 101 6 85 22 
Higher tertile (> 133.8 mg/100 ml) 105 =0.05 88 18 
TG/HDL NS 
Lower tertile (<3.371) 104 3 77 30 
Higher tertile (>6.263) 105 2 NS 91 16 <002 
P·values were analysed by Chi-square tests (2x2 contingency tables) and Fisher's exact test where appropriate. 
Discussion 
Th S . +1-7.,., .. e enne - ler vanant 1S the first common cod-
ing sequence mutation at the LPL gene locus that 
appears to have beneficial effects on plasma lipid 
profiles. The functional significance of the carboxvl 
temiinal region of the LPL remains uncertain, but -it 
is highly conserved in all known mammalian spe-
cies .'(human, mouse, bovine and guinea pig) and 
may provide an anchor for the attachment of the 
enzyme to endothelial cell surfaces. Deletions of the 
terminal two residues (serine-glycine) of LPL have 
r~lted in conflicting reports on the kinetic proper-
ties of the truncated enzyme. In one study (Koba-
yashi et aL 1992), after transient transfection of wild 
type and mutant cDNA's into COS-l cells the 
mutant enzyme hydrolysed much less Triton-X 100 
triolein than wild type enzyme; in another study 110 
differences were found in secreted enzyme mass or 
specific activities (Faustinella et al. 1991); and in a 
third study (Kozaki et aL 1993), which specifically 
set out to study the effects of carboxyl-terminal 
truncation, the mutant enzyme showed greater mean 
specific activities than control (1 850'c); this was 
repeated in nine separate experiments. Successive 
truncation after residue 446 progressively resulted 
in the expected loss of specific activity of the 
enzyme. 
Some of these discrepancies may be due to varia-
tion in tertiary structure (e.g. glycosylation) of the 
enzyme secreted by different COS-cell lines, or to 
the differences in properties of the substrates used to 
measure enzymic activities. A study of the kinetic 
properties of the native enzyme purified from 
plasma of subjects homozygous for the rare or com-
mon alleles using a variety of substrates (chylo-
micra: intralipid; triton-triolein; and gum arabic-tri-
olein) found that the Km's and Vmax of the native 
and variant enzymes were similar. but that heparin 
appeared to release the variant enzyme more readily 
from endothelial binding sites. 
With regard to the asp9-asn mutation, no associa-
tions were found with plasma lipid levels, although 
there were weakly significant associations with 
apolipoprotein A-I levels when analysed by tertiles. 
Further work is needed to clarify this by study of 
other groups. 
Hypertriglyceridaemia (with low HDL) is an es-
tablished independent risk factor for the develop-
ment of coronary artery disease. Our data show that 
the truncated enzyme is found much more fre-
quently in the lowest tertiles of the triglyceride or 
VLDL distributions of our sampk population. 
There was also a trend for the truncation (in hetero-
and homozygous states) to be associated with lower 
plasma triglycerides (p=O.06) or lower VLDL-tri-
glycerides (p<0.05). The mutation appears to relate 
to the intermediate phenotype for coronary athero-
sclerosis, but the study is perhaps (00 small to show 
effects on the end-stage phenotype of atherosclero-
sis. r\ larger epidemiological study (n= 1273) did 
have the power to re\'eal difference~ in allele fre-
quencies between subjects with C-\O (n=-1.21) and 
control (n=852) (Mattu et Ji., in preparation). 
The mutation in LPL mJY be one ~)f many \ari-
ants that counteract the effect'> of (ardio\J~L'U lar 
risk factors, such JS the dyslipidaemi~h. The prcs-
ence of such beneficial mutation5 may accuunt for 
the clinical variJbility in the naturJI hi~tory of 
atherosclerosis in subjects v, ith J single \\ e ll-de-
fined cardiovascular risk factor. Further \vork is re-
quired to identify such putative protective \ariants 
and to elucidate the mechanism ,)1' their po~sible 
beneficial effect~ on lipoprotein proti les. 
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Science 1987: 235: 1638-10'+1. 
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ApoA-IHelsinki (LySl07~O) Associated With 
Reduced HDL Cholesterol 
and LpA-I:A-II Deficiency 
Marju Tilly-Kiesi, Zhang Qiuping, Sonja Ehnholm, luhani Kahri, Sanni Lahdenpera, 
Christian Ehnholm, Marja-Riitta Taskinen 
Abstract A Finnish kindred with premature coronary heart 
disease and decreased HDL cholesterol levels was identified as 
having an apoA-1 variant, apoA-I (LyS107~)' caused by a 3-bp 
deletion of nucleotides 1396 through 1398 in exon 4 of the 
apoA-1 gene. These subjects (n= 10) were heterozygous for this 
mutation. The mean serum HDL cholesterol concentration 
(26.7±9.7 mg/dL) of affected family members was 36% lower 
than that of unaffected family members (P<.05). Mean serum 
apoA-I and apoA-II concentrations in heterozygotes were 
reduced by 18% and 22%, respectively, compared with normal 
family members (P<.05). In heterozygotes the mean concen-
tration of lipoprotein containing both apoA-1 and apoA-II 
(LpA-I:A-II) was 31 % lower than in those with normal apoA-1 
(P<.001), while the mean level of lipoproteins containing 
apoA-I without apoA-II was similar in the two groups. HDL 
density-gradient ultracentrifugation showed a lack of HDL2 
and small dense HDL:J in heterozygotes compared with unaf-
fected family members. The HDL particle size distribution, as 
analyzed by nondenaturing gradient gel electrophoresis of 
heterozygotes, revealed one major peak at 8.0 to 9.7 nm, a 
minor peak at 7.8 to 8.5 nm, and an absence of HDL2b and 
HDL 2a peaks. These latter peaks were observed in unaffected 
D ecreased plasma HDL-C levels have been.asso-ciated with premature CHD.l ApoA-I IS the major protein of HDL, and with apoA-II 
accounts for about 85% of the protein within HDL.2,3 In 
some studies4-7 but not in others8-10 plasma apoA-I 
concentrations provide more information about CHD 
risk than do HDL-C levels. The protective role of HDL 
against CHD has been related to its function in the 
transport of cholesterol from peripheral cells to the liver 
for excretion, the so called "reverse cholesterol trans-
port process."1l,12 Two distinct populations of HDL, 
LpA-I and LpA-I:A-II, have been isolatedp-15 Recently 
it has been noted that reduced LpA-I but not LpA-I:A-II 
levels account for the decreased HDL-C concentrations 
in patients with CHD.16 In other studies ~ reduc~d 
HDL-C level in CHD patients was assocIated WIth 
decreases in both types of particles. 17-19 
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family members. Serum levels of LDL cholesterol, triglycer-
ides, VLDL, IDL, and LDL subclasses were similar in the two 
groups. However, in heterozygotes the cholest~rol-to-triglycer­
ide ratios in VLDL 2 , LOLl, LD~, HDL 2b , HDL Za , and HDL3a 
were 8% to 54% lower than in unaffected family members 
(P<.05). Cholesteryl ester transfer protein activity in heterozy-
gotes was reduced by 25% compared with unaffected family 
members (P<.05), while the plasma lecithin:cholesterol acyl-
transferase (LCA T) activity did not differ between heterozy-
gotes and unaffected family members. The ability of isolated 
variant apoA-I to serve as a cofactor for LCAT in vitro did not 
differ from that of normal apoA-I. Our data are consistent with 
the concept that a low HDL cholesterol level in subjects 
heterozygous for the apoA-IHelsinki mutation (LyS\o7~) having 
normal LCAT activity is a consequence of decreased concen-
tration of LpA-I:A-II particles and of a smaller size and 
reduced cholesterol content of HDL particles. (Arterioscler 
Thromb Vasc Bioi. 1995;15:1294-1306.) 
Key Words • apoA-I gene mutation • HDL deficiency • 
lecithin:cholesterol acyl transferase • CETP • coronary 
heart disease 
Some HDL-deficient syndromes, such as Tangier dis-
ease or familial apoA-UapoC-III or apoA-UapoC-III/ 
apoA-IV deficiency states, are characterized by premature 
coronary artery disease.20-23 In contrast, apoA-I variants, 
including apoA-IMilano, apoA-IMarourg, and apoA-IJowa, have 
not been associated with premature CHD.24-26 
In this article we describe a deletion mutation in the 
human apoA-I gene associated with low serum HDL-C 
and decreased apoA-I and apoA-II concentrations in a 
kindred with a high incidence of CHD. We have char-
acterized the association of this apoA-I variant on 
different lipoproteins and their subclasses, on lipopro-
tein particle size and density distribution, and on the 
activities of the major enzymes involved in lipoprotein 
metabolism. 
Methods 
Subjects 
A 51-year-old woman (AU.T.) from South Finland was 
referred to the Lipid Research Clinic, HUCH, hecause of her 
low HDL-C concentration (0.24 mmollL [9 mgldL]). She had 
significant obesity (body mass index, 38.9 kg/m") and had 
received medication for essential hypertension for 14 years. For 
the previous 3 years she had received a combination of 
captopril and indapamidc. She had no history of angina 
pectoris or other vascular disease and h.ad never smoked. On 
physical examination she had normal skm, no xanthomas, and 
Selected Abbreviations and Acronyms 
CETP = cholesleryl ester transfer protein 
CHD = coronary heart disease 
HDL-C = HDL chol es terol 
HUCI-I = Helsinki University Central Hospital 
LCAT = lecithin :choles terol acyltransferase 
LpA-1 = lipoprotein with apoA-1 but no apoA-1I 
LpA-I :A-1I = lipoprotein with both apoA-1 and apoA-1I 
MI = myocardial infarction 
PCR = polymerase chain reaction 
SSCP = single-strand conformation polymorphism 
no xanthelasmas, and the ophtha lmoscopic examin ation 
showed no corneal opacification . Her liver was not enl arged, 
and her spleen was not palpable. Her tonsils had been removed 
after the delivery of her first child. The peripheral pulses were 
mmetrical and easily palpable. The laboratory resu lts showed 
I1 0rmal thyroid, liver, and renal function . Her fasting blood 
glucose and glycosylated hemoglobin levels were normal. 
The proband's family was from southern Finland. Altogether 
25 relatives participated in the study. Her mother (K.K.) was in 
excellent physical health and was not taking any medication . 
Her father had received medication for anginal symptoms for 3 
years and died of cerebral hemorrhage at the age of 69 years. 
The father had five brothers and three sisters, of whom only 
('.e sister (A.A.S.) was still alive and in good health at age 85 
yc:ars. The medical records of the proband's fath er, four uncles, 
and two aunts revealed that one aunt was diagnosed as having 
ischemic heart disease based on symptoms and electrocardio-
graphic findings. She received medication for CHD symptoms 
and died suddenly at age 48 years. The other aunt had di ed at 
the age of 66 years of heart fai lure after she had three prior 
admissions to HUCH for acute MI. An uncle of the proband 
had died of his fourth acute MI at HUCH at age 54 yea rs. The 
il opsy confirmed coronary atherosclerosis. One uncle had 
dh.:d of MI at age 63 years. The autopsy confirmed substanti al 
atherosclerotic changes in the coronary arteries and abdomin al 
aorta. According to medical records two other uncl e died of 
CHD at 63 and 66 years, respectively. The latter uncle suffered 
his first MI at age 53 years. No HDL-C values for the proband 's 
aunts or uncles were available in their medical records . In 
addition, three of the proband 's cousins had died of CHD 
between the ages of 46 and 62 years, one of th em after 
w eiving a heart transplantation at HUCH. His HDL-C level 
Tilly-Kiesi ef al ApoA-I llc"in~i 1295 
(measured on severa l occas ions) was below thc norma l rangc 
(0.80 mmol/L [31 mgld L)). 
The proba nd 's olde r sister (K.A. P.) and two brotheL 
(R.O.K. and K.K.K.) had no hi tory of cardiovascular di ea e 
and were hea lthy as assessed by physical examination and 
laboratory tes ts. The proba nd's two sons (M .1 .V. and K.P. .) 
and her broth ers' sons (R.K. and J.K.) were al 0 health,. In 
additi on, 14 cousins participated in th e stu dy. Two of thcm 
(TM.A. and O.E.O.) had suffe rcd an Mr, but the other had no 
clinica l signs or symptoms of CHD. Two unaffected ubject. 
(P.E.K. and R.E.K.) were di agnosed as havi ng non-in ulin-
dependent di abetes mellitus acco rding to the re ult of labora-
tory tes ts. A pedigree of the family is presented in Fig l. The 
experimental protoco l was approved by the Ethical Commi ttee 
of the Third Department of Medicine of Helsinki Unive rsity. 
. 
Methods 
DNA Preparation 
Genomic DNA was i olated from frozen whole blood of the 
proband, her family members, and a series of normal control 
subjects. 27 
Amplification of DNA 
Oligodeoxynucleotide primers used in amplifica tion and 
sequencing were chosen according to the published apoA-I 
gene structure28 and synthesized on an Applied Biosys tems 
model 381A DNA synthesizer. The sequences and pos ition of 
these primers are shown in Table 1. Six fragments of the 
apoA-I gene of the subjects were amplified by using PCR with 
genomic DNA as a template. The PCR was perform ed in a 
reaction mixture containing 1 J.Lmol/L of primers, 0.2 mmolfL 
each dATP, dCTP, dGTP, and dTTP, 50 mmol/L Tris-HCI (pH 
8.8) , 1.5 mmol/L MgClz, 15 mmolfL (NHq)zS04, 0.1 % Triton 
X-IOO, 0.1 mglmL gelatin, and 2.5 U Taq DNA polymerase 
(Promega Corp) in a fin al volume of 100 J.LL. The reaction 
conditions on a programmable hea ting block (MJ Resea rch 
Inc) were as foll ows: 95°C for 1 minute, 58°C to 63°C for 1 
minute, and noc for 2.5 minutes, 30 cycl es. 
SSCP Analysis 
Six fragm ents of the apoA-I gene of the subjects were 
amplified by PCR following the reaction conditions descri bed 
above, and 2 to 3 J.LL [a -32P]dATP or dCTP (3000 Ci/mmol/L; 
Amersham) was added to each tube. The PCR product was 
diluted 1:1.5 with 0.1 % sodium dodecyl sulfate and 10 mmol/L 
EDTA, denatured, and loaded on neutral 5% polyacryl amide 
GdI -Heterozygotea 
(;j K Heterozygotea 
** c Prematurw CHD 
* = CHD 
FIG 1. Pedigree of the family having the apoA-1 (LYSI07->O) deletion. Affected fami ly members were all heterozygous for the defect. 
Squares indicate men; circles, women; and diagonal line, deceased. 
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TABLE 1. Sequence and Position of 
Oligodeoxynucleotide Primers 
5' Primer Sequence Position 
1 5' -CACCCGGGAGACCTGCAAGC- 3' 
-256 
2 5' - AGTGACCGGGGCAGGCAGCA - 3 ' +26 
3 5' - GCTGGCTGCTTAGAGACTGC - 3 ' 
-12 
4 5' -CGATGGTTGGCTCCCTAGGT- 3' +293 
5 5' -GGCTCAGATCTCAGCCCACA - 3' +408 
6 5' -CATCATCCCACAGGCCTCTG- 3' +660 
7 5' -CTGATAGGCTGGGGCGCTGG- 3' +1153 
8 5' - AGCGGCTCCACCTTCTGGCG- 3 ' +1426 
9 5' -GGCAGGAGGAGATGGAGCTC - 3 ' +1403 
10 5'-CCGCCGTTCTCCTTGAGAGC-3' +1618 
11 5' -GAGGCTCTCAAGGAGAACGG- 3 ' +1615 
12 5' -GAAGCTGCTTCCCACTTTGG- 3 ' +1858 
13 5' -GGGCCTGAGGCAGGA - 3 ' +1320 
14 5' - GGGCCTGAGGCAGGAGATGA - 3 ' +1320 
15 5'-CATCTCCTCCTGCCACTTCT-3' +1397 
Primers 1-13 were used for PCR and sequencing. Primers 8, 14, and 15 
were used for minisequencing. Primer 14 was biotinylated, and primer 15 
was used as detection primer for the mutation. The 5' position indicates 
the position of the 5' end of the primer on the apo A-I gene (1 + is the first 
base of exon 1). 
gel for mobility-shift electrophoresis. 2'i Autoradiography was 
performed by using an intensifying screen with Kodak X-omat 
film at room temperature for 24 to 72 hours. 
Direct Sequencing 
The PCR products were purified by Qiaex (Diagen GmbH) 
and directly sequenced with the dideoxy chain-termination 
reaction by using a sequence kit (US Biochemical Corp). For 
sequencing of the fourth exon, an additional primer, No. 13, 
which is located 76 nucleotides 5' of the mutation point, was 
used. 
Solid-Phase Minisequencing 
The solid-phase minisequencing and the preparation of the 
batches of pooled leukocyte DNA were performed as described 
by Syvanen et al.30 The 127-bp fragment located 111 nucleo-
tides downstream of the) end of the apoA-1 gene exon 4 was 
amplified for minisequencing. The PCR reaction mixture and 
the conditions were as mentioned above except that the 
primers used were 2 /Lmol/L biotinylated primer No. 14 and 10 
/Lmol/L primer No.8, and the annealing temperature was 60°C. 
The detection-reaction mixture, which consisted of 0.2 /Lmol/L 
detection primer No. 15 and 0.4 /Lmol/L FH]dTTP (34 Ci/ 
mmol; Arnersham) to detect the mutation as well as 1 U Taq 
DNA polymerase in 50 /LL PCR buffer, was added to each well. 
The radioactivity was measured in a liquid scintillation counter 
(1210 Ultrobeta, LKB). 
ApoA-I Isoform Analysis 
The apoA-I isoforms of the subjects were determined by 
isoelectric focusing and immunoblotting. 31 
Lipids and Lipoproteins 
Blood samples were obtained in the morning after a 12-hour 
fast. Serum lipoproteins were isolated by sequential ultracen-
trifugation in a Beckman L8-70 ultracentrifuge (Beckman 
Instruments) with a Beckman 50 TI rotor. 32 
Density-Gradient Ultracentrifugation 
of Lipoproteins 
Density-gradient ultLlel'ntrifugation of VLDL and lDL was 
performed in a Beckman L8-70 ultracentrifuge with an SW.+() 
TI swinging-bucket rotor with centrifuge tubes by using a 2-mL 
V.LDL and lDL preparation isolated by sequential ultracen-
trIfugation and the method described previously." 
The LDL subfractions LDLI, LDL 2 , and LDL, \\erc ~cpa­
rated by density-gradient ultracentrifugation in a Beckman 
SW40 TI swinging-bucket rotor from the LDL sample obtained 
by sequential ultracentrifugation. The method used is slightly 
modified from that described by Griffin et a13 -l for plasma 
samples. Briefly, the discontinuous NaBr gradient was pre-
pared by layering, from bottom to top, 0.5 mL d= 1.1900 g/mL, 
1.2 mL sample solution (0.9 mL LDL obtained from sequential 
ultracentrifugation in 0.3 mL NaBr, d= 1.5350 glmLl, 1.5 mL 
d=1.0630 glmL, 1.5 mL d=1.0560 glmL 1.5 mL d= 1.()'+50 
glmL, 2.0 mL d= 1.0340 glmL, 2.0 mL d= 1.()2'+0 glmL, and 0.7 
mL d = 1.0190 glmL. The tubes were centrifuged in a Beckman 
L8-70 ultracentrifuge at 40000 rpm for 2.+ hours at 2ye and 
the rotor was allowed to stop without braking. 
After ultracentrifugation the tubes were discharged from the 
top by using a Beckman Recovery System, Perfusor V (B. 
Braun) infusion pump and Maxidens solvent (Nyegaard & Co 
A/S). The protein-absorbance profiles of the tubes were mon-
itored with an absorbance meter (Pharmacia), and the density 
gradient was controlled by using a DMA 46 density meter 
(Anton Paar). Three 1.5-mL fractions were collected: LDLI 
(d= 1.024 to 1.0330 glmL), LDL2 (d= 1.0330 to 1.042 glmL), 
and LD~ (d=1.0420 to 1.0550 glmL). 
The HDL density-gradient ultracentrifugation method was 
based on the method described by Groot et al" except that first 
all apoB-containing lipoproteins (ie, VLDL, IDL and LDLl 
were removed from the serum samples by ultracentrifugation. 
A serum sample of 2.0 mL in 0.3 mL NaBr solution (d= 1.5350 
glmL) was overlaid with 0.7 mL NaBr solution (d= 1.0600 
glmL) by using Beckman l/2x2 polycarbonate centrifuge 
tubes. After ultracentrifugation in a Beckman Optima TL 
ultracentrifuge with a Beckman TLA 100.3 rotor at 100000 
rpm for 5 hours at 20°C, the thin yellowish supernatant layer 
containing VLDL, IDL, and LDL was removed by aspiration. 
The density of the infranatant was increased by adding 1.0 g dry 
NaBr, and a 2.0-mL volume of this sample solvent was trans-
ferred by pipette into the bottom of a Beckman Ultraclear 
9/16X33/4 tube. The discontinuous gradient above the sample 
was then prepared by layering NaBr solution in the following 
order: 1.5 mL d = 1.2500 glmL, 6.7 mL d = 1.2200 glm L, and 2.0 
mL distilled water. After ultracentrifugation in a Beckman 
L8-70 ultracentrifuge with an S\\/40 TI swinging-bucket rotor 
at 40 000 rpm for 18 hours at 20°C, the tubes were emptied as 
described for LDL separation. Five fractions of 1.3 mL each, 
representing HDL cb , HDL 2", HDL,;o, HD~b' and HD~" 
were collected. 
LDL Gradient Gel Electrophoresis 
Nondenaturing polyacrylamide gradient gel electrophoresis 
of LDL was performed on serum samples with 20c to 16(01(. gels 
(Pharmacia) by using the method of Nichols et al. 36 The gels were 
stained with Sudan Black B lipid stainY After the gels were 
destained and scanned, the particle diameter of the major 
LDL peak was defined by comparing the mobility of the 
sample with that of reference LDLY 
HDL Gradient Gel Electrophoresis 
The HDL gradient gel electrophoresis was performed'" with 
Pharmacia 4% to 30c/( gels. Serum was adjusted to d= 1.2100 
glmL with NaBr solution (d= 1.335 glmL) and ultracentrifuged 
in a Beckman L8-70 ultracentrifuge at 35000 rpm fur ()5 hours 
at 4°C in a Beckman 50 TI rotor. The supernatant (1 ml) was 
rccmered by tube slicing and mixed with 0.25 mL 01 '+W; 
sucrose. Using commercially available gels (Ph;lrmacia) and a 
sample volume of 10 ILL the gradient gel electrophore\is was 
run in Gel Electrophoresis Apparatus (;1 2/.+ (Pharn1acla) for 
3000 Volt-hours in a buffer containing XU mnwl'\ borate. 9() 
mmol/L Tris-HCL 3 mmol/l EDTA and 3 mmol/L \:,1'\ , pH 
K.35. The gels were fixed \\ ith I W; sulfos;tilc\lic acid . ..,tained 
1 2 
-'G 2. Isoelectric focusing of apoA-1. Lane 1, control apoA-I; 
_:ne 2, apoA-1 (Lys1Or-c>O). Arrow indicates shift mobility caused 
by mutation. An anode appears at the bottom. 
with 3.S% Coomassie G-250 brilliant blue, destained with sr,( 
acetic acid, and scanned at 595 nm by using a computer-assisted 
Cliniscan 2 (Beckman Instruments). Particle diameters of HDL 
fractions were assessed by comparing the mobility of the 
sample with the mobility of molecular-weight calibration pro-
tc~ins (Pharmacia). 
Measurement of CETP and LCAT Activity 
LDL and HDL isolated from the plasma of healthy donors 
were dialyzed extensively against 10 mmollL Tris HCI, pH 7.4, 
containing ISO mmollL N aCI, 1 mmollL EDT A, and 0.1 giL 
NaN). The LDL was labeled with cholesteryl(l-14C)oleate 
(Amersham) by using the lipid-dispersion method described by 
\1(lrton and Zilversmit.·'~ The labeled LDL was ultracentri-
.! ;Igain at 40000 rpm for 24 hours at 20°C in an SW40 TI 
.: ,'he measurement of CETP activity was accomplished by 
.i-: "ldhod of Groener et :11.-'<) The results were calculated by 
measuring the CETP activity of plasma samples divided by the 
CETP activity of the reference sample in the same assay"l and 
are expressed in arbitrary units. The LCAT activity was mea-
sured41 by using proteoliposome substrates containing either 
control apoA-I or apoA-I (LySI1l7~)' 
Measurement of LpA-I and 
Lp.\-l:A-II Concentrations 
Ille concentration of LpA-I particles was measured by 
e!ectroimmunoassay (Sebia) as described by Parra et al .. 12 
The concentration of LpA-I:A-II was calculated by subtract-
ing the LpA-I concentration from the serum apoA-I concen-
tration. The interassay variation for LpA-I particle measure-
ments was 7.3C'/c. 
Analytical Methods 
('1 1•llesterol, free cholesterol, phospholipid, and triglyceride 
1-:. '':1\ were analyzed by using enzymatic colorimetric methods 
with a Cobas Mira analyzer (Hoffmann-La Roche) and reagent 
kits (for cholesterol and triglycerides, Nos. 071S166 and 
0722138, Hoffmann-La Roche; for free cholesterol, No. 
310328, Boehringer Mannheim GmbH Diagnostica; and for 
phospholipids, No. 990-S-W09, Wako Chemicals GmbH). Se-
rum apoA-I, apoA-II, and apoB concentrations were measured 
11\ llsing an immunoturbidometric assay (Orion Diagnostica). 
TIlt' 'l'l'um concentrations of apolipoproteins C-II and C-III 
letermined by using immunochemical agarose plates 
d~l"1 Liing to the instructions of the manufacturer (Daiichi Pure 
Chemicals Co). The normal ranges of apoC-I1 ,trL' .\ . .'):!:: 1.2 and 
3.3:!:: 1.2 mg!dL and those of apoe-III are 7.6:+:.2.2 and 7 .. \:!::~7 
mg/dl for men and women. respectively. Blood glul'llse COIl-
centration was measured \1\ using the glucose oxidase method 
(Auto-Analyzer. Technico~). (ilycosylatecl hen~oglobin (nol'O. 
l11al range. 4'; to h',) \\as measured hy USII1!2 a Diamat 
TiIl.I-I\/csi 1'( at \I)()·\ I 
.. ,- II<hinki 1297 
.... e ..... 
, ~ 
.. ,., .. 
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.. • • • II • *-
1 2 3 4 5 6 7 
FIG 3. PCR-SSCP analysis of exon 4 of apoA-1. Genomic DNA 
from leukocytes was subjected to PCR-SSCP amplification by 
using a pair of primers in exon 4 of apoA-1. Amplified DNA from 
the proband (lane 1), her brother (lane 2), and her brother's son 
(lane 4) was used; lanes 3, 6, and 7 show control DNA. Lane 5 
contains a mixture of normal and mutated DNA. Electrophoresis 
was performed in nondenaturing 5% polyacrylamide gels con-
taining 10% glycerol at room temperature for 12 hours. 
Analyzer System (BioRad, Clinical Division). Serum insulin 
levels were measured by using a radioimmunoassay after 
precipitation with polyethylene glycol with the Phadeseph 
insulin radioimmunoassay kit (Pharmacia). 
Statistical Analyses 
The significances of differences between allected and unaf-
fected subjects were assessed hy Mann-Whitney nonparallletric 
tests using I3MDP statistical software (University of California). 
Pearson's correlation coefficient analysis was llsed to eslimak 
the relationship between variables. 
Results 
Analysis of the ApoA-I Variant 
I~oelectric focusing of the plasma of the proband 
(A.U.T.) and nine family members (K.K.K., R.O.K.. 
K.P.V., T.M.A., O.E.O., P.P.V., M.V., R.K., and L.ST.) 
TABLE 2. Determination and Quantification of the 3-bp 
Deletion Causing Removal of LYS107 of ApoA-1 DNA in 
Affected and Control Individuals by Solid-
Phase Minisequencing 
Incorporated Radioactivity 
Sample G, cpm T, cpm T/G, cpm 
Brother 1 1428 1306 0.90 
Brother 2 1324 1276 0.96 
K.K. 26 3514 135.00 
A.U.T. 2018 1944 0.96 
K.P.V. 1754 1706 0.97 
K.A.P. 80 3090 38.60 
Normal subject 1 70 1522 21.70 
Normal subject 2 16 2544 15.90 
Pooled DNA 
A (n~921) 36 1052 29.00 
B (n= 189) 3~ 1072 32.00 
C (n=180) 36 1502 42.00 
In the solid-phase minisequenclng reaction. T/G cpm was >10 Ii" 
normal. 0.1-10 for heterozygous. and· 0.1 for homozygous IndiViduals n 
Indicates number of Individuals. 
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TABLE 3. .C.li~ical Char~cteristics, Lipi~, Lipoprotein, Apolipoprotein, LpA-I, and LpA-I:A-1I Levels, and LCAT and 
CETP Activities of Family Members With (n=10) and Without (n=15) the ApoA-1 (LYS107~) Mutation 
BMI, TC, Tg, HDL-C, LDL-C, ApoA-I, ApoA-II, 
Sex Age,y kg/m2 mmollL mmollL mmollL mmollL mg% mg% 
A.U.T: F 51 38.9 5.98 5.87 0.28 3.57 50 28 
KKK: M 55 27.7 4.50 1.13 0.67 3.13 105 26 
R.O.K: M 40 25.6 3.64 0.85 0.73 2.33 108 32 
K.P.V: M 27 26.9 5.39 1.27 1.02 3.46 132 42 
T.M.A: F 68 39.3 4.75 2.40 0.46 2.75 83 22 
O.E.O: M 63 32.2 6.81 2.49 0.99 4.67 151 31 
P.P.V: M 49 26.8 5.54 1.11 0.54 4.31 93 25 
M.V: F 56 28.1 2.97 2.22 0.60 1.45 113 20 
R.K: M 35 22.1 6.49 1.27 0.98 • 3.32 131 28 
L.S.T: F 33 21.9 3.99 0.81 0.67 2.84 108 23 
M.J.V. M 32 28.8 5.51 2.72 0.69 3.90 110 38 
K.A.P. F 59 28.3 4.99 0.95 0.67 3.65 100 33 
K.K. F 79 25.8 5.56 0.83 1.51 3.55 138 42 
A.A.S. F 84 36.3 5.50 1.57 0.63 3.50 98 r 30 
A.K.S. F 49 29.4 4.76 1.85 0.76 2.71 114 37 
A.K.U. F 52 31.0 5.05 0.73 1.80 2.43 ~ 173 37 
P.E.K. M 64 45.6 6.44 2.84 0.76 3.85 112 31 
P.M.K. F 59 24.3 7.70 1.10 1.61 4.86 170 42 
P.K.B. M 48 34.9 5.55 0.91 1.15 3.44 132 31 
R.EK M 55 31.3 6.69 3.16 1.11 4.08 160 40 
R.T.K. M 58 22.9 6.36 1.51 1.18 3.37 145 41 
R.E.N. F 56 43.4 5.65 1.42 0.75 3.80 114 26 
R.A.T.K. F 41 31.0 4.36 1.00 1.07 2.80 127 30 
R.E.O.K. M 46 27.7 6.18 1.18 1.23 3.60 141 
39 
J.K. M 11 16.1 3.07 0.38 1.07 NO 121 
40 
Mean::tSO 
Mutation 47.7::t13.5 29.0::t6.1 5.01 ::t1.26 1.94::t1.51 0.69::tO.25t 3.18::t1.10 107::t28t 
28::t6t 
No mutation 55.9::t13.7 31.5::t6.6 5.74::tO.87 1.56::tO.80 1.07::tO.38 3.54::t1.42 
131::t25 36::t5 
BMI indicates body mass index; TC, total serum cholesterol; Tg, serum triglycerides; LOL-C, LOL cholesterol; AU, arbitrary unit; and NO, not determined. 
'Subjects with the apoA-1 (LyS107~) gene mutation. 
tP<.05, tP<.01, §P<.001 affected vs unaffected family members. 
revealed a variant apoA-I isoprotein that had a decrease 
of one positive charge compared with normal mature 
apoA-I (Fig 2). The relative plasma concentrations of 
the variant apoA-I isoform and normal apoA-I were 
similar as judged from the isoelectric focusing pattern. 
To localize the mutation that caused the net charge 
change of the variant isoprotein, all exons of the apoA-I 
genes of the propositus and her relatives were amplified 
by PCR and subjected to SSCP analysis. Fig 3 shows the 
first fragment of exon 4 of the apoA-I gene of the 
proband and some of the affected family members. 
Compared with the DNA migration pattern of control 
subjects, they had two additional bands with faster 
mobility. 
Direct sequencing of the coding region of the apoA-I 
gene revealed that the proband and the nine other 
affected family members (Fig 1) were heterozygous for a 
3-bp deletion in exon 4 from nucleotides 1396 through 
1398, removing the codon (AAG) for LYS107 of the 
mature apolipoprotein. Exon 4 of the apoA-I gene 
contains six 66-bp-long homologous tandem repeats that 
code for six 22-amino acid segments.28 The 3-bp deletion 
described 'above occurred within repeat number one. 
The rest of the apoA-I gene sequence was normal. 
The 3-bp deletion in the apoA-I DNA of the proband 
and affected family members was further confirmed by 
using solid-phase minisequencing, in which a detection 
primer, annealing immediately adjacent to the mutation 
site, is elongated by a DNA polymerase with a single 
dNTP corresponding to the nucleotide at the site of the 
mutation. To identify the normal sequence (TGAA-
GAA) and the sequence including the 3-bp deletion 
(TGAAGAC), [3H]dTTP is included in one mini-
sequencing reaction and [3H]dGTP in another reaction. 
The ratio between the incorporated nucleotides directly 
reflects the ratio between the two sequences present in 
the PCR product. 
DNA samples from the proband (A.U.T.), her two 
brothers (KKK and R.O.K), and her son (KP.V.) as 
well as DNA samples from two unaffected family mem-
bers (KK and KA.P.) and two unrelated control sub-
jects were analyzed by solid-phase minisequencing. The 
presence of the mutation resulted in a significant incor-
poration of [3H]GTP, leading to a T/G ratio of about 1, 
while this ratio in unaffected family members and con-
trol subjects was > 10 (Table 2). 
To determine the prevalence of the mutation apoA-I 
(LyS107~0) in the Finnish population, solid-phase 
minisequencing of pooled DNA from Finnish subjects 
was performed. Three separate pools containing DNA 
from 921, 189, and 180 individuals, respectively, were 
analyzed. In these population samples no subjects with 
the apoA-I (LyS107~) mutation could be identified 
(Table 2). 
Serum Lipoprotein and Apolipoprotein Levels and 
Enzyme Activities 
The clinical characteristics and lipid values measured 
in subjects of the pedigree are presented in Table 3. The 
TABLE 3. (Continued) 
LpA-I, LpA-I:A-II, ApoB, LCAT, CETP, 
mg% mg % mg% nmol . mL -1 • h- 1 AU 
17 33 107 25.1 1.0 
:)1 54 91 41.4 1.1 
46 64 71 58.2 0.8 
57 75 97 55.4 1.2 
39 44 115 44.3 0.8 
63 88 156 36.8 0.8 
35 58 110 74.8 0.9 
57 56 70 45.0 0.7 
66 65 96 32.4 1.1 
51 57 74 46.0 1.1 
28 82 129 39.0 1.4 
..2-+ 76 91 42.2 1.7 
58 80 94 35.2 1.1 
26 72 111 35.7 1.7 
29 85 95 46.9 1.3 
78 95 70 42.5 1.0 
40 72 126 35.5 0.7 
64 106 124 33.7 1.2 
46 86 92 38.2 1.0 
53 107 157 42.5 0.8 
rlt) 79 115 47.0 1.4 
36 78 114 52.2 1.5 
43 84 115 67.9 1.4 
54 87 111 41.8 1.4 
39 82 39 58.1 NO 
48±14 59±15§ 99±26 45.9±14.1 0.9±0.2t 
46±17 85±11 110±21 42.9±8.9 1.2+0.2 
mean serum HDL-C concentration of the affected family 
members was clearly below the normal range and was 
reduced by 36% compared with the mean HDL-C value 
of the unaffected family members. Total serum choles-
terol, LDL cholesterol, and triglyceride concentrations 
were similar in apoA-I (Lysl07~O)-affected and unaf-
fected su~jects. The proband had moderately increased 
~~rum tnglycerides, while the rest of the apoA-1 
\:)" I07~) heterozygotes were normotriglyceridemic.43 
1 he fa~tIng ?lood glucose, glycosylated hemoglobin, and 
serum Insulin values were within the normal ranges for 
all affected subjects (data not shown). 
The mean serum apoA-1 concentration of heterozy-
g.otes was reduced by 18.3% and the apoA-II concentra-
tIon by 22.2% compared with unaffected family members 
(P<.05 and P<.Ol, respectively, Table 3). The mean 
ap,()C-II. a~d apoC-III concentrations of heterozygotes 
\vcrt: wIthIn the normal ranges and were similar to 
unaffected family members (data not shown). 
The mean plasma LCAT activity in carriers of the 
mu.t~nt apoA-1 gene did not differ from the LCAT 
activIty of unaffected family members. In vitro no defect 
~as observed in the LCAT activation properties of the 
~so~a~ed mutant apoA-I. However, the mean CETP 
,ctlvlty was reduced by 25% in affected family members 
" 'f",)ared with unaffected family members (P<.05, Ta-
11,,- .;). The mean CETP activity of the unaffected family 
rembers was similar to the level measured 10 our 
aboratory for healthy control subjects. 44 
Characteristics of HOL 
d T~e two most prominent characteristics of the HDL 
enslty distrihution profiles of the affected suhjects were 
Tillr-I\.icsi et at ApoA-I " IIc\Sln~1 
the tota~ absence of HpL 2 and the shift of the HDLl 
s~bfractlOn toward a hIgher density compared with the 
plOfiles of unaffected family members (Fig -1-). The 
percentages of HDL found in the five subfractions 
HDL 2b , HDL 2;" HDL." HDL1h , and HDL. were "i Y: 
7.3%, 18.1:0, 33.Y/r, and 35.2%, respecti~ely, f(;~ a~~ 
fect~d famIly members compared with (>.4{( (P<.OI), 
12.:;: (P<.OOI), 19.4r;;- (NS), 29.1 % (P<.OOl), and 
29. ~ Ic, (P:=.0.5) 10 una~ected family members (Table -1-). 
T.he ?at~ md.lcate that 10 heterozygotes the HDL density 
dlstnbutlo~ IS altered, with more than two thirds of the 
HDL p~rtlcles being in the two most dense HDL 
subfractlOns, HDL3h and HDL3c-
:rhe HD~ particle size distribution was determined by 
usm? gr~dlent gel electrophoresis (Fig 5). The HDL 
particle size distribution profiles of all the affected family 
members were charactenzed by a predominance of the 
HDL3 subclass. In the subjects with the apoA-I 
(LySI(J7~) v~riant one major peak appeared at 8.0 to 9.7 
nm .and a mmor peak at 7.8 to 8.5 nm. In unaffected 
famIl~ members the HDL particle profile was more 
p,ol~dlsperse .. and consisted of two to five peaks with 
SimIlar mobility. The major peak appeared at 8.0 to 8.9 
nm and a minor peak between 7.8 to 8.0 nm, and most 
unaffected subjects also displayed one or two prominent 
peaks at 9.3 to 11.5 nm. The results indicate that the 
apoA-1 (LySI07~) variant is associated with a very low 
level of the HDL 20 subclass, similar to subjects with 
apoA-IMilano.45 
The mean concentrations of LpA-I particles were 
comparable in affected and unaffected family members, 
but the. concentration of LpA-I:A-II particles was 31 % 
lower 10 affected than in normal family members 
(P<.OOl; Table 3). 
Characteristics of VLOL, IOL, and LDL 
The density distribution curves of VLDL, IDL, and 
LDL did not show any characteristic features or specific 
particle subpopulations in affected compared with unaf-
fected family members (data nut shown). 
In all 10 subjects with the apoA-I (LySIU7~O) deletion 
the LDL particle size distribution revealed one major 
peak without clearly distinguishable minor peaks (data 
not shown), The computer-calculated particle diameter 
of the major LDL peak was 25.7 nm for both the apoA-1 
(LyS107~) carriers and noncarriers. The presence of the 
apoA-1 (LyS107~) deletion did not seem to affect the 
LDL particle size distribution. In all family members the 
particle diameter of the major LDL peak correlated 
negatively with the serum triglyceride concentration 
(r 2=.5809, P<.OOI), serum insulin level (r 2=.2464, 
P<.05), and VLDL1, VLDL 2 , and IDL concentrations 
(r 2=.4268, r2=.5466, and r2=.3084, respectively, P::s.05). 
A positive correlation was observed between the particle 
diameter of the major LDL peak and the concentrations 
of the HDL 20 (r 2=.1773), HDL 2a (r 2=.2758). HDL,;o 
(r 2=.3128), and HDL3b (r 2=.2227) subfractions (all 
P<.05). 
Composition of Lipoprotein Subclasses 
In the HDL 20 subfraction of affected family members 
the percentage of triglycerides was increased by Cl3 r ;, 
and in HDL 2;o and HDL., the percentagl's of cholesterol 
were decreased by 1.5'·'; lind 1-1- 1';, respecti\ely (both 
P:::;.05). The most significant characteristic of the liD!. 
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comp~sition of subjects with the apoA-I (LySI1J7---?Q) 
mutation was the low cholesterol-to-triglyceride ratio in 
the largest HDL subclasses (Table 4). In HDL 
HDL 2.'" and .HDL3a subfractions the cholesterol-to-t~t 
glycen~e ratIo was reduced by 54%, 39%, and 35%, 
respectIvely (P<.05), compared with unaffected family 
members. Compositions of the two most dense HDL 
subfractions, HDL3h and HDL1C! were comparable in 
affected and unaffected subjects. Similarly, in subclasses 
of LDL and VLDL the heterozygotes tended to have a 
moderately increased content of triglycerides and a 
lower cholesterol-to-triglyceride ratio, with a significant 
difference in LDL
" 
LDL." and VLDL? (P<.05; Table 4). 
Discussion 
We report an apoA-I variant detected in a Finnish 
kindre? Isoelectric fo~using of plasma from the proband 
and nIne other famIly members revealed a variant 
apoA-I isopr<?tein with a decrease of one positive charge 
c?mpared WIt? normal apoA-I. PCR-SSCP analysis, 
dl:ect sequencIng, and solid-phase minisequencing anal-
YSIS showed that the variant apoA-I isoprotein was 
cause? by a 3-bp deletion of nucleotides 1396 through 
1398 In exon 4 of the apoA-I gene, resulting in the lack 
of the codon for LYSI07 of apoA- I. 
The mean HDL-C concentration of affected family 
members was reduced by one third compared with 
unaffected family members, while mean total and LDL 
cholesterol concentrations were similar in affected and 
unaffected subjects. An increased incidence of hypertri-
glyceridemia is typical of some apoA-I variants,25,46,47 but 
the serum triglyceride concentrations of all the apoA-I 
(LySI07---?Q) heterozygotes except one were normal. The 
proband had moderately increased serum triglycerides, 
possibly as a consequence of obesity and low lipoprotein 
lipase activity.48,49 Concomitant moderate hypertriglyc-
eridemia explains the proband's exceptionally low 
HDL-C concentration compared with the HDL-C levels 
of other affected family members.50 
Heterozygous subjects had mean serrn apoA-I and 
apoA-1I concentrations that were reduced by a similar 
extent. The mean concentrations of LpA-I particles were 
the same in affected and unaffected subjects, while 
affected family members had a 31 % lower mean concen-
tration of LpA-I:A-1I particles than unaffected family 
members. Puchois et al 16 and Barkia et al51 have shown 
that reduced concentrations of LpA-I but not LpA-
I:A-II are associated with coronary artery disease, and in 
vitro studies support the assumption that LpA-I is 
cardioprotective. 16.51 In contrast, other studies have 
shown that LpA-I and LpA-I:A-1I are reduced in coro-
nary artery disease or CHD patients to a similar 
degree. 17-19,52 
An inverse correlation between the HDL-C level and 
the fractional catabolic rate of apoA-I and apoA-II has 
been demonstrated,53-s6 and in heterozygous apoA-IMi'ano 
(Argl73~Cys) and apoA-Ilowa (GlY26~Arg) subjects both 
the mutant and the normal apoA- I are catabolized at an 
increased rate. 26,S7 In addition, apoA-II levels are de-
creased in subjects with apoA-I (Argl73~Cys) or apoA-I 
(GlY26~Arg), which suggests that apoA-II may be more 
rapidly catabolized in these subjects as well. 21> However, 
apoA-II kinetics have not been studied in subjects with 
apoA-I variants, and no data have been reported on the 
metabolism of the two HDL particle populations in 
HDL2b HDL2a HD1..3a HD1..3b HD1..3c 
HDL2b HDL2a HD1..3a HD1..3b 1 HD1..3c 
FIG 4. Protein absorbance profiles of HDL subclasses obtained 
by density-gradient ultracentrifugation. Individual curves of 
apoA-1 (LyS107~) carriers (top) and unaffected family members 
(bottom) are shown. 
apoA-I-variant subjects. On the basis of the normal 
concentration of LpA-I particles and the decreased 
concentration of LpA-I:A-II particles in apoA-I 
(LySI07---?Q) Helsinki heterozygotes, we hypothesize that 
this mutation primarily affects the metabolism of HDL 
particles containing both apoA-I and apoA-II. Our 
preliminary data from in vivo turnover studies in two 
apoA-I (LySI07---?Q) heterozygotes show an increase in the 
fractional catabolic rate of both apoA-I and apoA-II 
(Tilly-Kiesi et ai, unpublished data, 1995). 
Several characteristic features of the HDL of het-
erozygotes were observed in comparison with the HDL 
of unaffected family members. Density-gradient ultra-
centrifugation studies demonstrated that the heterozy-
gotes lacked HDL?, and more than two thirds of their 
total HDL was found in subfractions HDLlo and HDL,e , 
which have the highest density and the lowest cholester-
ol/protein ratio.2.J These data are consistent with the 
observation that these subjects have a greater percent-
age reduction in serum HDL-C le\'els than in ap\l:\-I 
and apoA-II concentrations. HDL particle size distribu-
tion studies revealed that hcterozygotes lackeJ III)L 
peaks in the particle size range >9.7 nm. indicating a 
deficiency of larger HDL particles.':-; 
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TABLE 4. Concentration and Compositio f L' . . 
Density-Gra.dient Ultracentrifugation of R:I~te~P;~~f:~:~ ~~r:~~I~~has ~~~ar:ted by 
Gene Mutation I ou e poA-1 
Total 
Concentration, Cholesterol, Triglycerides, Phospholipids, Proteins, mg!dL Cholesterol! % % % % Triglycerides 
HDL 2b 
Mutation 12.8~4.8:j: 17.7:!::4.2 17.1 ~4.2· 22.5N.7t 
No mutation 32.9~17.8 
42.7:!::8.2 1.2~0.7t 
19.4~1.7 10.5:!::6.6 28.7~4.1 
HDL 2a 
41.5:!::6.3 2.6:!::1.5 
Mutation 17.2~6.3t 14.6:!::2.9· 12.2:!::7.7 26.2~6.5 47.0:!::5.7 1.7~1.2· No mutation 42.5~23.8 17.2~1.9 8.0~4.5 29.8~3.7 
HDL3a 
45'.0::'::3.7 2.8~1.6 
Mutation 44.1 ~19.8· 12.9~2.3t 7.5:!::4.4 28.3~4.0 51.4~3.1 2.2~1.1· No mutation 65.1 ~24.6 15.1~1.6 5.3:!::2.2 28.4:!::3.0 
HDL3b 
51.2~3.3 3.4:!::1.6 
Mutation 79.7~25.4 12.2~2.4 5.1 :!::2.6 26.7~2.8 56.0:!::3.5 ~ 3.1 :!::1.8 r 
No mutation 93.3:!::17.7 13.6~1.5 4.3~0.1 25.3~2.8 56.8~3.9 
HDL3C 
3.6~1.5 
Mutation 80.1 ~20.2 11.2~3.2 4.9~2.0 21.8~4.2 62.1 :!::3.9 2.7~1.2 
No mutation 93.6~13.2 11.7~1.4 3.7~1.2 21.1 ~2.7 63.6~3.9 3.4~1.3 
LDLI 
Mutation 53.4~12.4 37.4~4.0 11.4~3.8· 26.3~1.1* 24.9~ 1.3 3.6~1.2* 
No mutation 64.9~27.3 40.1 ~2.8 8.5~0.2 27.2~0.7 24.3~1.9 5.2~1.9 
LDL2 
Mutation 114.1 ~40.3 38.6~2.8 7.3~2.9 26.0~0.8 28.1 ~1.1 6.1 ~2.5 
No mutation 108.5~20.8 40.3~1.5 6.1 :!:: 1.4 26.3:!::0.6 27.3:!::1.1 6.9~1.6 
LDL3 
Mutation 48.4~19.1 36.9~3.5 9.3~3.0' 25.2:!::1.1 28.6~1.6 4.4:!::1.7* 
No mutation 59.1 ~21.4 38.9:!::1.1 6.7~1.3 25.3~0.6 29.1:!::1.2 6.1 :!::1.4 
VLDLI 
Mutation 33.7~36.9 9.9~1.1 66.9:!::1.7 15.8:!::0.9 7.4:!::1.1 0.15:!::0.02 
No mutation 20.9~18.3 10.5:!::1.4 65.7~3.1 16.2~2.0 7.6~1.0 0.16~0.03 
VLDL 2 
Mutation 58.3~33.1 12.9:!::0.9 56.4:!:: 1.4' 19.3:!::1.5 11.4:!::1.3 0.23:!::0.02* 
No mutation 53.1 ~32.1 13.7~1.6 54.5~2.6 20.2~1.5 11.6:!::1.2 0.25:!::0.04 
IDL 
Mutation 61.5~24.3 17.0~1.6 38.0:!::4.2 18.7~1.9* 26.2:!::5.1 0.44~0.07 
No mutation 65.0~26.2 17.9~2.3 36.4~2.1 20.9:!::2.1 24.8:!::3.4 0.49:!::0.06 
Values are given as mean~SD. 
·P<.05, tP<.01, :j:P<.001 affected vs unaffected family members. 
'he LDL subclass concentrations, density distribu-
I, and particle size of heterozygotes resembled those 
maffected family members. The concentrations and 
.sity distribution of VLDL and IDL were also similar 
jlected and unaffected family members. Lipoprotein 
se and hepatic lipase, which are related to the 
version of VLDL to IDL and LDL, are also involved 
he conversion of large LDL to smaller LDL parti-
.59-62 Similar mean postheparin lipoprotein lipase 
hepatic lipase activities were found in affected and 
ffected family members (data not shown), consistent 
1 the similarity of VLDL, IDL, and LDL subclass 
ributions in these two groups. 
I Tangier homozygotes and in subjects homozygous 
the apoA-I (GluI36~ Lys) mutation, the content of 
ycerides in LDL is increased.63•64 In heterozygotes 
cholesterol-to-triglyceride ratio was significantly re-
~d in VLDL 2 , LDL" LDL) , HDL 2b , HDL 2a , and 
~a, and in all other lipoprotein subclasses a similar 
d was noted. An imbalance in the amounts of donor 
)L) and acceptor (VLDL, LDL) particles for cho-
:ryl ester transfer may account for the diminished 
esterol-to-triglyceride ratio in the plasma lipopro-
; of heterozygotes.65 .o6 The reduced CETP activity of 
heterozygotes compared with unaffected family mem-
bers may be a compensatory alteration to increase the 
HDL2/HDL3 ratio and to correct the HDL 
composition.67 
ApoA-I is an important activator of the LCAT en-
zyme.68.69 As summarized in Table 5, partial LCA T 
deficiency due to reduced LCAT mass or to reduced 
ability of the variant apoA-I to activate LCAT is associ-
ated with apoA-I variants such as apoA-I (Cysl73~Arg), 
apoA-I (Gua202~)' apoA-I (Glu'46~Arg'60) deletion, 
apoA-I (LyS107~)' and apoA-I (Pro'43~Arg).47.70-7J We 
isolated mutant apoA-I (Lysl(J7~) from our proband 
and studied the interaction of mutant apoA-I with 
LCAT in vitro. No defect in the LCAT activating 
properties of the mutant apoA-I was observed. In addi-
tion, the mean plasma LCA T activity of affected subjects 
was similar to that found in unaffected subjects. 
HDL deficiency due to Tangier disease or apoA-1/ 
apoC-I1I or apoA-I/apoC-IIl/apoA-IV deficiency syn-
dromes has been associated with premature CHD.2('-2~ In 
addition, apoA-I gene mutations causing a truncated 
apoA-I protein (Glnx4~stop) and an absence of ;t[1\):\-I 
(Q[ - 2]X) are associated with xanthomas and premature 
CHD.74:·N The majority of apoA-I variants have not been 
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FIG 5. Individual HDL gradient gel electrophoretic profiles from family members with (upper two rows) and without (lower three rows) the apoA-1 (Lys1Or .... O) gene mutation. 
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TABLE 5" Characteristics of Previously Described ApoA-1 Variants 
-
Amino Acid Mean 
Defect Year n Age, y HDL-C ApoA-1 Clinical ApoA-1i LCAT Findings Reference 
Reduced HOL 
CyS173-> Arg 1980 33 33 
:.lIY26->Arg 1988 3 
MI None 24.58.71.75.76 
30 
Jwa NO Systemic 26,77 
Pro l6s->Arg 1989 17 33 
amyloidosis 
GlnS4->stoP 1991 
NO NO None 78,79 l' 52 
Tsukuba NO CHO 74 
Gua202->O 1991 5' 26 
Xanthomas 
MIAI Corneal 47 
Glu14S->Arglso 1991 34 
opacities 
Seattle MI Arcus 73 
senilis 
Absence 1994 9" 29 
)f apoA-1 NO Xanthelasmata 89 
J[-2jX premature CHO 
LYSI07->0 1994 10 48 
Helsinki 
M<--+A Premature 
CHO in 
kindred 
Normal HOL 
GIU13S-> Lys 1983 23" 43 NO A<--+ None 64,80 
Prol43->Arg 1984 3 37 <--+ <--+ NO Al None 
Giessen 70 
LyslOr~O 1984 35 29 <--> 
rv1arburg 
NO NO Al None 25,72,79 
ISP103->Asn 1984 2 26 <--+ NO NO NO None 78,79,81 
Pr04->Arg 7 NO NO NO NO None 
Pro3-> His NO <--+ NO NO NO None 
Munster 
GIU19S->Lys 1988 9 32 <--+ <--> <--+ A<--+ None 79,82,83,84 
Pr03->Arg 1989 2 27 <--+ NO NO None 78,79 
Glu1lo->Lys 1990 3 56 <--+ A<--> None 85 
Fukuoka 
Arg,o-> Leu 1990 9 50 <--> <--+ NO NO None 86 
'1altimore 
\sPs9->Glu 1990 1 NO NO NO NO NO NO 79 
LYS107-> Met 2 NO NO NO NO NO 
GIU139->Gly 2 NO NO NO NO NO 
Glu 147->Val NO NO NO NO NO 
ASP13-> Tyr 1991 54 <--> NO None 87 
Yame 
Leu60->Arg 1992 4 NO NO NO NO NO None 88 
M indicates mass or (;oncentration; NO, not determined; and A, activity. 
'One homozygous subject found. 
associated with low HDL-C levels or premature CHD. 
Of the 23 reported apoA-I variants that we reviewed 
(Table 5), only seven are clearly associated with reduced 
plasma HDL-C and apoA-I concentrations, and the 
mean age of the 69 subjects was 33 years, a very low age 
to make accurate estimations of any association with 
CHD. Interestingly, in three apoA-I variants causing 
{DL deficiency the ability of variant apoA-I to activate 
LCAT and/or the plasma concentration of LCAT is 
markedly reduced.47.7 1.7:l In contrast, apoA-I (Lysl(J7~O) 
heterozygotes had HDL deficiency and normal LCAT 
activity. It should be noted that markedly premature 
CHD has not been observed in LCAT deficiency or 
fish-eye disease despite strikingly low levels of HDL-C. 11 
Therefore, normal LCA T activity may be necessary for 
)w HDL-C to he a CHD risk factor. 
In kindred studies it is hard to actually assess associ-
ations of mutations with CHD because of the limited 
number of subjects and the strong association of CHD 
with age and gender. Pedigree analysis indicated that 
the proband received the mutation from her father. 
Medical-record review re\edled that the father and six 
of his siblings had CHD; in four of these siblings CHD 
was present before the age of 55 years. These six siblings 
died of CHD, while the father died of cerebral hemor-
rhage. The mean age of death in these seven subjects at 
61 years is earlier than that observed in the normal 
population. The one remaining sibling of the father was 
an unaffected subject and healthy at age 84 years. 
Among the seven heterozygotes (mean age, 56 years) of 
the proband and her generation, two (T.M.A.) and 
(O.E.O.) had CHD at age 65 and 63 years, respectively. 
without any other risk factors except for a low HDL-C 
level. In addition, three other subjects of this genera-
tion, including T.M.A.'s sister and brother, had died 
of CHD at the ages of 46,55, and 62 years. It was not 
possible to determine whether they were hetel'll/\-
gotes. None of the unaffected family member" had 
symptoms or signs of CHD. 
The combined data indicate that the apoA-Illc[,"I' 
mutation (Lys[II----~()) results in decreased serum HDL-c' 
apoA-l, apoA-II, and LpA-I:A-II kvcls. reduced ('FTP 
acti"ity, normal lipolytic enzyme and Le.\T ;\cti\ Itie,,_ 
and may be ass(K'iatcd wit h premature ('lID. 
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European perspectives 
Coronary artery disease in Europe: 
what are the genetic risk factors? 
Mortality rates from coronary artery disease (CAD) in 
men in the CK and Germanv are more than tvvice as 
high as those in Italy or Spai~. In Germanv, diseases of 
the heart and circulatory system are not only the most 
important cause of death but also the most important 
cause of reduced life expectancy due to premature 
death. The European Cnion recognises that pre-
mature coronary artery disease in Europe is a major 
health problem of great socio-economic impact. In 
both direct and indirect costs, ischaemic heart disease 
accounts for about 15% of all illness-related costs in 
Germanv, coming second only to diseases of the 
digestive system (nearly 19%). 
Although dietary habits and lifestyle differences may 
contribute in part to the differences in mortality rates 
from CAD between North and South Europe, genetic 
differences may predispose or protect one population 
more than another. Moreover, any gene loci thar 
confer susceptibility to, or protection from, CAD may 
be quite different between north and south Europe. 
Knowledge of such susceptibilitv loci and their 
frequencies in the populations of north and south 
Europe would be of use in several major wavs. 
• 
• 
• 
• 
• 
It would allow us to assign personal risk on a much 
surer foundation than at present possible. 
Such high risk individuals could then be a target 
for prevenri\'e therapies which would eventuall\' 
reduce the long-term social and economic burden 
of CAD in our European populations. 
It may point to critical environmental factors that 
intenct with the genotype for development of the 
disease. 
IdentifvinO" such key environmental determinants 
I b , 
from knowledge of the genes inyoh'ed may aid in 
disease prevention both at the population and 
individual levels. 
\Jew lines of therapy mav be formulated once the 
defective genes are known bY either replacing, 
modulating or blocking their gene products. 
Our laboratorv at St Bartholomew's Hospital 
provides the lead f~r a project to study the differences 
in frequency of coronarv arterv disease between north 
and south Europe. Participating cities are Colog-ne, 
Freiburg, Rome, Barcelona, Bratislava, London and 
D J GALTON, DSc, FRCP, Professor of Human Metabolism 
J CAVANNA, PhD, Senior Scientist 
A KAY, MSc, Research Assistant 
Q ZHANG, MSc, Research Assistant 
Department of Human Metabolism and Genetics, 
St Bartholomew's Hospital, London 
Cardiff. We will attempt to identify common O"enetic 
, b 
determinants for premature coronan- arten' disease 
and assess their possible interactions. The effects of 
genetic and environmental risk factors (smoking, 
dif'tarY fat intake and blol)d pre'isure) are to be 
studied in relation to the clge of clinical presentation 
and se\eritv of coronarv atherosclero'iis ,lsse-;:-,ed 
angiographicallv. 
Questions to be answered 
1 
C) 
3 
<Are an\' of the described genetic variants that have 
been related to the deyelopment of premature 
atherosclerosis found more frequentl\' in subjects 
with CAD? Can ne\\' \-ariants at other loci be 
identified as genetic risk factors? 
Do "ud: genetic determinants differ benveen north 
and south Europe in patients with premature CAD? 
If so, what is the relative incidence of each of thne 
mutations and its impact on the occurrence of 
CAD at each centre? 
Do em'ironmental risk factors such as smoking-, 
dietarv fat and alcohol intake, body mass index 
and blood pressure interact with genetic factors to 
accelerate the age of presentation or the se\erin' of 
pre mature a the roscle ro s is ~lS defi ne d angio-
graphicallv~ 
The work of the laboratorv measurements (serum 
lipids, lipoprotein (a), and the genetic analyses includ-
ing common \'ariancs at the .-\po AI/CIL <--\1\ gene 
cluster, the lipl)protein lipase gene, and the 
apolipoprotein E poln11orphisms) are bein<.; shared 
among the participating European centres. There are 
reO"ular discussions (b\' fax and E-mail) to ensure the 
i:) 
progress of the project; and we all meet once \e~rh. 
usually to coincide \\'ith a European medical SOClety 
meetil~g, to discuss iSSlles and problems. 
It is hoped that eventually identifiettion of 'iLlch 
susceptibilin- loci will pro\'ide ne\\' biological targets 
for acti\'e therapeutic intervention for this common 
disorder 
.-\ rk n owledgf men Is 
This project is :supported by grant P~~~3l ~ 11 of the 
Commission of the European (ommUIllUe:-" 
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A review of health systems in the 1990s 
Edi ted by Roger Williams 
n the last ten years or so it has become evident to all nations in the developed world that simply spendinCT 
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lIld Sweden, and from the UK. They included health care planners, members of government. clinicians from 
lOspitals and general practice and officers of the medical Royal Colleges. 
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Abstract 
The large ethnic differences in prevalence of coronary artery disease between China and 
Europe may relate to genetic differences. We have therefore studied the frequencies of 
disease-related variants of genes involved in lipid transport in 69 hypertriglyceridaemic 
Chinese subjects and 74 healthy Chinese controls. The loci studied include Lipoprotein 
lipase ( Asp9Asn, Asn29ISer, Ser447Ter and restriction site at Hindl1l)~ Apolipoprotein 
Al ( restriction sites at Msp-l ,Xmn-l, and Pst-I); Apolipoprotein C III (G3l75C)~ and 
Hepatic lipase (Thr202Thr). Two disease related genetic variants in Europeans ( Asp9Asn 
and Asn29l Ser) were not found in the Chinese sample (p<O.03). The apo Clll G3l75C 
variant was found more frequently in the upper terile distributions for apolipoprotein Clll, 
apolipoprotein E and plasma triglyceride/HDL ratios (P<O.05). The rare allele of the apo 
Al Msp-l restriction site polymorphic variant was also found more frequently in the upper 
tertiles for apo CIll, apo E and plasma triglyceridelHDL ratios (p<0.04). Eleven of the 
most lipaemic Chinese subjects ( with fasting plasma triglycerides >700 mg./dl.) were 
analysed for DNA sequence variation. One novel mutatioin was observed C1338A (which 
is a silent mutation at Thr36l-Thr) and two others that are also found in European subjects 
(Ala261 Thr and Ser447Ter). We conclude that genetic differences between Chinese and 
Europeans may have an effect on the prevalence of coronary artery risk factors involved in 
lipid transport; and a further extended study IS warranted. 
KEY WORDS: Coronary artery disese; China; Europe; genetic variants~ plasma lipids~ 
apolipoproteins; lipoprotein lipase. 
Introduction 
The dyslipidaemic syndrome of raised plasma triglycerides and low HDL occurs commonly 
in European populations at frequencies of greater than 50/0 and is a well established risk 
factor for premature coronary heart disease (Carlson 1979; Austin 1989; Assmann 1991). 
Several common genetic variants have been detected that associate with this dyslipidaemia 
and in some cases may constitute genetic determinants for the condition. F or example a 
common G3175 - C transversion that is transcribed but not translated in exon 4 of the 
apolipoprotein CIn gene on chromosome 11 p21 has been found in association (Rees 
1983;Rees 1985) and pedigree studies (Wojcrechowski 1991) to link with dyslipidaemia; 
two apo-ClII promoter mutations at position C-482 - T and T-455 -C have also been found to 
associate with hypertriglyceridaemia (Dammerman 1995). In addition several common 
mutations in the gene encoding lipoprotein lipase on chromosome 8p have also been found 
to relate to this dyslipidaemia. For example, a C 1595 - G transversion that converts serine 447 
to a stop codon thereby prematurely truncating the enzyme protein by 2 amino-acids has 
been shown to relate to hypertriglyceridaemia in several studies (Stocks 1992; Zhang 1995). 
Two other common mutations at lipoprotein lipase, namely ASp9 - Asn and ASp291_ Ser 
have also been shown to associate with dyslipidaemia (Mailly 1995; Ma 1993) and in vitro 
transfection studies show a decreased activity of both mutant enzymes. 
There are large ethnic differences in the prevalence of coronary artery disease manifesting 
before the age of 60 years between Western Europe and China. For example, the UK 
standardized mortality rates in men aged 35-64 for coronary heart disease is approximately 
350/1 00,000 compared to 30/1 00,000 in rural China and 6011 00,000 in urban China for men 
aged 35-74 years in 1988 (Tao 1993). It is therefore of great interest to compare frequencies 
of the common genetic variants of the apo A 1- ClII -AIV gene cluster and lipoprotein lipase 
genes that have been postulated to contribute to the atherogenic dyslipidaemia of raised 
plasma triglycerides / low HDL in Chinese and European populations to see if genetic 
factors may account for such ethnic differences. 
Methods 
Subjects 
881 subjects under the age of six-five years were selected randomly from the staff 
members of Hong Guang Electron Tube Factory and 4 Universities in the Chengdu area. 
Those with hepatic, renal and thyroid diseases were excluded from study. The subjects 
were asked to fast 12-14 hours before venous blood was taken. From this survey 69 subjects 
were identified with fasting plasma triglycerides >204 mg/dl. and selected for further study. 
Controls (n=74) came from the same survey who had fasting plasma triglycerides <177 
mg/dl. The presence of other related diseases ( diabetes m., coronary artery disease etc.) 
were established by a questionaire. Full clinical details of the study groups are presented in 
Table 1. 
Lipoprotein Analyses 
Total serum cholesterol and triglycerides were measured by the enzymatic method.(kits, 
Zhong Sen Co., Beijing). HDL-C was determined after sodium 
phosphotungstate/Magnesium Chloride precipitation. Serum apolipoprotein AI, All, B 1 00, 
ClI, ClII and E were quantified by the radial-immunodiffusion kits developed by 
Apolipoprotein Research Laboratory in West China University of Medical Sciences, China 
(Liu 1995). 
Isolation of DNA: DNA was isolated from fresh or frozen EDTA whole blood cells using a 
Nucleon II Kit (Scotlabs Lt,UK) and resuspended in TE buffer and stored at -20°C. 
PeR-Restriction Enzyme Digestion: 
Oligonucleotides: Primers for polymerase chain reaction were synthesized by standard B-
cyanoethyl phosphoramidite chemistry using a Biotech BT 8500 DNA Synthesizer and 
purified on a Sephadex G-25 column. The primer sequences were derived from published 
data (Zhang 1995). Primer sets were as follows: 
LPL: Hind III RFLP: 
5 '-upstream, 5 '-GATGTCTACCTGGATAATCAAAG-3 , 
3 '-downstream, 5'-CTTCAGCTAGACATTGCTAGTGT -3' 
Ser44 7 -Ter mutation: 
5 '-upstream, 5' -CATCCATTTTCTTCCACAGGG-3' 
3 '-downstream, 5 '-AGTCTGGTGAGCATTCTGGGCTA-3 , 
Asp9-Asn mutation: 
5 '-upstream, 5'-AAAATCAAGCAACCCTCCAG-3' 
3 '-downstream, 5'-TAGGGCAAA TTTACTTGCGA-3' 
Asn291-Ser mutation: 
5' -upstream, 5' -TCTGCCGAGAT ACAA TCTTGG-3' 
3' -downsream, 
5'_ATAATATAAAATATAAATACTGCTTCTTTTGGCTCTGACTGTA-3' 
HL: Msp I RFLP: 
5'_upstream,5'-CCCGCGTAACCCTTACCCCT-3' 
3' -downstream 5'-GCTCCCGGCCCATGACTTC_ 3' 
ApoAI -ClII: 
Msp I RFLP: 
5 '-upstream , 5'-ATGTGCTCAAAGACAGCGG_3' 
3 '-downstream, 5'-AGCAGAGGAGGTGGTGAAGA_3' 
Pst I RFLP: 
5 '-upstream, 5'-GAGCGCTCTCGAGGAGTACAC-3' 
3'-downstream 5'-GACTGGCTTCCACTGCTGTGC-3' 
Sst I RFLP: 
5 '-upstream, 5 '-CACTCATAGCAGCTTCTTGTCC-3 , 
3 '-downstream, 5'-TACAGAGGAGTTCTCATGCCC-3' 
XmnI RFLP: 
5 '-upstream, 5'-TGCCAGACCTAGCAGGGGACA-3' 
3 '-downstream, 5'-GCATCTTACCAAGCAGGCAGTTTC-3' 
Amplification of Genomic DNA 
Genomic (0.2-0.5 ug) was amplified in 25 ul reaction mixture containing 10 mmoliL 
Tris-HCL(pH 8.3); 50 mmol/L KCL; 0.001% gelatin, 200 umol/L each of dATP. dCTP. 
7 
dGTP and dTTP~ 1-4 mmollL MgCI2; 0.5 umollL each primer and 2.5 U Taq DNA 
polymerase (GIBCO BRL). The mixture was overlaid with mineral oil. All tubes, tips and 
buffers were autoclaved and the reaction mixture was UV irradiated before addition of 
genomic DNA and Taq DNA polymerase to minize contamination( 44).Blank controls 
containing no genomic DNA were run with each set of amplifications. The amplification 
cycle was performed on a Perkin-Elmer Cetus 480 Thermal cycler and entailed 5 minutes of 
denaturation at 96°C followed by 35cycles of 1 minute at 94°C, 1 minute at 48-630C and 1 
minute at 72°C. This was followed by 10 minutes of extension at 72°C. 
Digestion and Electrophoresis 
Five microliters of digestion mixture containing the manufacturer's recommended 
restriction buffer and 5 U restriction enzyme (Gibco BRL) were added to the amplification 
product and incubated at 65°C 3 hrs with Taq I for the exon 2 of LPL gene or 37°C 
overnight: Hind III for the intron 8 RFLP, Rsal for Asn291-Ser and Mnll for the Ser447-Ter 
mutation of LPL gene; Msp I for the exon 5 RFLP of HL gene and apo-A1 gene~ Pst and 
Xmn I for the apo Al gene, and Sst! for apo C111 gene. Subsequently, the samples were 
electrophoresed in 1 x TBE buffer( 89 mmol/Tris-borate, 2mmolIL EDTA pH 8.3) in 2-3% 
agrose gels at 150 V for 1-l.5 hrs. DNA was visualized by staining the gels with ethidium 
bromide(0.5 ug/ml) and transillumination with UV light. 
peR-Sequencing 
Amplication of LPL gene exons: Oligonucleotide primers were synthesised (IGI Ltd.UK) 
to allow the amplification of individual exons of the LPL gene. For each exon, flanking 
intronic DNA ( sequence courtesy of K. Oka) was examined for potential PCR primer sites 
using PRIMER software and Primer pairs idenified. In each pair. one primer was 
biotinylated at the 5' end. Typical PCR reaction conditions were as follows: 
50-100 ng DNA, 50 mM KCL, 10 mM Tris-HCL(pH8.3), 2.0mM MuCL,. 
'- -
O.OOl%(wfv)gelatin, 200uM dNTPs, 100nM each primer and 2 units Tag polymerase (Life 
Sciences, UK) in a 100ul reaction. Amplification was achieved in a Perkin Elmer Cetus 480 
thermal cycler using an initial denauring step of 94°C for 1 min and then 35 cycles of 94°C 
30 secs, 60° 1 min, 72° 1 min followed by a final elongation step of 72° for 10 min. Small 
aliquots were removed to test the PCR reactions on 1.5% agarose gels. 
Sequencing of PCR Products 
PCR products were sequenced using the dideoxy chain termination method and were 
sequenced directly after treatment with Exonuclease I and Shrimp Alkaline Phosphatase 
(Sequenase PCR product sequencing kit, Amersham Life Sciences, UK).The reaction 
products from sequencing reactions were electrophoresed on 6% acrylamide-bisacrylamide 
(19: 1), 7M urea gels using a glycerol tolerant gel buffer. The gels were prewarmed and 
samples were electrophoresed at 50V fcm. Subsequent to electrophoresis, the gels were fixed 
in 100/0 acetic acid and 100/0 methanol and vacuum dired. Dry gels were autoradiographed 
for 18-72 hours with Hyperfilm (Amersham Life Sciences, UK) and the sequence read off 
the developed autoradiograph. 
Statistical Analysis 
Genotype distributions between the study groups were analyzed by 2x2 and 3x2 
contingency tables and performing chi2 analysis. Variation in the biochemical traits with 
respect to genotypes were analyzed by performing analysis of covariance . Similar 
comparisons of genotype distribution were undertaken using chi2 analysis after biochemical 
traits were divided into tertiles. Analyses were performed using SPSS for Windows 
statistical packages. 
Results 
The clinical and biochemical characteristics of the Chinese group are presented in Table I. 
The hypertriglyceridaemic Chinese group had raised plasma levels of apolipoproteins -B,-
ClI, -ClII and -E due probably to the increased circulating levels of triglyceride rich 
lipoproteins compared to Chinese controls. They also had decreased levels of 
apolipoproteins -AI and -All and HDL. 
Allele Frequencies 
With regard to allele frequencies of common genetic variants that have been reported in 
European populations to relate to the hypertriglyceridaemic / low HDL syndrome, the 
Asn291 _ Ser and ASp9 - Asn variants of lipoprotein lipase were not detected in the Chinese 
group (n=74). The Serine 447_ Ter variant and the HindlII restriction length polymorphism 
in intron 8 of the lipase gene were found at similar frequencies to European groups (Table 
2). 
The two disease related restriction length polymorphisms of the apo-AI gene (detected with 
Msp I and Xmn I) were also significantly different in frequencies between Chinese and 
. 3175 . bl 2) CaucaSIan groups; as was the apo-CIII G -C vanant (Ta e . 
Disease Associations 
Apolipoproteins AlICIII variants. 
The apolipoprotein AlICIII variants ( the apo AI-Mspl and apo C-lil polymorphisms) 
that have shown disease relationships in European studies also appear in the Chinese group 
. 3175 C)·.c d fr tl' th ( Table 3). Thus the rare apo-CIII varIant (G - IS loun more equen y 111 e upper 
tertile for plasma apo CIII and TGIHDL ratios. The apo AI-MspI rare \'ariant is also found 
more frequently in the upper terti Ie for plasma TG / HDL ratio. The similar results found 
with plasma apo-E tertiles probably reflect the increased amounts of apolipoprotein E 
carried on VLDL in lipaemic plasma. 
Lipoprotein Lipase Mutations 
The frequencies of lipoprotein lipase mutants in Chinese hyperlipidaemic subjects are 
presented in Table 4. The Ala261 _ Thr variant was found more frequently in Chinese 
lipaemic subjects than controls but did not reach statistical significance possibly because of 
small samples. None of the other common variants showed significant differences. The 
S . 447 T . h enne - er varIant s owed a tendency to be found at lower frequencies in the lipaemic 
subjects. 
Eleven of the most lipaemic Chinese subjects ( fasting plasma triglycerides >700 mg/dl.) 
were analysed for DNA sequence variation in the lipoprotein lipase genes. Analysis of the 9 
coding sequence exons revealed only one novel mutation where C1338 is substituted by A ~ 
this is a silent mutation at Thr361 _ Thr (Table 5). The gel sequences for detection of the 
Thr361 _ Thr variant are presented in Fig.1 . 
DISCUSSION 
The question whether genetic variants at loci involved in lipid transport could in part 
account for differences in mortality rates from coronary heart disease between Chinese and 
European populations has been considered in this paper. In support of this hypothesis we 
have found that two common disease related mutants of lipoprotein lipase in Caucasian 
groups do not occur in our Chinese samples. The Asn291 _Ser mutant (Reymer 1995) is 
found at increased frequencies in Caucasian male patients with premature atherosclerosis 
who have low levels of HDL. This variant results in a significant decrease in LPL catalytic 
activity and in vitro expression studies confirm that this variant is associated \\ith a 
significant reduction in LPL activity. The Asp9-Asn variant (Mailly 1996) lowers 
lipoprotein lipase expression by about 25-30% and is found at higher frequencies in patients 
with hypertriglyceridaemia than in healthy controls. Healthy carriers of the mutation also 
have plasma triglyceride levels 25-30% higher than non-carriers~ and survivors of 
myocardial infarction who were both obese and were carriers were found to have hioher 
~ 
plasma triglyceride levels than non-carriers. The fact that these mutations were not observed 
in a Chinese sample may add weight to the hypothesis that they have an impact on the 
development of coronary heart disease. 
No ethnic differences were found in other reported LPL variants (Ser-l-P-Ter, or the Hind 
111 restriction length polymorphism) ; and no differences in allelic frequencies were found 
within the Chinese sample between upper and lower tertiles for plasma triglyceride, or 
HDL. 
With regard to the apoAlICI111Al V gene cluster the common apo-C111 variant ( 03175_C ) 
was found at higher frequencies in the upper tertiles for plasma triglyceridelHDL ratios and 
apoliprotein C 111 levels in the Chinese sample. This apo-C III variant has been 
consistently found at higher frequencies in Caucasian subjects with hypertriglyceridaemia 
(Jowett 1984; Aalto-Setala 1987; Stocks 1987), Familial combined hyperlipidaemia 
(Hayden 1987), and other dyslipidaemias. It has also beeen observed at increased 
frequencies in Caucasian subjects with premature coronary artery disease (Ferns 1986; Rees 
1985). The same relationship appears to hold for Chinese subjects with 
hypertriglyceridaemia/low HDL. However the observation that the C 111 variant occurs 
more commonly in a normolipidaemic Chinese group suggests that the variant is not 
directly involved as an aetiological factor but is probably acting as a genetic marker for an 
aetiological mutant with which it is in linkage disequilibrium. 
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Figure 1. Autoradiograph of DNA gel sequences. 
Nucleotide sequence of the coding strand for the mutant and normal exon 8 of lipoprotein 
lipase showing a C-A transversion at nucleotide 1338 that results in a silent mutation at 
Threonine 361 . 
Normal Mutant 
ACGT ACGT 
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Figure 1: Autoradiograph of DNA gel sequences of Thr361 silent mutation ofLPL gene, 
Nucleotide sequence of the coding strand for the mutant and normal exon 8 of the LPL gene showing a 
C-A transversion at nucleotide 1338 that results in a silent mutation at Thr36 I , 
Table 1. Clinical and Biochemical Characteristics (Adjusted for Age and BMI) of Chinese Subjects 
with and without Hyperlipideamia. 
Hyperlipideamia Controls 
(n=69) (n=74) 
Age (years) 54.69+6.83 52.81 +8.03 
Sex (male+female~ no & %) 64+5(92.8% +7.2%) 68+6(91.9% +8.1 %) 
Weight (Kg) 70.32+9.23 62.86+8.67 
BMI (Kg/M2) 25.42+2.76 22.67+2.76 
Diabetes mellitus (no & %) 5 (7.2%) 5 (6.8%) 
Hypertension( > 130mmHg~no & % ) 15 (21.7%) 10 (13.5%) 
Blood Glucose, mg/dl 101.64±19.30 98.94±30.42 
Triglycerides, mg/dl 440. 16±363.16 125.55±29.81 
Cholesterol, mg/dl 227. 83±223 .80 184.70±34.30 
HD L-C, mg/ dl 36.58±9.52 50.58±10.21 
ApoAI, mg/dl 108.05±14.86 117.43±19.85 
ApoAII, mg/dl 23.40±5.16 27.04±3.41 
ApoB, mg/dl 117.92±29.56 93.67±23.50 
ApoCII, mg/ dl 6.89±3.10 3.46±1.07 
ApoCIII, mg/ dl 18.95±10.83 9.13+2.44 
ApoE, mgdl 7.20±5.19 3.97±0.82 
TG/HDL 13.54±16.68 2.62±0.91 
BMI indicates body mass index. p values were analysed by Chi-square test*, Oneway Anova# and 
Analysis of Covariance and triglycerides were log 10 transformed before analysis. 
p 
NS# 
NS* 
<0.001# 
<0.001# 
NS* 
NS* 
NS 
<0.0001 
NS 
<0.0001 
0.004 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
< 0.0001 
Table 2. Observed Distribution of Allele Frequencies for the LPL Gene, HL Gene and 
ApoAI-CIII Gene Mutations Compared between Chinese and Caucasian Controls 
Chinese Caucasian 
(n=74) (n=54) 
Gene allele frequencies p 
common allele rare allele common allele rare allele 
LPL 
Asp9-Asn 1.000(140) 0.000(0) 0.991(107) 0.009(1) NS 
291 Asn -Ser 1.000(140) 0.000(0) 0.963(104) 0.037(4) <0.03 
447 Ser -Ter 0.893(125) 0.107(15) 0.880(95) 0.120(13) NS 
LPL-HindIII 0.771«(108) 0.229(32) 0.704(76) 0.296(32) NS 
Thr361 -Thr (HaeHI) 0.886(124) 0.114(16) 0.870(94) 0.130(14) NS 
HL 
Thr202 -Thr (MspI) 0.943(132) 0.057(8) 0.500(54) 0.500(54) <0.0001 
ApoAI 
AI-MspI 0.707(99) 0.293(41) 0.889(96) 0.111(12) <0.0006 
AI-XmnI 0.714(100) 0.286(40) 0.870(94) 0.130(14) <0.004 
AI-PstI 0.929(130) 0.071(10) 0.954(103) 0.046(5) NS 
ApoCIH 
CHI-Sst! 0.721(101) 0.279(39) 0.880(95) 0.120(13) <0.003 
The number of observed alleles are presented in parentheses. Values for Caucasian controls 
are taken from our previous publication (Zhang 1995). 
Table 3. Lipid and Lipoprotein Tertiles Related to ApoA1-CII1 Genotypes 
No. of Subjects Represented by Genotypes 
ApoA1-Msp1 ApoCII1 -Sst1 
MIM MIM M2M P S1S1 S1S2 S2S2 P 
2 2 2 
Blood Glucose 
lower tertile 19 26 3 NS 20 25 3 <0.0 
« 90.00mg/dl) 27 15 6 (0.07) 29 13 6 4 
higher tertile 
(> 98.53mg/dl) 
ApoCII1 
lower tertile ( < 9. 72mg/ dl) 26 17 4 NS 28 16 3 0.05 
higher tertile 25 14 11 25 13 12 
(> 13. 90mg/dl) 
ApoE 
lower tertile « 3.75mg/dl) 20 24 6 <0.0 20 24 6 <0.0 
higher tertile (> 5.15mg/dl) 31 11 8 3 31 11 8 3 
TG/HDL 
lower tertile ( < 3.06) 23 22 2 <0.0 25 20 2 0.05 
higher tertile (> 7.08) 25 15 10 4 25 15 10 
p Values were analysed by Chi-Square Tests (2x2 contingency tables) and Fisher's exact test where appropriate. 
Table 4. Observed Distribution of Allele Frequencies for the LPL Gene, HL Gene and 
ApoAI -CIII Gene Mutations Compared between Chinese Patients and Controls 
Controls Patients 
(n=70) (n=68) 
Gene allele frequencies 
common allele rare allele common allele rare allele 
LPL 
Asp9-Asn 1.000(140) 0.000(0) 1.000(136) 0.000(0) 
Ala261 _Thr 1.000(140) 0.000(0) 0.993(135) 0.007(1) 
291 Asn -Ser 1.000(140) 0.000(0) 1.000(136) 0.000(0) 
Ser447-Ter 0.893(125) 0.107(15) 0.926(126) 0.074 (10) 
LPL-HindIII 0.771((108) 0.229(32) 0.824(112) 0.176(24) 
Thr361_ Thr (HaeIII) 0.886(124) 0.114(16) 0.904(123) 0.096(13) 
HL 
Thr202 -Thr (MspI) 0.943(132) 0.057(8) 0.904(123) 0.096(13) 
ApoAI 
AI-MspI 0.707(99) 0.293(41) 0.647(88) 0.353(48) 
AI-XmnI 0.714(100) 0.286(40) 0.721(98) 0.279(38) 
AI-PstI 0.929(130) 0.071(10) 0.949(129) 0.051(7) 
ApoCIII 
CIII-SstI 0.721(101) 0.279(39) 0.647(88) 0.353(48) 
The observed alleles are presented in parentheses. Comparisons show no significant difference. 
Table 5. Lipoprotein Lipase Gene Mutations Found in Eleven Chinese Severely Hyperlipideamic 
Subjects (Plasma Triglycerides > 700 mg/dl). 
Location in LPL 
gene 
Exon 6 
Exon 8 
Exon 9 
Nucleotide Change Code Change 
G IUT! -A AiaLb I - Thr 
C\338_A 
C1595_G 
GCC=>ACC 
Thr361 _Thr 
ACC=>ACA 
447 Ser -Ter 
TCA=>TGA 
information 
in literature (Hayden 1993) 
this study 
in literature (Stocks 1992) 
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ABSTRACT 
The common association of obesity, diabetes m., and hyperlipidaemia may have a primary 
aetiological basis. Insulin resistance has been postulated as a possible cause; but defects in 
the plasma transport of triglyceride or fatty acids could also be primary determinants. We 
have therefore studied 18 patients with diabetes m., obesity and severe 
hypertriglyceridaemia for defects of a key protein involved in the clearance of plasma 
triglycerides, lipoprotein lipase. 
DNA was prepared from leucocytes of 18 patients with the above syndrome and exons 
encoding lipoprotein lipase were amplified by PCR. The products were sequenced using the 
dideoxy chain termination method. Eight of the subjects were found to possess genetic 
variants at the lipoprotein lipase gene locus. These were: 
(a) G579_A (VaII08-Val) (b) G818_A (GIYI88-Glu); (c) C829_ T(Arg192-Ter); (d) Al I 27_G(Asn291-Ser); 
(e) C1308_ G(Phe351-Leu); (f) C 1338_ A(Thr361-Thr) and (g) C 1595_ G(Ser447-Ter). 
Three of these, (c),(e),and (f) have not hitherto been described. (f) appears to be a 
population polymorphism whose allele frequency in normolipidaemic diabetics was found 
to be 0.12 (162 chromosomes studied). The others are all rare at frequencies of <0.01 and 
may contribute to the phenotype by impairing clearance of plasma triglycerides.We 
conclude that genetic variants at the lipoprotein lipase locus occur commonly in subjects 
with this syndrome and may affect the individual's response to obesity and diabetes m. for 
the development of lipaemia. 
Keywords: Diabetes m.; obesity; lipaemia; mutations; lipoprotein lipase. 
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INTRODUCTION 
Untreated non-insulin dependent diabetics frequently have abnonnal fasting lipid profiles 
with elevation of plasma triglycerides greater than 2.8 mmolll and reduced HDL cholesterol 
to less than 0.9 mmol/l in more than 25% of cases (1). Factors responsible for this rna\' be 
the increased flow of free fatty acids to the liver that augments hepatic synthesis and 
secretion of triglyceride-rich lipoprotein combined with a clearance defect of triglyceride-
rich lipoproteins in the periphery by muscle and adipose tissue by impaired action of 
lipoprotein lipase(2). However, some non-insulin dependent diabetics develop a severe 
lipaemia with fasting plasma triglycerides greater than 20 mmolll suggesting that additional 
factors are operating. 
Recently more than fifty mutations of lipoprotein lipase have been described including large 
insertions and deletions, frameshift mutations, splicing defects, nonsense and missense 
mutations ( for review see reference 3). In the homozygous state these can impair the 
activity of the enzyme leading to a Type I chylomicronaemia syndrome associated with 
eruptive xanthomata, episodes of acute pancreatitis, and lipaemia retinalis (4 ). Presumptive 
carriers for these mutations can also show severely abnonnal lipid profiles when factors 
such as obesity, pregnancy, or exposure to oral contraceptives are present( 6). The 
possibility therefore arises that subjects with severe diabetic lipidaemia are carriers for such 
mutants and the interaction of the metabolic state of diabetes in the presence of mutants of 
lipoprotein lipase predisposes to the lipaemia (5). We have therefore examined 18 subjects 
with severe diabetic lipaemia (plasma triglycerides ranging from 20 to 80 mmol/l) and have 
found 8 subjects to possess mutations in the lipoprotein lipase gene. Five of these mutations 
are previously reported in the literature whereas three are described here for the first time. 
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PATIENTS 
Subjects under Study. 
Eighteen obese subjects ( Table 1) with known or recently diagnosed NIDDM 
(Type II diabetes m.) and severe hyperlipemia (fasting TG > 1000 mg/dl or 11.4 mmolll), 
were referred for admission to the Endocrinology or Lipid Units of the H. Mondor Hospital 
between March 1993 and February 1994 and were included in this study. There were 15 
men (mean age 45.6; range 39-72 years; mean BMI 31 kg/m2 ;mean fasting blood glucose 
15.2 mmol/l; and mean alcohol intake 191 gmlwk). The three women had mean age of 43 
years; mean BMI of 37 kg/m2; mean fasting blood glucose 12.5 mmolll and mean alcohol 
intake of 13 g/wk. Five patients had eruptive xanthomata and six had symptoms of 
pancreatitis. The other main clinical and metabolic features are outlined in Table I. Eleven 
patients were of French origin; 3 were North African; and the other 4 patients' origins were: 
Spain, Italy, China and Haiti. All patients received strict hypo caloric nutritional therapy on 
admission combined with several hypoglycaemic and/or hypolipidaemic drugs depending 
on clinical features. Additional therapies were: the insulin pump for patients 
1,4,5,7,9,10,11,12,17 usually for 48 hours; combined oral hypoglycaemic therapy with 
metformin, sulphonylureas and/or fibrates for subjects 3,6,8,13,14.; and diet alone for 
subject 2 whose dietary record showed a daily caloric intake of 7200 Kcal., the highest of 
all subjects studied. The different treatments the patients thus received during 
hospitalisation do not allow reliable conclusions about lipid responses to therapies. The 
diagnosis of NIDDM and hypertriglyceridaemia occurring together was responsible for the 
hospital admission of patients 4,5,7,10,12,15,16,17. A family history of NIDDM was 
present in 10 out of the 18 patients (l,2,3,5,6,7,8,9,10,16,and 18; patients 6 and 14 had a 
family history of dyslipidaemia). 
Eighty one control subjects were recruited randomly from the Hopital Mondor with 
diabetes m. and no overt hyperlipidaemia. These were used to analyse the frequencies of the 
3 new mutants that we found in this study. 
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METHODS 
Total cholesterol triglyceride and HDL hi" . 
, -c 0 estero I ( after precIpItatIOn of B-containing 
lipoproteins by phosphotungstic acid and magnesium chloride) were determined with an 
Abbot Diagnostics VP analyser using enzymatic reagents (Boehringer Mannheim, 
Germany). Apolipoproteins Al and apo-B were measured by immunoturbidometric 
methods using Daichi kits ( Tokyo, Japan) 
DNA Methods 
DNA Extraction 
DNA was prepared from peripheralleucocytes using a Nucleon II kit (Scotlabs Ltd, UK) 
and resuspended in TE buffer. 
Amplification of LPL gene exons 
Oligonucleotide primers were synthesised (IGI Ltd. UK) to allow the amplification of 
individual exons of the LPL gene. For each exon, flanking intronic DNA (sequence 
courtesy of K. Oka) was examined for potential PCR primer sites using PRIMER software 
and primer pairs identified. In each pair, one primer was biotinylated at the 5' end. Typical 
PCR reaction conditions were as follows: 50-100 ng DNA, 50 mM KCl, 10 mM Tris-HCl 
(PH 8.3), 2.0 mM MgCI 2, 0.001 % (w/v) gelatin, 200 mM dNTPs, 100 nM each primer and 
2 units Taq polymerase (Life Sciences, UK) in a 100ml reaction. Amplification was 
achieved in a Perkin Elmer Cetus 480 thermal cycler using an initial denaturing step of 
94°C for 1 min and then 35 cycles of 94° 30 secs, 60° 1 min, 72° Imin followed by a final 
elongation step of 72° for 10 min. Small aliquots were removed to test the PCR reactions 
on 1.50/0 agarose gels. 
Sequencing of PCR Products 
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peR products were sequenced using the dideoxy chain tennination method. The PCR 
products were pretreated by one of two methods. 
(1). peR products were incubated with streptavidin coated magnetic beads (Dynal Ltd. 
UK). After washing, the bound PCR product was denatured and the biotinylated strand 
recovered. The bound single stranded product was then sequenced using the Sequenase II 
kit (Amersham Life Sciences, UK) with the non biotinylated primer(7). 
(2). The peR product was sequenced directly after treatment with Exonuclease I and 
Shrimp Alkaline Phosphatase (Sequenase PCR product sequencing kit, Amersham Life 
Sciences, UK). 
The reaction products from sequencing reactions were electrophoresed on 60/0 acrylamide-
bisacrylamide (19: I), 7 M urea gels using a glycerol tolerant gel buffer. The gels were 
prewarmed and samples were electrophoresed at 50V/cm. Subsequent to electrophoresis, 
the gels were fixed in 10% acetic acid and 100/0 methanol and vacuum dried. Dry gels were 
autoradiographed for 18-72 hours with Hypertilm (Amersham Life Sciences, UK) and the 
sequence read off the developed autoradiograph. 
Site-Directed Mutagenesis 
Site-directed mutagenesis of the LPL cDNA (9) was carried out by using the splicing 
overlap extension method (22). The oligonucleotide primers ( LPLF351L sense: 5'gag aac 
atc cca ttg act ctg 3'; LPL F3 51 L antisense 5' aac ttc agg cag agt caa tgg 3 ') used for 
mutagensis ( MWG, Egersberg, Gennany) contained the substitution TTC ( Phe35 1) by a 
TTG (Leu). The mutant LPL cDNA was continned by sequencing. For expression in 
HEK293 cells the wild type and the mutant cDNA's were cloned into the BamHUI~coRl 
sites of the expression vector pCDNA3 (Invitrogen), which contains the CMV promotor. 
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Expresion Studies 
DNA transfection wa r:D d 
s pe orme by electroporation (Electroporator II; 
Invitrogen).Subconfluent HEK293 11 h " . 
ce s were arvested by tryplll1SatIOn and resuspended in 
DMEM. O.5m!. of a suspension containing 5xl06 cells and 1 ug plasmid DNA were loaded 
into a 0.4 cm electroporation cuvette. After 10 min. on ice the cuvette was pulsed at 71 
uFa/500, the cells were then seeded in four 100-mm cell culture dishes and selected with 
DMEM, 10% (by volume) fetal bovine serum containing 500 ug.lml G4l8. After two 
weeks positive clones were picked and characterised by Northern blotting, enzyme 
immunoassay, and assays for lipase activity. 
Lipase Measurements 
Lipolytic activities in culture medium and cell extracts were determined by using 
radiolabelled triolein ( Amersham) as substrate as described by Hoffmann et al (9). LPL 
mass was determined three times by a sandwhich enzyme immunoassay ( MARKIT -F LPL; 
Daini ppon Pharmaceutical). 
RESULTS 
Mutations Detected 
The mutations in the lipoprotein lipase gene revealed by DNA sequence analysis are shown 
in Table 2, and eight of the eighteen subjects carried mutants in the heterozygous state. 
Three previously unpublished mutations were found. No mutations were found in the 
.. 'd A 156 H' 241 S 132) b hr f h' d . catalytIc tnad (resl ues sp - IS - er ut t ee 0 t e mutatIOns occurre III exons 
3 and 5 which code for protein domains flanking the catalytic cleft of the enzyme. With 
regard to the most severely lipaemic subjects at presentation (patients 16, 3 and 11, \vith 
plasma triglycerides of 79, 76 and 45 mmolll respectively) no mutations were detected at 
the LPL locus. Possibly regulatory sequences of the LPL gene or other genetic loci may be 
involved in their predisposition to develop a severe dyslipidaemia. The mean plasma 
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triglycerides of the patients carrying the LPL mutants after treatment was 5.0+2.3 (n=8) 
mmol/l compared to 7.9+5.5 (n=10) mmoVl of the others. The numbers studied are too 
small to draw conclusions regarding the impact of these mutants on effects of therapy. 
The New Mutations 
The DNA sequence gels showing the Arg l92 and Phe351 mutations are presented in Figure 
1a and lb. Sequence analysis reveals that both subjects ( numbers 8 and 12 ) are 
heterozygous for the C 1308 -G and C829 -T substitutions respectively. The first mutation 
results in an amino-acid susbstitution of phenylalanine (TTC) for leucine (TTG) at residue 
351. Site directed mutagenesis for this variant was performed and the DNA transfected into 
HEK293 cells. Lipase activity and mass was measured in culture medium and cell extracts. 
LPL specific activities were: Wildtype (n=6) 23.74+ 2.01 versus Phe351Leu (n=6) 
23.88+ 1. 7 umol/h./ug.LPL protein. 
The second mutation results in a substitution of arginine (CGA) at residue 192 by a stop 
codon (TGA). PCR amplifications of exons 5 and 7 and subsequent DNA sequencing on 
several occasions for both coding and non-coding strands were performed to confirm the 
presence of these two new mutations. 
The silent codon mutation ofC 1338_A at threonine 361 (sequence gels not presented) would 
not be expected to have any functional effects on the activity of lipoprotein lipase but could 
be used as a bi-allelic disease marker. 
The Allele Frequencies 
The Arg 192 variant was subsequently analysed by PCR amplification of exon 5 and 
digestion with Taq 1. This produces bands for the common allele of 123 bp and 140 bp~ and 
the variant abolishes the Taq 1 site to produce a 263 bp band on gel electrophoresis. The 
Phe351 variant was further analysed by using a modified amplimer that introduces a Hinc 11 
site in the presence of the mutant allele. 
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The Thr
361 
mutation was analysed by using a modified 5'amplimer (-Gee TGA AGT TIe 
CAC AAA T AA GGC-) where an additional mutation (A-G) was introduced at nucleotide 
1336 into the amplification product. Thus a novel Hae 111 restriction site was created as the 
enzyme has the recognition sequence of GGCC. Amplification followed by digestion with 
Hae 111 yielded bands of214 and 23 bp. for the common allele: and as the Thr361 mutation 
abolishes the Hae 111 site yielding three bands of 237 bp, 214 and 23 bp for the rare 
heterozygote. The frequencies of these three new variants in 81 subjects tested are presented 
in Table 3. 
DISCUSSION 
It is surprizing to be able to identify three new mutatations of the lipoprotein lipase gene by 
DNA analysis of 18 patients with marked diabetic lipaemia. One of these in exon 5 predicts 
termination of the enzyme protein at amino-acid 192. This would be expected to abolish 
catalytic activity of the enzyme since it is known that carboxy terminal truncation at residue 
381 reduces catalytic activity by about 85% (8). The heterozygous state may be unaffected 
or show a mild lipaemia; but when associated with diabetes m, a condition that predisposes 
to hypertriglyceridaemia, the mutant could lead to a severe lipaemia. The other newly 
described variant (Phe351 _Leu) may have some effect on enzyme function due to steric 
differences betwen the 2 amino-acids; however this mutant did not show any differences 
from wildtype enzyme by site-directed mutagenesis and expression by transfection into 
HEK 293 cells. It is of interest however that the severity of the lipaemia in this case (fasting 
plasma triglycerides of 19 mmol/l at presentation) was similar to the lipaemia with the 
truncated mutant (18.9 mmol/l). 
The third newly described mutation ( C1338_A) is conservative and does not change the 
amino-acid sequence of the protein product. Other than its possible use as a bi-allelic 
marker for the locus we are not investigating this further. 
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More than 50 disease related mutations of lipoprotein lipase have been documented since 
the initial report in 1989 (10,11). The majority of these appear to be rare occurring at 
frequencies of less than 1: 1 000. However four common population polymorphisms 
(frequencies of > 1 %) at the LPL locus have been documented that show disease 
relationships. The first to be published was an bi-allelic marker in intron 8 at an Hind III 
restriction site (11) whose alleles showed asymetric frequencies in subjects with 
dyslipidaemias compared to controls (11,12,13 ) and in subjects with premature coronary 
artery disease (14). These effects were subsequently attributed to linkage disequilibrium to a 
common exon mutation 635 base pairs downstream at a Ser.f.f7_Ter mutation (15) in exon 9 
(16). This variant truncates the mature protein by 2 amino-acids and associated alleles have 
been found to show disease associations with some dyslipidaemias (1 7,18), although it is 
probably not affecting the hyperlipidaemia of the current patients. Other common 
polymorphic variants ( population frequencies of> 1 %) at LPL have been found at ASp9_ 
Asn (19) and at Asn291 _Ser (20). These have been reported to have disease associations with 
. b . l' . b' +. d h A 291 d S .f.f7 dyslipidaemia (21). In our 18 dm ehc IpaemlC su ~ects we loun t e sn an er 
variants but not the ASp9 mutant. However three new variants came to light suggesting that 
there is much more genetic diversity at this locus than was previously recognised. 
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LEGENDS 
Table 1: Clinical data of the patients at admission. 
Table 2: Lipoprotein lipase gene mutations in French diabetic hyperlipidaemic individuals. 
Table 3: Frequencies of novel mutations of lipoprotein lipase in diabetic hyper- and normo-
lipidaemic sUbjects. 
Figure 1a and 1 b: Autoradiographs of DNA gel sequences. 
(a) Nucleotide sequence of the non-coding strand for the mutant and normal exon 7 
showing a C-G transversion at nucleotide 1308 that results in the substitution of 
pheny lalanine for leucine at codon 351. 
(b) Nucleotide sequence of the non-coding strand for the mutant and normal exon 5 
showing a C-T transversion at nucleotide 829 resulting in the substitution of arginine for a 
stop codon at position 192. 
Table 1. 
CLINICAL DATA OF THE PATIENTS AT ADMISSION 
Patient Age BMI Sex PI.Chol. PI.Tg. HDL-C HDL-C Fasting Alcohol Complications 
(kg/ml) (ruM) (mM) (mM) (mM) glucose intake 
At entry At disch. (mM) (g/wk.) 
1 42 29.3 M 9.3 24.1 0.67 0.93 17.5 1050 liver steatosis 
2 39 36.3 M 6.3 13.3 0.49 0.67 9.5 0 liver steatosis 
3 41 39.7 M 11.3 75.0 0.36 0.49 11.7 0 eruptive xanthomatosis 
4 43 27.0 M 19.3 41.2 0.65 19.5 175 eruptive xanthomatosis 
5 36 32.1 M 7.61 12.5 0.60 16.7 0 liver steatosis 
pancreatitis 
6 45 33.5 M 14.7 14.7 0.72 7.2 350 liver steatosis 
7 28 32.0 F 23.0 76.0 0.39 0.85 11.7 40 liver steatosis 
pancreatitis 
8 42 42.9 F 9.0 18.9 0.60 13.7 0 
9 58 40.1 M 8.2 30.8 0.36 0.60 27.9 518 liver steatosis 
10 39 30.7 M 16.6 33.3 1.06 12.2 56 
11 46 25.7 M 5.6 44.9 0.26 0.31 12.8 0 liver steatosis 
12 58 30.9 M 14.0 0.39 19.5 pancreatitis 
13 72 28.0 M 3.6 20.5 0.75 0.57 17.2 liver steatosis 
eruptive xanthomatosis 
14 56 27.8 M 4.0 26.2 
history of possible pancreatitis 
0.70 11.0 280 liver steatosis 
15 36 28.1 M 8.0 28.0 0.52 19.5 230 liver steatosis 
eruptive xanthomatosis 
16 47 29.4 M 8.0 79.0 0.49 16.1 140 liver steatosis 
eruptive xanthomatosis 
17 27 27.7 M 4.5 28.0 
history of possible pancre.atitis 
0.41 0.67 11.1 70 pancreatitis 
18 58 32.1 F 44.2 33.0 0.80 12.2 0 
Ahbn:viatlOns used: Pl. =plasma; Chol. = cholesterol; HDL=high density lipoprotein; C=cholesterol. 
Table 2 Lipoprotein lipase gene mutations in French diabetic hyperlipidaemic individuals 
Exon Nucleotide aa residue individuals Publication information 
3 G579 _ A Val108 - Val 17, 18 in literature + 
GTG=?GTA 
5 G818 _ A Gly188 - Glu 13, 17 in literature + 
GGG=?GAG 
C829 _ T 192 Arg - Ter 12 This study 
CGA=?TGA 
6 A1127 _G A 291 sn - Ser 6,9 in literature + 
AAT=?AGT 
7 C1308 _ G 351 Phe - Leu 8 This study 
TTC=?TTG 
8 C1338 _ A Thr361 - Thr 9, 14 This study 
ACC=?ACA 
9 ('1595 _ G .+.+7 Ser - Ter 12, 13 in literature + 
TCA=?TGA 
+scc rnicw ref. for further details 
Table 3 
Frequencies of novel mutations of lipoprotein lipase in diabetic hyper- and normolipidaemic subjects. 
Location in LPL Nucleotide Change Codon Change Allele Frequency 
Gene 
Control Subjects 
Exon 5 C829_T Arg192_ Ter 0(162) 0.027(36) 
Exon 7 C1308_G Phe351 -Leu 0(162) 0.027(36) 
Exon 8 Cl338 _A Th~61-Thr 0.12(162) 0.055(36) 
Numbers in brackets (n) represent chromosomes scored. 
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